<!DOCTYPE html><html  lang="en" data-capo=""><head><meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Frontiers | Identification of BRCA2 Cis Double Heterozygous Breast Cancer Cases Using Whole Exome Sequencing: Phenotypic Expression and Impact on Personalized Oncology</title>
<link rel="stylesheet" href="/ap-2024/_nuxt/entry.CWBB-NGm.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/vue-core.B-WA3Vg5.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/explainer.CMppEa5M.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleDetails.B93eTAmx.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleLayoutHeader.CKWUz2Al.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/AnnouncementCard.Db7nmstV.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/FloatingButtons.xuP8gC33.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleEvent.D0PaxIW7.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/SimilarArticles.BMee4Fk4.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleTemplateBanner.CXmOJ7NH.css">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/v1IBIWh4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/B674Mi_H.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BXedFy5e.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/eQMj-Fph.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Y8NTh2i4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUyL5Z_3.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/m8mdd2tc.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DHv8pTSw.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BHPWSuhB.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/x5HZk7Le.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CNJXQ6ZR.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dss5ciUI.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Do5q9QoL.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BhVAcJSK.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/y69VltF1.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Bw-bWKkJ.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/sQBxgu5L.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/D5YKKJGW.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CSLdjdGS.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUN89Jk2.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CCeQzihV.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DVDwh0-U.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dw4ta0fP.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CYv-CzHi.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/U-mJlaMn.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/NhyIC1F3.js">
<link rel="prefetch" as="style" crossorigin href="/ap-2024/_nuxt/ArticleHubLayout.q6CU8_bN.css">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/CKQJuUlk.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/D3plh7Cs.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/GWtHKqLR.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/DS3EY-DL.js">
<meta name="theme-color" content="#0C4DED">
<meta name="mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-capable" content="yes">
<script type="text/javascript" data-hid="4cd079c">window.NREUM||(NREUM={});NREUM.info = {"agent":"","beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"598a124f17","applicationID":"586843029","agentToken":null,"applicationTime":4.988988,"transactionName":"MQcDMkECCkNSW0YMWghNLwlBDgVcWkJXAWAUC04MXBYWXlJUQUpSAwwEEloAFx9SSkYMVgoHEkkZTAJXVlZXSwdWUFBIBVRQCQoIHQNACg4=","queueTime":0,"ttGuid":"0b8b357af7dcc1c4"}; (window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]},feature_flags:["soft_nav"],distributed_tracing:{enabled:true}};(window.NREUM||(NREUM={})).loader_config={agentID:"594460232",accountID:"230385",trustKey:"230385",xpid:"VgUHUl5WGwYIUllWBAEFXw==",licenseKey:"598a124f17",applicationID:"586843029",browserID:"594460232"};;/*! For license information please see nr-loader-spa-1.303.0.min.js.LICENSE.txt */
(()=>{var e,t,r={384:(e,t,r)=>{"use strict";r.d(t,{NT:()=>s,US:()=>d,Zm:()=>a,bQ:()=>u,dV:()=>c,pV:()=>l});var n=r(6154),i=r(1863),o=r(1910);const s={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return n.gm.NREUM||(n.gm.NREUM={}),void 0===n.gm.newrelic&&(n.gm.newrelic=n.gm.NREUM),n.gm.NREUM}function c(){let e=a();return e.o||(e.o={ST:n.gm.setTimeout,SI:n.gm.setImmediate||n.gm.setInterval,CT:n.gm.clearTimeout,XHR:n.gm.XMLHttpRequest,REQ:n.gm.Request,EV:n.gm.Event,PR:n.gm.Promise,MO:n.gm.MutationObserver,FETCH:n.gm.fetch,WS:n.gm.WebSocket},(0,o.i)(...Object.values(e.o))),e}function u(e,t){let r=a();r.initializedAgents??={},t.initializedAt={ms:(0,i.t)(),date:new Date},r.initializedAgents[e]=t}function d(e,t){a()[e]=t}function l(){return function(){let e=a();const t=e.info||{};e.info={beacon:s.beacon,errorBeacon:s.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),c(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},782:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewTiming},860:(e,t,r)=>{"use strict";r.d(t,{$J:()=>d,K7:()=>c,P3:()=>u,XX:()=>i,Yy:()=>a,df:()=>o,qY:()=>n,v4:()=>s});const n="events",i="jserrors",o="browser/blobs",s="rum",a="browser/logs",c={ajax:"ajax",genericEvents:"generic_events",jserrors:i,logging:"logging",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",softNav:"soft_navigations",spa:"spa"},u={[c.pageViewEvent]:1,[c.pageViewTiming]:2,[c.metrics]:3,[c.jserrors]:4,[c.spa]:5,[c.ajax]:6,[c.sessionTrace]:7,[c.softNav]:8,[c.sessionReplay]:9,[c.logging]:10,[c.genericEvents]:11},d={[c.pageViewEvent]:s,[c.pageViewTiming]:n,[c.ajax]:n,[c.spa]:n,[c.softNav]:n,[c.metrics]:i,[c.jserrors]:i,[c.sessionTrace]:o,[c.sessionReplay]:o,[c.logging]:a,[c.genericEvents]:"ins"}},944:(e,t,r)=>{"use strict";r.d(t,{R:()=>i});var n=r(3241);function i(e,t){"function"==typeof console.debug&&(console.debug("New Relic Warning: https://github.com/newrelic/newrelic-browser-agent/blob/main/docs/warning-codes.md#".concat(e),t),(0,n.W)({agentIdentifier:null,drained:null,type:"data",name:"warn",feature:"warn",data:{code:e,secondary:t}}))}},993:(e,t,r)=>{"use strict";r.d(t,{A$:()=>o,ET:()=>s,TZ:()=>a,p_:()=>i});var n=r(860);const i={ERROR:"ERROR",WARN:"WARN",INFO:"INFO",DEBUG:"DEBUG",TRACE:"TRACE"},o={OFF:0,ERROR:1,WARN:2,INFO:3,DEBUG:4,TRACE:5},s="log",a=n.K7.logging},1687:(e,t,r)=>{"use strict";r.d(t,{Ak:()=>u,Ze:()=>f,x3:()=>d});var n=r(3241),i=r(7836),o=r(3606),s=r(860),a=r(2646);const c={};function u(e,t){const r={staged:!1,priority:s.P3[t]||0};l(e),c[e].get(t)||c[e].set(t,r)}function d(e,t){e&&c[e]&&(c[e].get(t)&&c[e].delete(t),p(e,t,!1),c[e].size&&h(e))}function l(e){if(!e)throw new Error("agentIdentifier required");c[e]||(c[e]=new Map)}function f(e="",t="feature",r=!1){if(l(e),!e||!c[e].get(t)||r)return p(e,t);c[e].get(t).staged=!0,h(e)}function h(e){const t=Array.from(c[e]);t.every(([e,t])=>t.staged)&&(t.sort((e,t)=>e[1].priority-t[1].priority),t.forEach(([t])=>{c[e].delete(t),p(e,t)}))}function p(e,t,r=!0){const s=e?i.ee.get(e):i.ee,c=o.i.handlers;if(!s.aborted&&s.backlog&&c){if((0,n.W)({agentIdentifier:e,type:"lifecycle",name:"drain",feature:t}),r){const e=s.backlog[t],r=c[t];if(r){for(let t=0;e&&t<e.length;++t)g(e[t],r);Object.entries(r).forEach(([e,t])=>{Object.values(t||{}).forEach(t=>{t[0]?.on&&t[0]?.context()instanceof a.y&&t[0].on(e,t[1])})})}}s.isolatedBacklog||delete c[t],s.backlog[t]=null,s.emit("drain-"+t,[])}}function g(e,t){var r=e[1];Object.values(t[r]||{}).forEach(t=>{var r=e[0];if(t[0]===r){var n=t[1],i=e[3],o=e[2];n.apply(i,o)}})}},1741:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(944),i=r(4261);class o{#e(e,...t){if(this[e]!==o.prototype[e])return this[e](...t);(0,n.R)(35,e)}addPageAction(e,t){return this.#e(i.hG,e,t)}register(e){return this.#e(i.eY,e)}recordCustomEvent(e,t){return this.#e(i.fF,e,t)}setPageViewName(e,t){return this.#e(i.Fw,e,t)}setCustomAttribute(e,t,r){return this.#e(i.cD,e,t,r)}noticeError(e,t){return this.#e(i.o5,e,t)}setUserId(e){return this.#e(i.Dl,e)}setApplicationVersion(e){return this.#e(i.nb,e)}setErrorHandler(e){return this.#e(i.bt,e)}addRelease(e,t){return this.#e(i.k6,e,t)}log(e,t){return this.#e(i.$9,e,t)}start(){return this.#e(i.d3)}finished(e){return this.#e(i.BL,e)}recordReplay(){return this.#e(i.CH)}pauseReplay(){return this.#e(i.Tb)}addToTrace(e){return this.#e(i.U2,e)}setCurrentRouteName(e){return this.#e(i.PA,e)}interaction(e){return this.#e(i.dT,e)}wrapLogger(e,t,r){return this.#e(i.Wb,e,t,r)}measure(e,t){return this.#e(i.V1,e,t)}consent(e){return this.#e(i.Pv,e)}}},1863:(e,t,r)=>{"use strict";function n(){return Math.floor(performance.now())}r.d(t,{t:()=>n})},1910:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(944);const i=new Map;function o(...e){return e.every(e=>{if(i.has(e))return i.get(e);const t="function"==typeof e&&e.toString().includes("[native code]");return t||(0,n.R)(64,e?.name||e?.toString()),i.set(e,t),t})}},2555:(e,t,r)=>{"use strict";r.d(t,{D:()=>a,f:()=>s});var n=r(384),i=r(8122);const o={beacon:n.NT.beacon,errorBeacon:n.NT.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0};function s(e){try{return!!e.licenseKey&&!!e.errorBeacon&&!!e.applicationID}catch(e){return!1}}const a=e=>(0,i.a)(e,o)},2614:(e,t,r)=>{"use strict";r.d(t,{BB:()=>s,H3:()=>n,g:()=>u,iL:()=>c,tS:()=>a,uh:()=>i,wk:()=>o});const n="NRBA",i="SESSION",o=144e5,s=18e5,a={STARTED:"session-started",PAUSE:"session-pause",RESET:"session-reset",RESUME:"session-resume",UPDATE:"session-update"},c={SAME_TAB:"same-tab",CROSS_TAB:"cross-tab"},u={OFF:0,FULL:1,ERROR:2}},2646:(e,t,r)=>{"use strict";r.d(t,{y:()=>n});class n{constructor(e){this.contextId=e}}},2843:(e,t,r)=>{"use strict";r.d(t,{u:()=>i});var n=r(3878);function i(e,t=!1,r,i){(0,n.DD)("visibilitychange",function(){if(t)return void("hidden"===document.visibilityState&&e());e(document.visibilityState)},r,i)}},3241:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(6154);const i="newrelic";function o(e={}){try{n.gm.dispatchEvent(new CustomEvent(i,{detail:e}))}catch(e){}}},3304:(e,t,r)=>{"use strict";r.d(t,{A:()=>o});var n=r(7836);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())??""}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}return""}}},3333:(e,t,r)=>{"use strict";r.d(t,{$v:()=>d,TZ:()=>n,Xh:()=>c,Zp:()=>i,kd:()=>u,mq:()=>a,nf:()=>s,qN:()=>o});const n=r(860).K7.genericEvents,i=["auxclick","click","copy","keydown","paste","scrollend"],o=["focus","blur"],s=4,a=1e3,c=2e3,u=["PageAction","UserAction","BrowserPerformance"],d={RESOURCES:"experimental.resources",REGISTER:"register"}},3434:(e,t,r)=>{"use strict";r.d(t,{Jt:()=>o,YM:()=>u});var n=r(7836),i=r(5607);const o="nr@original:".concat(i.W),s=50;var a=Object.prototype.hasOwnProperty,c=!1;function u(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");const s="-"===n.charAt(0);for(let a=0;a<t.length;a++){const c=t[a],u=e[c];l(u)||(e[c]=r(u,s?c+n:n,i,c,o))}},r.flag=o,r;function r(t,r,n,c,u){return l(t)?t:(r||(r=""),nrWrapper[o]=t,function(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach(function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})}),t}catch(e){d([e],r)}for(var n in e)a.call(e,n)&&(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var o,a,l,f;let h;try{a=this,o=[...arguments],l="function"==typeof n?n(o,a):n||{}}catch(t){d([t,"",[o,a,c],l],e)}i(r+"start",[o,a,c],l,u);const p=performance.now();let g;try{return f=t.apply(a,o),g=performance.now(),f}catch(e){throw g=performance.now(),i(r+"err",[o,a,e],l,u),h=e,h}finally{const e=g-p,t={start:p,end:g,duration:e,isLongTask:e>=s,methodName:c,thrownError:h};t.isLongTask&&i("long-task",[t,a],l,u),i(r+"end",[o,a,f],l,u)}}}function i(r,n,i,o){if(!c||t){var s=c;c=!0;try{e.emit(r,n,i,t,o)}catch(t){d([t,r,n,i],e)}c=s}}}function d(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function l(e){return!(e&&"function"==typeof e&&e.apply&&!e[o])}},3606:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(9908);o.on=s;var i=o.handlers={};function o(e,t,r,o){s(o||n.d,i,e,t,r)}function s(e,t,r,i,o){o||(o="feature"),e||(e=n.d);var s=t[o]=t[o]||{};(s[r]=s[r]||[]).push([e,i])}},3738:(e,t,r)=>{"use strict";r.d(t,{He:()=>i,Kp:()=>a,Lc:()=>u,Rz:()=>d,TZ:()=>n,bD:()=>o,d3:()=>s,jx:()=>l,sl:()=>f,uP:()=>c});const n=r(860).K7.sessionTrace,i="bstResource",o="resource",s="-start",a="-end",c="fn"+s,u="fn"+a,d="pushState",l=1e3,f=3e4},3785:(e,t,r)=>{"use strict";r.d(t,{R:()=>c,b:()=>u});var n=r(9908),i=r(1863),o=r(860),s=r(8154),a=r(993);function c(e,t,r={},c=a.p_.INFO,u,d=(0,i.t)()){(0,n.p)(s.xV,["API/logging/".concat(c.toLowerCase(),"/called")],void 0,o.K7.metrics,e),(0,n.p)(a.ET,[d,t,r,c,u],void 0,o.K7.logging,e)}function u(e){return"string"==typeof e&&Object.values(a.p_).some(t=>t===e.toUpperCase().trim())}},3878:(e,t,r)=>{"use strict";function n(e,t){return{capture:e,passive:!1,signal:t}}function i(e,t,r=!1,i){window.addEventListener(e,t,n(r,i))}function o(e,t,r=!1,i){document.addEventListener(e,t,n(r,i))}r.d(t,{DD:()=>o,jT:()=>n,sp:()=>i})},3962:(e,t,r)=>{"use strict";r.d(t,{AM:()=>s,O2:()=>l,OV:()=>o,Qu:()=>f,TZ:()=>c,ih:()=>h,pP:()=>a,t1:()=>d,tC:()=>i,wD:()=>u});var n=r(860);const i=["click","keydown","submit"],o="popstate",s="api",a="initialPageLoad",c=n.K7.softNav,u=5e3,d=500,l={INITIAL_PAGE_LOAD:"",ROUTE_CHANGE:1,UNSPECIFIED:2},f={INTERACTION:1,AJAX:2,CUSTOM_END:3,CUSTOM_TRACER:4},h={IP:"in progress",PF:"pending finish",FIN:"finished",CAN:"cancelled"}},4234:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(7836),i=r(1687);class o{constructor(e,t){this.agentIdentifier=e,this.ee=n.ee.get(e),this.featureName=t,this.blocked=!1}deregisterDrain(){(0,i.x3)(this.agentIdentifier,this.featureName)}}},4261:(e,t,r)=>{"use strict";r.d(t,{$9:()=>d,BL:()=>c,CH:()=>p,Dl:()=>R,Fw:()=>w,PA:()=>v,Pl:()=>n,Pv:()=>A,Tb:()=>f,U2:()=>s,V1:()=>E,Wb:()=>T,bt:()=>y,cD:()=>b,d3:()=>x,dT:()=>u,eY:()=>g,fF:()=>h,hG:()=>o,hw:()=>i,k6:()=>a,nb:()=>m,o5:()=>l});const n="api-",i=n+"ixn-",o="addPageAction",s="addToTrace",a="addRelease",c="finished",u="interaction",d="log",l="noticeError",f="pauseReplay",h="recordCustomEvent",p="recordReplay",g="register",m="setApplicationVersion",v="setCurrentRouteName",b="setCustomAttribute",y="setErrorHandler",w="setPageViewName",R="setUserId",x="start",T="wrapLogger",E="measure",A="consent"},4387:(e,t,r)=>{"use strict";function n(e={}){return!(!e.id||!e.name)}function i(e){return"string"==typeof e&&e.trim().length<501||"number"==typeof e}function o(e,t){if(2!==t?.harvestEndpointVersion)return{};const r=t.agentRef.runtime.appMetadata.agents[0].entityGuid;return n(e)?{"mfe.id":e.id,"mfe.name":e.name,eventSource:e.eventSource,"parent.id":e.parent?.id||r}:{"entity.guid":r,appId:t.agentRef.info.applicationID}}r.d(t,{Ux:()=>o,c7:()=>n,yo:()=>i})},5205:(e,t,r)=>{"use strict";r.d(t,{j:()=>_});var n=r(384),i=r(1741);var o=r(2555),s=r(3333);const a=e=>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var c=r(2614),u=r(944),d=r(8122);const l="[data-nr-mask]",f=e=>(0,d.a)(e,(()=>{const e={feature_flags:[],experimental:{allow_registered_children:!1,resources:!1},mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{ajax:{deny_list:void 0,block_internal:!0,enabled:!0,autoStart:!0},api:{get allow_registered_children(){return e.feature_flags.includes(s.$v.REGISTER)||e.experimental.allow_registered_children},set allow_registered_children(t){e.experimental.allow_registered_children=t},duplicate_registered_data:!1},browser_consent_mode:{enabled:!1},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},get feature_flags(){return e.feature_flags},set feature_flags(t){e.feature_flags=t},generic_events:{enabled:!0,autoStart:!0},harvest:{interval:30},jserrors:{enabled:!0,autoStart:!0},logging:{enabled:!0,autoStart:!0},metrics:{enabled:!0,autoStart:!0},obfuscate:void 0,page_action:{enabled:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,autoStart:!0},performance:{capture_marks:!1,capture_measures:!1,capture_detail:!0,resources:{get enabled(){return e.feature_flags.includes(s.$v.RESOURCES)||e.experimental.resources},set enabled(t){e.experimental.resources=t},asset_types:[],first_party_domains:[],ignore_newrelic:!0}},privacy:{cookies_enabled:!0},proxy:{assets:void 0,beacon:void 0},session:{expiresMs:c.wk,inactiveMs:c.BB},session_replay:{autoStart:!0,enabled:!1,preload:!1,sampling_rate:10,error_sampling_rate:100,collect_fonts:!1,inline_images:!1,fix_stylesheets:!0,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){a(t)?e.mask_selector="".concat(t,",").concat(l):""===t||null===t?e.mask_selector=l:(0,u.R)(5,t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){a(t)?e.block_selector+=",".concat(t):""!==t&&(0,u.R)(6,t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&&"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,u.R)(7,t)}},session_trace:{enabled:!0,autoStart:!0},soft_navigations:{enabled:!0,autoStart:!0},spa:{enabled:!0,autoStart:!0},ssl:void 0,user_actions:{enabled:!0,elementAttributes:["id","className","tagName","type"]}}})());var h=r(6154),p=r(9324);let g=0;const m={buildEnv:p.F3,distMethod:p.Xs,version:p.xv,originTime:h.WN},v={consented:!1},b={appMetadata:{},get consented(){return this.session?.state?.consent||v.consented},set consented(e){v.consented=e},customTransaction:void 0,denyList:void 0,disabled:!1,harvester:void 0,isolatedBacklog:!1,isRecording:!1,loaderType:void 0,maxBytes:3e4,obfuscator:void 0,onerror:void 0,ptid:void 0,releaseIds:{},session:void 0,timeKeeper:void 0,registeredEntities:[],jsAttributesMetadata:{bytes:0},get harvestCount(){return++g}},y=e=>{const t=(0,d.a)(e,b),r=Object.keys(m).reduce((e,t)=>(e[t]={value:m[t],writable:!1,configurable:!0,enumerable:!0},e),{});return Object.defineProperties(t,r)};var w=r(5701);const R=e=>{const t=e.startsWith("http");e+="/",r.p=t?e:"https://"+e};var x=r(7836),T=r(3241);const E={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},A=e=>(0,d.a)(e,E),S=new Set;function _(e,t={},r,s){let{init:a,info:c,loader_config:u,runtime:d={},exposed:l=!0}=t;if(!c){const e=(0,n.pV)();a=e.init,c=e.info,u=e.loader_config}e.init=f(a||{}),e.loader_config=A(u||{}),c.jsAttributes??={},h.bv&&(c.jsAttributes.isWorker=!0),e.info=(0,o.D)(c);const p=e.init,g=[c.beacon,c.errorBeacon];S.has(e.agentIdentifier)||(p.proxy.assets&&(R(p.proxy.assets),g.push(p.proxy.assets)),p.proxy.beacon&&g.push(p.proxy.beacon),e.beacons=[...g],function(e){const t=(0,n.pV)();Object.getOwnPropertyNames(i.W.prototype).forEach(r=>{const n=i.W.prototype[r];if("function"!=typeof n||"constructor"===n)return;let o=t[r];e[r]&&!1!==e.exposed&&"micro-agent"!==e.runtime?.loaderType&&(t[r]=(...t)=>{const n=e[r](...t);return o?o(...t):n})})}(e),(0,n.US)("activatedFeatures",w.B),e.runSoftNavOverSpa&&=!0===p.soft_navigations.enabled&&p.feature_flags.includes("soft_nav")),d.denyList=[...p.ajax.deny_list||[],...p.ajax.block_internal?g:[]],d.ptid=e.agentIdentifier,d.loaderType=r,e.runtime=y(d),S.has(e.agentIdentifier)||(e.ee=x.ee.get(e.agentIdentifier),e.exposed=l,(0,T.W)({agentIdentifier:e.agentIdentifier,drained:!!w.B?.[e.agentIdentifier],type:"lifecycle",name:"initialize",feature:void 0,data:e.config})),S.add(e.agentIdentifier)}},5270:(e,t,r)=>{"use strict";r.d(t,{Aw:()=>s,SR:()=>o,rF:()=>a});var n=r(384),i=r(7767);function o(e){return!!(0,n.dV)().o.MO&&(0,i.V)(e)&&!0===e?.session_trace.enabled}function s(e){return!0===e?.session_replay.preload&&o(e)}function a(e,t){try{if("string"==typeof t?.type){if("password"===t.type.toLowerCase())return"*".repeat(e?.length||0);if(void 0!==t?.dataset?.nrUnmask||t?.classList?.contains("nr-unmask"))return e}}catch(e){}return"string"==typeof e?e.replace(/[\S]/g,"*"):"*".repeat(e?.length||0)}},5289:(e,t,r)=>{"use strict";r.d(t,{GG:()=>o,Qr:()=>a,sB:()=>s});var n=r(3878);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.sp)("load",e,t)}function s(e){if(i())return e();(0,n.DD)("DOMContentLoaded",e)}function a(e){if(i())return e();(0,n.sp)("popstate",e)}},5607:(e,t,r)=>{"use strict";r.d(t,{W:()=>n});const n=(0,r(9566).bz)()},5701:(e,t,r)=>{"use strict";r.d(t,{B:()=>o,t:()=>s});var n=r(3241);const i=new Set,o={};function s(e,t){const r=t.agentIdentifier;o[r]??={},e&&"object"==typeof e&&(i.has(r)||(t.ee.emit("rumresp",[e]),o[r]=e,i.add(r),(0,n.W)({agentIdentifier:r,loaded:!0,drained:!0,type:"lifecycle",name:"load",feature:void 0,data:e})))}},6154:(e,t,r)=>{"use strict";r.d(t,{A4:()=>a,OF:()=>d,RI:()=>i,WN:()=>h,bv:()=>o,gm:()=>s,lR:()=>f,m:()=>u,mw:()=>c,sb:()=>l});var n=r(1863);const i="undefined"!=typeof window&&!!window.document,o="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),s=i?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a="complete"===s?.document?.readyState,c=Boolean("hidden"===s?.document?.visibilityState),u=""+s?.location,d=/iPad|iPhone|iPod/.test(s.navigator?.userAgent),l=d&&"undefined"==typeof SharedWorker,f=(()=>{const e=s.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),h=Date.now()-(0,n.t)()},6344:(e,t,r)=>{"use strict";r.d(t,{BB:()=>d,Qb:()=>l,TZ:()=>i,Ug:()=>s,Vh:()=>o,_s:()=>a,bc:()=>u,yP:()=>c});var n=r(2614);const i=r(860).K7.sessionReplay,o="errorDuringReplay",s=.12,a={DomContentLoaded:0,Load:1,FullSnapshot:2,IncrementalSnapshot:3,Meta:4,Custom:5},c={[n.g.ERROR]:15e3,[n.g.FULL]:3e5,[n.g.OFF]:0},u={RESET:{message:"Session was reset",sm:"Reset"},IMPORT:{message:"Recorder failed to import",sm:"Import"},TOO_MANY:{message:"429: Too Many Requests",sm:"Too-Many"},TOO_BIG:{message:"Payload was too large",sm:"Too-Big"},CROSS_TAB:{message:"Session Entity was set to OFF on another tab",sm:"Cross-Tab"},ENTITLEMENTS:{message:"Session Replay is not allowed and will not be started",sm:"Entitlement"}},d=5e3,l={API:"api",RESUME:"resume",SWITCH_TO_FULL:"switchToFull",INITIALIZE:"initialize",PRELOAD:"preload"}},6389:(e,t,r)=>{"use strict";function n(e,t=500,r={}){const n=r?.leading||!1;let i;return(...r)=>{n&&void 0===i&&(e.apply(this,r),i=setTimeout(()=>{i=clearTimeout(i)},t)),n||(clearTimeout(i),i=setTimeout(()=>{e.apply(this,r)},t))}}function i(e){let t=!1;return(...r)=>{t||(t=!0,e.apply(this,r))}}r.d(t,{J:()=>i,s:()=>n})},6630:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewEvent},6774:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.jserrors},7295:(e,t,r)=>{"use strict";r.d(t,{Xv:()=>s,gX:()=>i,iW:()=>o});var n=[];function i(e){if(!e||o(e))return!1;if(0===n.length)return!0;for(var t=0;t<n.length;t++){var r=n[t];if("*"===r.hostname)return!1;if(a(r.hostname,e.hostname)&&c(r.pathname,e.pathname))return!1}return!0}function o(e){return void 0===e.hostname}function s(e){if(n=[],e&&e.length)for(var t=0;t<e.length;t++){let r=e[t];if(!r)continue;0===r.indexOf("http://")?r=r.substring(7):0===r.indexOf("https://")&&(r=r.substring(8));const i=r.indexOf("/");let o,s;i>0?(o=r.substring(0,i),s=r.substring(i)):(o=r,s="");let[a]=o.split(":");n.push({hostname:a,pathname:s})}}function a(e,t){return!(e.length>t.length)&&t.indexOf(e)===t.length-e.length}function c(e,t){return 0===e.indexOf("/")&&(e=e.substring(1)),0===t.indexOf("/")&&(t=t.substring(1)),""===e||e===t}},7378:(e,t,r)=>{"use strict";r.d(t,{$p:()=>x,BR:()=>b,Kp:()=>R,L3:()=>y,Lc:()=>c,NC:()=>o,SG:()=>d,TZ:()=>i,U6:()=>p,UT:()=>m,d3:()=>w,dT:()=>f,e5:()=>E,gx:()=>v,l9:()=>l,oW:()=>h,op:()=>g,rw:()=>u,tH:()=>A,uP:()=>a,wW:()=>T,xq:()=>s});var n=r(384);const i=r(860).K7.spa,o=["click","submit","keypress","keydown","keyup","change"],s=999,a="fn-start",c="fn-end",u="cb-start",d="api-ixn-",l="remaining",f="interaction",h="spaNode",p="jsonpNode",g="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=(0,n.dV)().o.ST,w="-start",R="-end",x="-body",T="cb"+R,E="jsTime",A="fetch"},7485:(e,t,r)=>{"use strict";r.d(t,{D:()=>i});var n=r(6154);function i(e){if(0===(e||"").indexOf("data:"))return{protocol:"data"};try{const t=new URL(e,location.href),r={port:t.port,hostname:t.hostname,pathname:t.pathname,search:t.search,protocol:t.protocol.slice(0,t.protocol.indexOf(":")),sameOrigin:t.protocol===n.gm?.location?.protocol&&t.host===n.gm?.location?.host};return r.port&&""!==r.port||("http:"===t.protocol&&(r.port="80"),"https:"===t.protocol&&(r.port="443")),r.pathname&&""!==r.pathname?r.pathname.startsWith("/")||(r.pathname="/".concat(r.pathname)):r.pathname="/",r}catch(e){return{}}}},7699:(e,t,r)=>{"use strict";r.d(t,{It:()=>o,KC:()=>a,No:()=>i,qh:()=>s});var n=r(860);const i=16e3,o=1e6,s="SESSION_ERROR",a={[n.K7.logging]:!0,[n.K7.genericEvents]:!1,[n.K7.jserrors]:!1,[n.K7.ajax]:!1}},7767:(e,t,r)=>{"use strict";r.d(t,{V:()=>i});var n=r(6154);const i=e=>n.RI&&!0===e?.privacy.cookies_enabled},7836:(e,t,r)=>{"use strict";r.d(t,{P:()=>a,ee:()=>c});var n=r(384),i=r(8990),o=r(2646),s=r(5607);const a="nr@context:".concat(s.W),c=function e(t,r){var n={},s={},d={},l=!1;try{l=16===r.length&&u.initializedAgents?.[r]?.runtime.isolatedBacklog}catch(e){}var f={on:p,addEventListener:p,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)},emit:function(e,r,n,i,o){!1!==o&&(o=!0);if(c.aborted&&!i)return;t&&o&&t.emit(e,r,n);var a=h(n);g(e).forEach(e=>{e.apply(a,r)});var u=v()[s[e]];u&&u.push([f,e,r,a]);return a},get:m,listeners:g,context:h,buffer:function(e,t){const r=v();if(t=t||"feature",f.aborted)return;Object.entries(e||{}).forEach(([e,n])=>{s[n]=t,t in r||(r[t]=[])})},abort:function(){f._aborted=!0,Object.keys(f.backlog).forEach(e=>{delete f.backlog[e]})},isBuffering:function(e){return!!v()[s[e]]},debugId:r,backlog:l?{}:t&&"object"==typeof t.backlog?t.backlog:{},isolatedBacklog:l};return Object.defineProperty(f,"aborted",{get:()=>{let e=f._aborted||!1;return e||(t&&(e=t.aborted),e)}}),f;function h(e){return e&&e instanceof o.y?e:e?(0,i.I)(e,a,()=>new o.y(a)):new o.y(a)}function p(e,t){n[e]=g(e).concat(t)}function g(e){return n[e]||[]}function m(t){return d[t]=d[t]||e(f,t)}function v(){return f.backlog}}(void 0,"globalEE"),u=(0,n.Zm)();u.ee||(u.ee=c)},8122:(e,t,r)=>{"use strict";r.d(t,{a:()=>i});var n=r(944);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.R)(3);if(!t||"object"!=typeof t)return(0,n.R)(4);const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let s in o)if(void 0!==e[s])try{if(null===e[s]){r[s]=null;continue}Array.isArray(e[s])&&Array.isArray(t[s])?r[s]=Array.from(new Set([...e[s],...t[s]])):"object"==typeof e[s]&&"object"==typeof t[s]?r[s]=i(e[s],t[s]):r[s]=e[s]}catch(e){r[s]||(0,n.R)(1,e)}return r}catch(e){(0,n.R)(2,e)}}},8139:(e,t,r)=>{"use strict";r.d(t,{u:()=>f});var n=r(7836),i=r(3434),o=r(8990),s=r(6154);const a={},c=s.gm.XMLHttpRequest,u="addEventListener",d="removeEventListener",l="nr@wrapped:".concat(n.P);function f(e){var t=function(e){return(e||n.ee).get("events")}(e);if(a[t.debugId]++)return t;a[t.debugId]=1;var r=(0,i.YM)(t,!0);function f(e){r.inPlace(e,[u,d],"-",p)}function p(e,t){return e[1]}return"getPrototypeOf"in Object&&(s.RI&&h(document,f),c&&h(c.prototype,f),h(s.gm,f)),t.on(u+"-start",function(e,t){var n=e[1];if(null!==n&&("function"==typeof n||"object"==typeof n)&&"newrelic"!==e[0]){var i=(0,o.I)(n,l,function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=e[1]=i}}),t.on(d+"-start",function(e){e[1]=this.wrapped||e[1]}),t}function h(e,t,...r){let n=e;for(;"object"==typeof n&&!Object.prototype.hasOwnProperty.call(n,u);)n=Object.getPrototypeOf(n);n&&t(n,...r)}},8154:(e,t,r)=>{"use strict";r.d(t,{z_:()=>o,XG:()=>a,TZ:()=>n,rs:()=>i,xV:()=>s});r(6154),r(9566),r(384);const n=r(860).K7.metrics,i="sm",o="cm",s="storeSupportabilityMetrics",a="storeEventMetrics"},8374:(e,t,r)=>{r.nc=(()=>{try{return document?.currentScript?.nonce}catch(e){}return""})()},8990:(e,t,r)=>{"use strict";r.d(t,{I:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},9300:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.ajax},9324:(e,t,r)=>{"use strict";r.d(t,{AJ:()=>s,F3:()=>i,Xs:()=>o,Yq:()=>a,xv:()=>n});const n="1.303.0",i="PROD",o="CDN",s="@newrelic/rrweb",a="1.0.1"},9566:(e,t,r)=>{"use strict";r.d(t,{LA:()=>a,ZF:()=>c,bz:()=>s,el:()=>u});var n=r(6154);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function s(){const e=n.gm?.crypto||n.gm?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(30))),i.split("").map(e=>"x"===e?o(t,r++).toString(16):"y"===e?(3&o()|8).toString(16):e).join("")}function a(e){const t=n.gm?.crypto||n.gm?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(e)));const s=[];for(var a=0;a<e;a++)s.push(o(r,i++).toString(16));return s.join("")}function c(){return a(16)}function u(){return a(32)}},9908:(e,t,r)=>{"use strict";r.d(t,{d:()=>n,p:()=>i});var n=r(7836).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce((t,r)=>(i.f[r](e,t),t),[])),i.u=e=>({212:"nr-spa-compressor",249:"nr-spa-recorder",478:"nr-spa"}[e]+"-1.303.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.303.0.PROD:",i.l=(r,n,o,s)=>{if(e[r])e[r].push(n);else{var a,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d<u.length;d++){var l=u[d];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+o){a=l;break}}if(!a){c=!0;var f={478:"sha512-Q1pLqcoiNmLHv0rtq3wFkJBA3kofBdRJl0ExDl0mTuAoCBd0qe/1J0XWrDlQKuNlUryL6aZfVkAMPLmoikWIoQ==",249:"sha512-695ZzudsxlMtHKnpDNvkMlJd3tdMtY03IQKVCw9SX12tjUC+f7Nrx5tnWO72Vg9RFf6DSY6wVmM3cEkRM12kkQ==",212:"sha512-18Gx1wIBsppcn0AnKFhwgw4IciNgFxiw3J74W393Ape+wtg4hlg7t6SBKsIE/Dk/tfl2yltgcgBFvYRs283AFg=="};(a=document.createElement("script")).charset="utf-8",i.nc&&a.setAttribute("nonce",i.nc),a.setAttribute("data-webpack",t+o),a.src=r,0!==a.src.indexOf(window.location.origin+"/")&&(a.crossOrigin="anonymous"),f[s]&&(a.integrity=f[s])}e[r]=[n];var h=(t,n)=>{a.onerror=a.onload=null,clearTimeout(p);var i=e[r];if(delete e[r],a.parentNode&&a.parentNode.removeChild(a),i&&i.forEach(e=>e(n)),t)return t(n)},p=setTimeout(h.bind(null,void 0,{type:"timeout",target:a}),12e4);a.onerror=h.bind(null,a.onerror),a.onload=h.bind(null,a.onload),c&&document.head.appendChild(a)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=>{var e={38:0,788:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise((r,i)=>n=e[t]=[r,i]);r.push(n[2]=o);var s=i.p+i.u(t),a=new Error;i.l(s,r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),s=r&&r.target&&r.target.src;a.message="Loading chunk "+t+" failed.\n("+o+": "+s+")",a.name="ChunkLoadError",a.type=o,a.request=s,n[1](a)}},"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[s,a,c]=r,u=0;if(s.some(t=>0!==e[t])){for(n in a)i.o(a,n)&&(i.m[n]=a[n]);if(c)c(i)}for(t&&t(r);u<s.length;u++)o=s[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=self["webpackChunk:NRBA-1.303.0.PROD"]=self["webpackChunk:NRBA-1.303.0.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=>{"use strict";i(8374);var e=i(9566),t=i(1741);class r extends t.W{agentIdentifier=(0,e.LA)(16)}var n=i(860);const o=Object.values(n.K7);var s=i(5205);var a=i(9908),c=i(1863),u=i(4261),d=i(3241),l=i(944),f=i(5701),h=i(8154);function p(e,t,i,o){const s=o||i;!s||s[e]&&s[e]!==r.prototype[e]||(s[e]=function(){(0,a.p)(h.xV,["API/"+e+"/called"],void 0,n.K7.metrics,i.ee),(0,d.W)({agentIdentifier:i.agentIdentifier,drained:!!f.B?.[i.agentIdentifier],type:"data",name:"api",feature:u.Pl+e,data:{}});try{return t.apply(this,arguments)}catch(e){(0,l.R)(23,e)}})}function g(e,t,r,n,i){const o=e.info;null===r?delete o.jsAttributes[t]:o.jsAttributes[t]=r,(i||null===r)&&(0,a.p)(u.Pl+n,[(0,c.t)(),t,r],void 0,"session",e.ee)}var m=i(1687),v=i(4234),b=i(5289),y=i(6154),w=i(5270),R=i(7767),x=i(6389),T=i(7699);class E extends v.W{constructor(e,t){super(e.agentIdentifier,t),this.agentRef=e,this.abortHandler=void 0,this.featAggregate=void 0,this.loadedSuccessfully=void 0,this.onAggregateImported=new Promise(e=>{this.loadedSuccessfully=e}),this.deferred=Promise.resolve(),!1===e.init[this.featureName].autoStart?this.deferred=new Promise((t,r)=>{this.ee.on("manual-start-all",(0,x.J)(()=>{(0,m.Ak)(e.agentIdentifier,this.featureName),t()}))}):(0,m.Ak)(e.agentIdentifier,t)}importAggregator(e,t,r={}){if(this.featAggregate)return;const n=async()=>{let n;await this.deferred;try{if((0,R.V)(e.init)){const{setupAgentSession:t}=await i.e(478).then(i.bind(i,8766));n=t(e)}}catch(e){(0,l.R)(20,e),this.ee.emit("internal-error",[e]),(0,a.p)(T.qh,[e],void 0,this.featureName,this.ee)}try{if(!this.#t(this.featureName,n,e.init))return(0,m.Ze)(this.agentIdentifier,this.featureName),void this.loadedSuccessfully(!1);const{Aggregate:i}=await t();this.featAggregate=new i(e,r),e.runtime.harvester.initializedAggregates.push(this.featAggregate),this.loadedSuccessfully(!0)}catch(e){(0,l.R)(34,e),this.abortHandler?.(),(0,m.Ze)(this.agentIdentifier,this.featureName,!0),this.loadedSuccessfully(!1),this.ee&&this.ee.abort()}};y.RI?(0,b.GG)(()=>n(),!0):n()}#t(e,t,r){if(this.blocked)return!1;switch(e){case n.K7.sessionReplay:return(0,w.SR)(r)&&!!t;case n.K7.sessionTrace:return!!t;default:return!0}}}var A=i(6630),S=i(2614);class _ extends E{static featureName=A.T;constructor(e){var t;super(e,A.T),this.setupInspectionEvents(e.agentIdentifier),t=e,p(u.Fw,function(e,r){"string"==typeof e&&("/"!==e.charAt(0)&&(e="/"+e),t.runtime.customTransaction=(r||"http://custom.transaction")+e,(0,a.p)(u.Pl+u.Fw,[(0,c.t)()],void 0,void 0,t.ee))},t),this.importAggregator(e,()=>i.e(478).then(i.bind(i,1983)))}setupInspectionEvents(e){const t=(t,r)=>{t&&(0,d.W)({agentIdentifier:e,timeStamp:t.timeStamp,loaded:"complete"===t.target.readyState,type:"window",name:r,data:t.target.location+""})};(0,b.sB)(e=>{t(e,"DOMContentLoaded")}),(0,b.GG)(e=>{t(e,"load")}),(0,b.Qr)(e=>{t(e,"navigate")}),this.ee.on(S.tS.UPDATE,(t,r)=>{(0,d.W)({agentIdentifier:e,type:"lifecycle",name:"session",data:r})})}}var O=i(384);var N=i(2843),I=i(3878),P=i(782);class j extends E{static featureName=P.T;constructor(e){super(e,P.T),y.RI&&((0,N.u)(()=>(0,a.p)("docHidden",[(0,c.t)()],void 0,P.T,this.ee),!0),(0,I.sp)("pagehide",()=>(0,a.p)("winPagehide",[(0,c.t)()],void 0,P.T,this.ee)),this.importAggregator(e,()=>i.e(478).then(i.bind(i,9917))))}}class k extends E{static featureName=h.TZ;constructor(e){super(e,h.TZ),y.RI&&document.addEventListener("securitypolicyviolation",e=>{(0,a.p)(h.xV,["Generic/CSPViolation/Detected"],void 0,this.featureName,this.ee)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,6555)))}}var C=i(6774),L=i(3304);class H{constructor(e,t,r,n,i){this.name="UncaughtError",this.message="string"==typeof e?e:(0,L.A)(e),this.sourceURL=t,this.line=r,this.column=n,this.__newrelic=i}}function M(e){return U(e)?e:new H(void 0!==e?.message?e.message:e,e?.filename||e?.sourceURL,e?.lineno||e?.line,e?.colno||e?.col,e?.__newrelic,e?.cause)}function K(e){const t="Unhandled Promise Rejection: ";if(!e?.reason)return;if(U(e.reason)){try{e.reason.message.startsWith(t)||(e.reason.message=t+e.reason.message)}catch(e){}return M(e.reason)}const r=M(e.reason);return(r.message||"").startsWith(t)||(r.message=t+r.message),r}function D(e){if(e.error instanceof SyntaxError&&!/:\d+$/.test(e.error.stack?.trim())){const t=new H(e.message,e.filename,e.lineno,e.colno,e.error.__newrelic,e.cause);return t.name=SyntaxError.name,t}return U(e.error)?e.error:M(e)}function U(e){return e instanceof Error&&!!e.stack}function F(e,t,r,i,o=(0,c.t)()){"string"==typeof e&&(e=new Error(e)),(0,a.p)("err",[e,o,!1,t,r.runtime.isRecording,void 0,i],void 0,n.K7.jserrors,r.ee),(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,r.ee)}var W=i(4387),B=i(993),V=i(3785);function G(e,{customAttributes:t={},level:r=B.p_.INFO}={},n,i,o=(0,c.t)()){(0,V.R)(n.ee,e,t,r,i,o)}function z(e,t,r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.hG,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function Z(e,t,r,i,o=(0,c.t)()){const{start:s,end:d,customAttributes:f}=t||{},h={customAttributes:f||{}};if("object"!=typeof h.customAttributes||"string"!=typeof e||0===e.length)return void(0,l.R)(57);const p=(e,t)=>null==e?t:"number"==typeof e?e:e instanceof PerformanceMark?e.startTime:Number.NaN;if(h.start=p(s,0),h.end=p(d,o),Number.isNaN(h.start)||Number.isNaN(h.end))(0,l.R)(57);else{if(h.duration=h.end-h.start,!(h.duration<0))return(0,a.p)(u.Pl+u.V1,[h,e,i],void 0,n.K7.genericEvents,r.ee),h;(0,l.R)(58)}}function q(e,t={},r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.fF,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function X(e){p(u.eY,function(t){return Y(e,t)},e)}function Y(e,t,r){const i={};(0,l.R)(54,"newrelic.register"),t||={},t.eventSource="MicroFrontendBrowserAgent",t.licenseKey||=e.info.licenseKey,t.blocked=!1,t.parent=r||{};let o=()=>{};const s=e.runtime.registeredEntities,u=s.find(({metadata:{target:{id:e,name:r}}})=>e===t.id);if(u)return u.metadata.target.name!==t.name&&(u.metadata.target.name=t.name),u;const d=e=>{t.blocked=!0,o=e};e.init.api.allow_registered_children||d((0,x.J)(()=>(0,l.R)(55))),(0,W.c7)(t)||d((0,x.J)(()=>(0,l.R)(48,t))),(0,W.yo)(t.id)&&(0,W.yo)(t.name)||d((0,x.J)(()=>(0,l.R)(48,t)));const f={addPageAction:(r,n={})=>m(z,[r,{...i,...n},e],t),log:(r,n={})=>m(G,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),measure:(r,n={})=>m(Z,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),noticeError:(r,n={})=>m(F,[r,{...i,...n},e],t),register:(t={})=>m(Y,[e,t],f.metadata.target),recordCustomEvent:(r,n={})=>m(q,[r,{...i,...n},e],t),setApplicationVersion:e=>g("application.version",e),setCustomAttribute:(e,t)=>g(e,t),setUserId:e=>g("enduser.id",e),metadata:{customAttributes:i,target:t}},p=()=>(t.blocked&&o(),t.blocked);p()||s.push(f);const g=(e,t)=>{p()||(i[e]=t)},m=(t,r,i)=>{if(p())return;const o=(0,c.t)();(0,a.p)(h.xV,["API/register/".concat(t.name,"/called")],void 0,n.K7.metrics,e.ee);try{return e.init.api.duplicate_registered_data&&"register"!==t.name&&t(...r,void 0,o),t(...r,i,o)}catch(e){(0,l.R)(50,e)}};return f}class J extends E{static featureName=C.T;constructor(e){var t;super(e,C.T),t=e,p(u.o5,(e,r)=>F(e,r,t),t),function(e){p(u.bt,function(t){e.runtime.onerror=t},e)}(e),function(e){let t=0;p(u.k6,function(e,r){++t>10||(this.runtime.releaseIds[e.slice(-200)]=(""+r).slice(-200))},e)}(e),X(e);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("internal-error",(t,r)=>{this.abortHandler&&(0,a.p)("ierr",[M(t),(0,c.t)(),!0,{},e.runtime.isRecording,r],void 0,this.featureName,this.ee)}),y.gm.addEventListener("unhandledrejection",t=>{this.abortHandler&&(0,a.p)("err",[K(t),(0,c.t)(),!1,{unhandledPromiseRejection:1},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),y.gm.addEventListener("error",t=>{this.abortHandler&&(0,a.p)("err",[D(t),(0,c.t)(),!1,{},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,2176)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var Q=i(8990);let ee=1;function te(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===y.gm?0:(0,Q.I)(e,"nr@id",function(){return ee++})}function re(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,L.A)(e).length}catch(e){return}}}var ne=i(8139),ie=i(7836),oe=i(3434);const se={},ae=["open","send"];function ce(e){var t=e||ie.ee;const r=function(e){return(e||ie.ee).get("xhr")}(t);if(void 0===y.gm.XMLHttpRequest)return r;if(se[r.debugId]++)return r;se[r.debugId]=1,(0,ne.u)(t);var n=(0,oe.YM)(r),i=y.gm.XMLHttpRequest,o=y.gm.MutationObserver,s=y.gm.Promise,a=y.gm.setInterval,c="readystatechange",u=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],d=[],f=y.gm.XMLHttpRequest=function(e){const t=new i(e),o=r.context(t);try{r.emit("new-xhr",[t],o),t.addEventListener(c,(s=o,function(){var e=this;e.readyState>3&&!s.resolved&&(s.resolved=!0,r.emit("xhr-resolved",[],e)),n.inPlace(e,u,"fn-",b)}),(0,I.jT)(!1))}catch(e){(0,l.R)(15,e);try{r.emit("internal-error",[e])}catch(e){}}var s;return t};function h(e,t){n.inPlace(t,["onreadystatechange"],"fn-",b)}if(function(e,t){for(var r in e)t[r]=e[r]}(i,f),f.prototype=i.prototype,n.inPlace(f.prototype,ae,"-xhr-",b),r.on("send-xhr-start",function(e,t){h(e,t),function(e){d.push(e),o&&(p?p.then(v):a?a(v):(g=-g,m.data=g))}(t)}),r.on("open-xhr-start",h),o){var p=s&&s.resolve();if(!a&&!s){var g=1,m=document.createTextNode(g);new o(v).observe(m,{characterData:!0})}}else t.on("fn-end",function(e){e[0]&&e[0].type===c||v()});function v(){for(var e=0;e<d.length;e++)h(0,d[e]);d.length&&(d=[])}function b(e,t){return t}return r}var ue="fetch-",de=ue+"body-",le=["arrayBuffer","blob","json","text","formData"],fe=y.gm.Request,he=y.gm.Response,pe="prototype";const ge={};function me(e){const t=function(e){return(e||ie.ee).get("fetch")}(e);if(!(fe&&he&&y.gm.fetch))return t;if(ge[t.debugId]++)return t;function r(e,r,n){var i=e[r];"function"==typeof i&&(e[r]=function(){var e,r=[...arguments],o={};t.emit(n+"before-start",[r],o),o[ie.P]&&o[ie.P].dt&&(e=o[ie.P].dt);var s=i.apply(this,r);return t.emit(n+"start",[r,e],s),s.then(function(e){return t.emit(n+"end",[null,e],s),e},function(e){throw t.emit(n+"end",[e],s),e})})}return ge[t.debugId]=1,le.forEach(e=>{r(fe[pe],e,de),r(he[pe],e,de)}),r(y.gm,"fetch",ue),t.on(ue+"end",function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(ue+"done",[null,r],n)}else t.emit(ue+"done",[e],n)}),t}var ve=i(7485);class be{constructor(e){this.agentRef=e}generateTracePayload(t){const r=this.agentRef.loader_config;if(!this.shouldGenerateTrace(t)||!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var s=(0,e.ZF)(),a=(0,e.el)(),c=Date.now(),u={spanId:s,traceId:a,timestamp:c};return(t.sameOrigin||this.isAllowedOrigin(t)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(s,a),u.traceContextStateHeader=this.generateTraceContextStateHeader(s,c,n,i,o)),(t.sameOrigin&&!this.excludeNewrelicHeader()||!t.sameOrigin&&this.isAllowedOrigin(t)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(s,a,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof y.gm?.btoa))return null;var s={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(s.d.tk=o),btoa((0,L.A)(s))}shouldGenerateTrace(e){return this.agentRef.init?.distributed_tracing?.enabled&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1;const r=this.agentRef.init?.distributed_tracing;if(e.sameOrigin)t=!0;else if(r?.allowed_origins instanceof Array)for(var n=0;n<r.allowed_origins.length;n++){var i=(0,ve.D)(r.allowed_origins[n]);if(e.hostname===i.hostname&&e.protocol===i.protocol&&e.port===i.port){t=!0;break}}return t}excludeNewrelicHeader(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.cors_use_tracecontext_headers}}var ye=i(9300),we=i(7295);function Re(e){return"string"==typeof e?e:e instanceof(0,O.dV)().o.REQ?e.url:y.gm?.URL&&e instanceof URL?e.href:void 0}var xe=["load","error","abort","timeout"],Te=xe.length,Ee=(0,O.dV)().o.REQ,Ae=(0,O.dV)().o.XHR;const Se="X-NewRelic-App-Data";class _e extends E{static featureName=ye.T;constructor(e){super(e,ye.T),this.dt=new be(e),this.handler=(e,t,r,n)=>(0,a.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};y.gm?.performance?.getEntriesByType("resource").forEach(t=>{if(t.initiatorType in e&&0!==t.responseStatus){const r={status:t.responseStatus},i={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};Oe(r,t.name),this.handler("xhr",[r,i,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,n.K7.ajax)}})}catch(e){}me(this.ee),ce(this.ee),function(e,t,r,i){function o(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},t.latestLongtaskEnd=0,e.addEventListener("load",function(r){A(t,e)},(0,I.jT)(!1)),y.lR||e.addEventListener("progress",function(e){t.lastSize=e.loaded},(0,I.jT)(!1))}function s(e){this.params={method:e[0]},Oe(this,e[1]),this.metrics={}}function u(t,r){e.loader_config.xpid&&this.sameOrigin&&r.setRequestHeader("X-NewRelic-ID",e.loader_config.xpid);var n=i.generateTracePayload(this.parsedOrigin);if(n){var o=!1;n.newrelicHeader&&(r.setRequestHeader("newrelic",n.newrelicHeader),o=!0),n.traceContextParentHeader&&(r.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&r.setRequestHeader("tracestate",n.traceContextStateHeader),o=!0),o&&(this.dt=n)}}function d(e,r){var n=this.metrics,i=e[0],o=this;if(n&&i){var s=re(i);s&&(n.txSize=s)}this.startTime=(0,c.t)(),this.body=i,this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof r.onload)&&"function"==typeof o.end)&&o.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var a=0;a<Te;a++)r.addEventListener(xe[a],this.listener,(0,I.jT)(!1))}function l(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function f(e,t){var r=""+te(e)+!!t;this.xhrGuids&&!this.xhrGuids[r]&&(this.xhrGuids[r]=!0,this.totalCbs+=1)}function p(e,t){var r=""+te(e)+!!t;this.xhrGuids&&this.xhrGuids[r]&&(delete this.xhrGuids[r],this.totalCbs-=1)}function g(){this.endTime=(0,c.t)()}function m(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-added",[e[1],e[2]],r)}function v(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-removed",[e[1],e[2]],r)}function b(e,t,r){t instanceof Ae&&("onload"===r&&(this.onload=!0),("load"===(e[0]&&e[0].type)||this.onload)&&(this.xhrCbStart=(0,c.t)()))}function w(e,r){this.xhrCbStart&&t.emit("xhr-cb-time",[(0,c.t)()-this.xhrCbStart,this.onload,r],r)}function R(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&&y.RI&&(t=""+y.gm.location.href):e[0]&&e[0].url?t=e[0].url:y.gm?.URL&&e[0]&&e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&&(t=e[0].toString()),"string"==typeof t&&0!==t.length){t&&(this.parsedOrigin=(0,ve.D)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var n=i.generateTracePayload(this.parsedOrigin);if(n&&(n.newrelicHeader||n.traceContextParentHeader))if(e[0]&&e[0].headers)a(e[0].headers,n)&&(this.dt=n);else{var o={};for(var s in r)o[s]=r[s];o.headers=new Headers(r.headers||{}),a(o.headers,n)&&(this.dt=n),e.length>1?e[1]=o:e.push(o)}}function a(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,c.t)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r=this.opts||{},n=this.target;Oe(this,Re(n));var i=(""+(n&&n instanceof Ee&&n.method||r.method||"GET")).toUpperCase();this.params.method=i,this.body=r.body,this.txSize=re(r.body)||0}function T(e,t){if(this.endTime=(0,c.t)(),this.params||(this.params={}),(0,we.iW)(this.params))return;let i;this.params.status=t?t.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(i=+this.rxSize);const o={txSize:this.txSize,rxSize:i,duration:(0,c.t)()-this.startTime};r("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,n.K7.ajax)}function E(e){const t=this.params,i=this.metrics;if(!this.ended){this.ended=!0;for(let t=0;t<Te;t++)e.removeEventListener(xe[t],this.listener,!1);t.aborted||(0,we.iW)(t)||(i.duration=(0,c.t)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&&(t.status=0):A(this,e),i.cbTime=this.cbTime,r("xhr",[t,i,this.startTime,this.endTime,"xhr"],this,n.K7.ajax))}}function A(e,r){e.params.status=r.status;var i=function(e,t){var r=e.responseType;return"json"===r&&null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?re(e.response):"text"===r||""===r||void 0===r?re(e.responseText):void 0}(r,e.lastSize);if(i&&(e.metrics.rxSize=i),e.sameOrigin&&r.getAllResponseHeaders().indexOf(Se)>=0){var o=r.getResponseHeader(Se);o&&((0,a.p)(h.rs,["Ajax/CrossApplicationTracing/Header/Seen"],void 0,n.K7.metrics,t),e.params.cat=o.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",o),t.on("open-xhr-start",s),t.on("open-xhr-end",u),t.on("send-xhr-start",d),t.on("xhr-cb-time",l),t.on("xhr-load-added",f),t.on("xhr-load-removed",p),t.on("xhr-resolved",g),t.on("addEventListener-end",m),t.on("removeEventListener-end",v),t.on("fn-end",w),t.on("fetch-before-start",R),t.on("fetch-start",x),t.on("fn-start",b),t.on("fetch-done",T)}(e,this.ee,this.handler,this.dt),this.importAggregator(e,()=>i.e(478).then(i.bind(i,3845)))}}function Oe(e,t){var r=(0,ve.D)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}const Ne={},Ie=["pushState","replaceState"];function Pe(e){const t=function(e){return(e||ie.ee).get("history")}(e);return!y.RI||Ne[t.debugId]++||(Ne[t.debugId]=1,(0,oe.YM)(t).inPlace(window.history,Ie,"-")),t}var je=i(3738);function ke(e){p(u.BL,function(t=Date.now()){const r=t-y.WN;r<0&&(0,l.R)(62,t),(0,a.p)(h.XG,[u.BL,{time:r}],void 0,n.K7.metrics,e.ee),e.addToTrace({name:u.BL,start:t,origin:"nr"}),(0,a.p)(u.Pl+u.hG,[r,u.BL],void 0,n.K7.genericEvents,e.ee)},e)}const{He:Ce,bD:Le,d3:He,Kp:Me,TZ:Ke,Lc:De,uP:Ue,Rz:Fe}=je;class We extends E{static featureName=Ke;constructor(e){var t;super(e,Ke),t=e,p(u.U2,function(e){if(!(e&&"object"==typeof e&&e.name&&e.start))return;const r={n:e.name,s:e.start-y.WN,e:(e.end||e.start)-y.WN,o:e.origin||"",t:"api"};r.s<0||r.e<0||r.e<r.s?(0,l.R)(61,{start:r.s,end:r.e}):(0,a.p)("bstApi",[r],void 0,n.K7.sessionTrace,t.ee)},t),ke(e);if(!(0,R.V)(e.init))return void this.deregisterDrain();const r=this.ee;let o;Pe(r),this.eventsEE=(0,ne.u)(r),this.eventsEE.on(Ue,function(e,t){this.bstStart=(0,c.t)()}),this.eventsEE.on(De,function(e,t){(0,a.p)("bst",[e[0],t,this.bstStart,(0,c.t)()],void 0,n.K7.sessionTrace,r)}),r.on(Fe+He,function(e){this.time=(0,c.t)(),this.startPath=location.pathname+location.hash}),r.on(Fe+Me,function(e){(0,a.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,n.K7.sessionTrace,r)});try{o=new PerformanceObserver(e=>{const t=e.getEntries();(0,a.p)(Ce,[t],void 0,n.K7.sessionTrace,r)}),o.observe({type:Le,buffered:!0})}catch(e){}this.importAggregator(e,()=>i.e(478).then(i.bind(i,6974)),{resourceObserver:o})}}var Be=i(6344);class Ve extends E{static featureName=Be.TZ;#n;recorder;constructor(e){var t;let r;super(e,Be.TZ),t=e,p(u.CH,function(){(0,a.p)(u.CH,[],void 0,n.K7.sessionReplay,t.ee)},t),function(e){p(u.Tb,function(){(0,a.p)(u.Tb,[],void 0,n.K7.sessionReplay,e.ee)},e)}(e);try{r=JSON.parse(localStorage.getItem("".concat(S.H3,"_").concat(S.uh)))}catch(e){}(0,w.SR)(e.init)&&this.ee.on(u.CH,()=>this.#i()),this.#o(r)&&this.importRecorder().then(e=>{e.startRecording(Be.Qb.PRELOAD,r?.sessionReplayMode)}),this.importAggregator(this.agentRef,()=>i.e(478).then(i.bind(i,6167)),this),this.ee.on("err",e=>{this.blocked||this.agentRef.runtime.isRecording&&(this.errorNoticed=!0,(0,a.p)(Be.Vh,[e],void 0,this.featureName,this.ee))})}#o(e){return e&&(e.sessionReplayMode===S.g.FULL||e.sessionReplayMode===S.g.ERROR)||(0,w.Aw)(this.agentRef.init)}importRecorder(){return this.recorder?Promise.resolve(this.recorder):(this.#n??=Promise.all([i.e(478),i.e(249)]).then(i.bind(i,4866)).then(({Recorder:e})=>(this.recorder=new e(this),this.recorder)).catch(e=>{throw this.ee.emit("internal-error",[e]),this.blocked=!0,e}),this.#n)}#i(){this.blocked||(this.featAggregate?this.featAggregate.mode!==S.g.FULL&&this.featAggregate.initializeRecording(S.g.FULL,!0,Be.Qb.API):this.importRecorder().then(()=>{this.recorder.startRecording(Be.Qb.API,S.g.FULL)}))}}var Ge=i(3962);function ze(e){const t=e.ee.get("tracer");function r(){}p(u.dT,function(e){return(new r).get("object"==typeof e?e:{})},e);const i=r.prototype={createTracer:function(r,i){var o={},s=this,d="function"==typeof i;return(0,a.p)(h.xV,["API/createTracer/called"],void 0,n.K7.metrics,e.ee),e.runSoftNavOverSpa||(0,a.p)(u.hw+"tracer",[(0,c.t)(),r,o],s,n.K7.spa,e.ee),function(){if(t.emit((d?"":"no-")+"fn-start",[(0,c.t)(),s,d],o),d)try{return i.apply(this,arguments)}catch(e){const r="string"==typeof e?new Error(e):e;throw t.emit("fn-err",[arguments,this,r],o),r}finally{t.emit("fn-end",[(0,c.t)()],o)}}}};["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach(t=>{p.apply(this,[t,function(){return(0,a.p)(u.hw+t,[(0,c.t)(),...arguments],this,e.runSoftNavOverSpa?n.K7.softNav:n.K7.spa,e.ee),this},e,i])}),p(u.PA,function(){e.runSoftNavOverSpa?(0,a.p)(u.hw+"routeName",[performance.now(),...arguments],void 0,n.K7.softNav,e.ee):(0,a.p)(u.Pl+"routeName",[(0,c.t)(),...arguments],this,n.K7.spa,e.ee)},e)}class Ze extends E{static featureName=Ge.TZ;constructor(e){if(super(e,Ge.TZ),ze(e),!y.RI||!(0,O.dV)().o.MO)return;const t=Pe(this.ee);try{this.removeOnAbort=new AbortController}catch(e){}Ge.tC.forEach(e=>{(0,I.sp)(e,e=>{s(e)},!0,this.removeOnAbort?.signal)});const r=()=>(0,a.p)("newURL",[(0,c.t)(),""+window.location],void 0,this.featureName,this.ee);t.on("pushState-end",r),t.on("replaceState-end",r),(0,I.sp)(Ge.OV,e=>{s(e),(0,a.p)("newURL",[e.timeStamp,""+window.location],void 0,this.featureName,this.ee)},!0,this.removeOnAbort?.signal);let n=!1;const o=new((0,O.dV)().o.MO)((e,t)=>{n||(n=!0,requestAnimationFrame(()=>{(0,a.p)("newDom",[(0,c.t)()],void 0,this.featureName,this.ee),n=!1}))}),s=(0,x.s)(e=>{(0,a.p)("newUIEvent",[e],void 0,this.featureName,this.ee),o.observe(document.body,{attributes:!0,childList:!0,subtree:!0,characterData:!0})},100,{leading:!0});this.abortHandler=function(){this.removeOnAbort?.abort(),o.disconnect(),this.abortHandler=void 0},this.importAggregator(e,()=>i.e(478).then(i.bind(i,4393)),{domObserver:o})}}var qe=i(7378);const Xe={},Ye=["appendChild","insertBefore","replaceChild"];function Je(e){const t=function(e){return(e||ie.ee).get("jsonp")}(e);if(!y.RI||Xe[t.debugId])return t;Xe[t.debugId]=!0;var r=(0,oe.YM)(t),n=/[?&](?:callback|cb)=([^&#]+)/,i=/(.*)\.([^.]+)/,o=/^(\w+)(\.|$)(.*)$/;function s(e,t){if(!e)return t;const r=e.match(o),n=r[1];return s(r[3],t[n])}return r.inPlace(Node.prototype,Ye,"dom-"),t.on("dom-start",function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var o=(a=e.src,c=a.match(n),c?c[1]:null);var a,c;if(!o)return;var u=function(e){var t=e.match(i);if(t&&t.length>=3)return{key:t[2],parent:s(t[1],window)};return{key:e,parent:window}}(o);if("function"!=typeof u.parent[u.key])return;var d={};function l(){t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}function f(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",l,(0,I.jT)(!1)),e.addEventListener("error",f,(0,I.jT)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])}),t}const $e={};function Qe(e){const t=function(e){return(e||ie.ee).get("promise")}(e);if($e[t.debugId])return t;$e[t.debugId]=!0;var r=t.context,n=(0,oe.YM)(t),i=y.gm.Promise;return i&&function(){function e(r){var o=t.context(),s=n(r,"executor-",o,null,!1);const a=Reflect.construct(i,[s],e);return t.context(a).getCtx=function(){return o},a}y.gm.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return i.toString()},Object.setPrototypeOf(e,i),["all","race"].forEach(function(r){const n=i[r];e[r]=function(e){let i=!1;[...e||[]].forEach(e=>{this.resolve(e).then(s("all"===r),s(!1))});const o=n.apply(this,arguments);return o;function s(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}}),["resolve","reject"].forEach(function(r){const n=i[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}}),e.prototype=i.prototype;const o=i.prototype.then;i.prototype.then=function(...e){var i=this,s=r(i);s.promise=i,e[0]=n(e[0],"cb-",s,null,!1),e[1]=n(e[1],"cb-",s,null,!1);const a=o.apply(this,e);return s.nextPromise=a,t.emit("propagate",[i,!0],a,!1,!1),a},i.prototype.then[oe.Jt]=o,t.on("executor-start",function(e){e[0]=n(e[0],"resolve-",this,null,!1),e[1]=n(e[1],"resolve-",this,null,!1)}),t.on("executor-err",function(e,t,r){e[1](r)}),t.on("cb-end",function(e,r,n){t.emit("propagate",[n,!0],this.nextPromise,!1,!1)}),t.on("propagate",function(e,r,n){if(!this.getCtx||r){const r=this,n=e instanceof Promise?t.context(e):null;let i;this.getCtx=function(){return i||(i=n&&n!==r?"function"==typeof n.getCtx?n.getCtx():n:r,i)}}})}(),t}const et={},tt="setTimeout",rt="setInterval",nt="clearTimeout",it="-start",ot=[tt,"setImmediate",rt,nt,"clearImmediate"];function st(e){const t=function(e){return(e||ie.ee).get("timer")}(e);if(et[t.debugId]++)return t;et[t.debugId]=1;var r=(0,oe.YM)(t);return r.inPlace(y.gm,ot.slice(0,2),tt+"-"),r.inPlace(y.gm,ot.slice(2,3),rt+"-"),r.inPlace(y.gm,ot.slice(3),nt+"-"),t.on(rt+it,function(e,t,n){e[0]=r(e[0],"fn-",null,n)}),t.on(tt+it,function(e,t,n){this.method=n,this.timerDuration=isNaN(e[1])?0:+e[1],e[0]=r(e[0],"fn-",this,n)}),t}const at={};function ct(e){const t=function(e){return(e||ie.ee).get("mutation")}(e);if(!y.RI||at[t.debugId])return t;at[t.debugId]=!0;var r=(0,oe.YM)(t),n=y.gm.MutationObserver;return n&&(window.MutationObserver=function(e){return this instanceof n?new n(r(e,"fn-")):n.apply(this,arguments)},MutationObserver.prototype=n.prototype),t}const{TZ:ut,d3:dt,Kp:lt,$p:ft,wW:ht,e5:pt,tH:gt,uP:mt,rw:vt,Lc:bt}=qe;class yt extends E{static featureName=ut;constructor(e){if(super(e,ut),ze(e),!y.RI)return;try{this.removeOnAbort=new AbortController}catch(e){}let t,r=0;const n=this.ee.get("tracer"),o=Je(this.ee),s=Qe(this.ee),u=st(this.ee),d=ce(this.ee),l=this.ee.get("events"),f=me(this.ee),h=Pe(this.ee),p=ct(this.ee);function g(e,t){h.emit("newURL",[""+window.location,t])}function m(){r++,t=window.location.hash,this[mt]=(0,c.t)()}function v(){r--,window.location.hash!==t&&g(0,!0);var e=(0,c.t)();this[pt]=~~this[pt]+e-this[mt],this[bt]=e}function b(e,t){e.on(t,function(){this[t]=(0,c.t)()})}this.ee.on(mt,m),s.on(vt,m),o.on(vt,m),this.ee.on(bt,v),s.on(ht,v),o.on(ht,v),this.ee.on("fn-err",(...t)=>{t[2]?.__newrelic?.[e.agentIdentifier]||(0,a.p)("function-err",[...t],void 0,this.featureName,this.ee)}),this.ee.buffer([mt,bt,"xhr-resolved"],this.featureName),l.buffer([mt],this.featureName),u.buffer(["setTimeout"+lt,"clearTimeout"+dt,mt],this.featureName),d.buffer([mt,"new-xhr","send-xhr"+dt],this.featureName),f.buffer([gt+dt,gt+"-done",gt+ft+dt,gt+ft+lt],this.featureName),h.buffer(["newURL"],this.featureName),p.buffer([mt],this.featureName),s.buffer(["propagate",vt,ht,"executor-err","resolve"+dt],this.featureName),n.buffer([mt,"no-"+mt],this.featureName),o.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),b(f,gt+dt),b(f,gt+"-done"),b(o,"new-jsonp"),b(o,"jsonp-end"),b(o,"cb-start"),h.on("pushState-end",g),h.on("replaceState-end",g),window.addEventListener("hashchange",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",function(){g(0,r>1)},(0,I.jT)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,5592)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var wt=i(3333);class Rt extends E{static featureName=wt.TZ;constructor(e){super(e,wt.TZ);const t=[e.init.page_action.enabled,e.init.performance.capture_marks,e.init.performance.capture_measures,e.init.user_actions.enabled,e.init.performance.resources.enabled];var r;r=e,p(u.hG,(e,t)=>z(e,t,r),r),function(e){p(u.fF,(t,r)=>q(t,r,e),e)}(e),ke(e),X(e),function(e){p(u.V1,(t,r)=>Z(t,r,e),e)}(e);const o=e.init.feature_flags.includes("user_frustrations");let s;if(y.RI&&o&&(me(this.ee),ce(this.ee),s=Pe(this.ee)),y.RI){if(e.init.user_actions.enabled&&(wt.Zp.forEach(e=>(0,I.sp)(e,e=>(0,a.p)("ua",[e],void 0,this.featureName,this.ee),!0)),wt.qN.forEach(e=>{const t=(0,x.s)(e=>{(0,a.p)("ua",[e],void 0,this.featureName,this.ee)},500,{leading:!0});(0,I.sp)(e,t)}),o)){function c(t){const r=(0,ve.D)(t);return e.beacons.includes(r.hostname+":"+r.port)}function d(){s.emit("navChange")}y.gm.addEventListener("error",()=>{(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.ee.on("open-xhr-start",(e,t)=>{c(e[1])||t.addEventListener("readystatechange",()=>{2===t.readyState&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)})}),this.ee.on("fetch-start",e=>{e.length>=1&&!c(Re(e[0]))&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)}),s.on("pushState-end",d),s.on("replaceState-end",d),window.addEventListener("hashchange",d,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",d,(0,I.jT)(!0,this.removeOnAbort?.signal))}if(e.init.performance.resources.enabled&&y.gm.PerformanceObserver?.supportedEntryTypes.includes("resource")){new PerformanceObserver(e=>{e.getEntries().forEach(e=>{(0,a.p)("browserPerformance.resource",[e],void 0,this.featureName,this.ee)})}).observe({type:"resource",buffered:!0})}}try{this.removeOnAbort=new AbortController}catch(l){}this.abortHandler=()=>{this.removeOnAbort?.abort(),this.abortHandler=void 0},t.some(e=>e)?this.importAggregator(e,()=>i.e(478).then(i.bind(i,8019))):this.deregisterDrain()}}var xt=i(2646);const Tt=new Map;function Et(e,t,r,n){if("object"!=typeof t||!t||"string"!=typeof r||!r||"function"!=typeof t[r])return(0,l.R)(29);const i=function(e){return(e||ie.ee).get("logger")}(e),o=(0,oe.YM)(i),s=new xt.y(ie.P);s.level=n.level,s.customAttributes=n.customAttributes;const a=t[r]?.[oe.Jt]||t[r];return Tt.set(a,s),o.inPlace(t,[r],"wrap-logger-",()=>Tt.get(a)),i}var At=i(1910);class St extends E{static featureName=B.TZ;constructor(e){var t;super(e,B.TZ),t=e,p(u.$9,(e,r)=>G(e,r,t),t),function(e){p(u.Wb,(t,r,{customAttributes:n={},level:i=B.p_.INFO}={})=>{Et(e.ee,t,r,{customAttributes:n,level:i})},e)}(e),X(e);const r=this.ee;["log","error","warn","info","debug","trace"].forEach(e=>{(0,At.i)(y.gm.console[e]),Et(r,y.gm.console,e,{level:"log"===e?"info":e})}),this.ee.on("wrap-logger-end",function([e]){const{level:t,customAttributes:n}=this;(0,V.R)(r,e,n,t)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,5288)))}}new class extends r{constructor(e){var t;(super(),y.gm)?(this.features={},(0,O.bQ)(this.agentIdentifier,this),this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(_),this.runSoftNavOverSpa=[...this.desiredFeatures].some(e=>e.featureName===n.K7.softNav),(0,s.j)(this,e,e.loaderType||"agent"),t=this,p(u.cD,function(e,r,n=!1){if("string"==typeof e){if(["string","number","boolean"].includes(typeof r)||null===r)return g(t,e,r,u.cD,n);(0,l.R)(40,typeof r)}else(0,l.R)(39,typeof e)},t),function(e){p(u.Dl,function(t){if("string"==typeof t||null===t)return g(e,"enduser.id",t,u.Dl,!0);(0,l.R)(41,typeof t)},e)}(this),function(e){p(u.nb,function(t){if("string"==typeof t||null===t)return g(e,"application.version",t,u.nb,!1);(0,l.R)(42,typeof t)},e)}(this),function(e){p(u.d3,function(){e.ee.emit("manual-start-all")},e)}(this),function(e){p(u.Pv,function(t=!0){if("boolean"==typeof t){if((0,a.p)(u.Pl+u.Pv,[t],void 0,"session",e.ee),e.runtime.consented=t,t){const t=e.features.page_view_event;t.onAggregateImported.then(e=>{const r=t.featAggregate;e&&!r.sentRum&&r.sendRum()})}}else(0,l.R)(65,typeof t)},e)}(this),this.run()):(0,l.R)(21)}get config(){return{info:this.info,init:this.init,loader_config:this.loader_config,runtime:this.runtime}}get api(){return this}run(){try{const e=function(e){const t={};return o.forEach(r=>{t[r]=!!e[r]?.enabled}),t}(this.init),t=[...this.desiredFeatures];t.sort((e,t)=>n.P3[e.featureName]-n.P3[t.featureName]),t.forEach(t=>{if(!e[t.featureName]&&t.featureName!==n.K7.pageViewEvent)return;if(this.runSoftNavOverSpa&&t.featureName===n.K7.spa)return;if(!this.runSoftNavOverSpa&&t.featureName===n.K7.softNav)return;const r=function(e){switch(e){case n.K7.ajax:return[n.K7.jserrors];case n.K7.sessionTrace:return[n.K7.ajax,n.K7.pageViewEvent];case n.K7.sessionReplay:return[n.K7.sessionTrace];case n.K7.pageViewTiming:return[n.K7.pageViewEvent];default:return[]}}(t.featureName).filter(e=>!(e in this.features));r.length>0&&(0,l.R)(36,{targetFeature:t.featureName,missingDependencies:r}),this.features[t.featureName]=new t(this)})}catch(e){(0,l.R)(22,e);for(const e in this.features)this.features[e].abortHandler?.();const t=(0,O.Zm)();delete t.initializedAgents[this.agentIdentifier]?.features,delete this.sharedAggregator;return t.ee.get(this.agentIdentifier).abort(),!1}}}({features:[_e,_,j,We,Ve,k,J,Rt,St,Ze,yt],loaderType:"spa"})})()})();</script>
<link rel="icon" type="image/png" sizes="16x16" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png">
<meta name="apple-mobile-web-app-title" content="Frontiers | Articles">
<link rel="manifest" href="/manifest.json">
<link rel="canonical" href="https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/full">
<meta property="description" name="description" content="BRCA1 and BRCA2 are the most commonly mutated breast cancer susceptibility genes that convey a high risk of breast and ovarian cancer. Most BRCA1 or BRCA2 mu...">
<meta property="og:title" name="title" content="Frontiers | Identification of BRCA2 Cis Double Heterozygous Breast Cancer Cases Using Whole Exome Sequencing: Phenotypic Expression and Impact on Personalized Oncology">
<meta property="og:description" name="description" content="BRCA1 and BRCA2 are the most commonly mutated breast cancer susceptibility genes that convey a high risk of breast and ovarian cancer. Most BRCA1 or BRCA2 mu...">
<meta name="keywords" content="Breast cancer susceptibility,whole exome sequencing,Cis double heterozygosity,BRCA2 mutations,Early age of onset,Phenotype genotype correlation">
<meta property="og:site_name" name="site_name" content="Frontiers">
<meta property="og:image" name="image" content="https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g001.jpg">
<meta property="og:type" name="type" content="article">
<meta property="og:url" name="url" content="https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/full">
<meta name="twitter:card" content="summary_large_image">
<meta name="citation_volume" content="12">
<meta name="citation_journal_title" content="Frontiers in Genetics">
<meta name="citation_publisher" content="Frontiers">
<meta name="citation_journal_abbrev" content="Front. Genet.">
<meta name="citation_issn" content="1664-8021">
<meta name="citation_doi" content="10.3389/fgene.2021.674990">
<meta name="citation_firstpage" content="674990">
<meta name="citation_language" content="English">
<meta name="citation_title" content="Identification of BRCA2 Cis Double Heterozygous Breast Cancer Cases Using Whole Exome Sequencing: Phenotypic Expression and Impact on Personalized Oncology">
<meta name="citation_keywords" content="Breast cancer susceptibility; whole exome sequencing; Cis double heterozygosity; BRCA2 mutations; Early age of onset; Phenotype genotype correlation">
<meta name="citation_abstract" content="BRCA1 and BRCA2 are the most commonly mutated breast cancer susceptibility genes that convey a high risk of breast and ovarian cancer. Most BRCA1 or BRCA2 mutation carriers have inherited a single heterozygous mutation. In recent years, very rare cases with biallelic or trans double heterozygous mutations on BRCA1 and or BRCA2 have been identified and seem to be associated with distinctive phenotypes. Given that this genotype-phenotype correlation in cancer-predisposing hereditary conditions is of relevance for oncological prevention and genetic testing, it is important to investigate these rare BRCA genotypes for better clinical management of BRCA mutation carriers. Here we present the first report on Cis double heterozygosity (Cis DH) on BRCA2 gene identified using Whole exome sequencing (WES) in a Tunisian family with two BRCA2 mutations namely: c.632-1G>A and c.1310_1313DelAAGA that are both reported as pathogenic in ClinVar database. Subsequent analysis in 300 high-risk Tunisian breast cancer families detected this Cis double heterozygous genotype in 8 additional individuals belonging to 5 families from the same geographic origin suggesting a founder effect. Moreover, the observed Cis DH seems to be associated with an early age of onset (mean age = 35.33 years) and severe phenotype of the disease with high breast cancer grade and multiple cancer cases in the family. The identification of unusual BRCA genotypes in this Tunisian cohort highlights the importance of performing genetic studies in under-investigated populations. This will also potentially help to avoid erroneous classifications of genetic variants in African population and therefore avoiding clinical misdiagnosis of BRCA related cancers.  Our findings will also have an impact on the genetic testing and the clinical management of North African breast cancer patients as well as patients from different other ethnic groups in regard to several emerging target therapies such as PARP inhibitors.">
<meta name="citation_article_type" content="Original Research">
<meta name="citation_pdf_url" content="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/pdf">
<meta name="citation_xml_url" content="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/xml">
<meta name="citation_fulltext_world_readable" content="yes">
<meta name="citation_online_date" content="2021/07/08">
<meta name="citation_publication_date" content="2021/08/12">
<meta name="citation_author" content="Hamdi, Yosr ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Boujemaa, Maroua ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Mighri, Najah ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Mejri, Nesrine ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Jaidane, Olfa ">
<meta name="citation_author_institution" content="Surgical Oncology Department, Salah Azaiez Institute of Cancer, Tunisia">
<meta name="citation_author" content="Ben Nasr, Sonia ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Bouaziz, Hanen ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Hassouna, Jamel Ben ">
<meta name="citation_author_institution" content="Surgical Oncology Department, Salah Azaiez Institute of Cancer, Tunisia">
<meta name="citation_author" content="Zribi, Aref ">
<meta name="citation_author_institution" content="Department of Medical Oncology, Military Hospital, Tunisia">
<meta name="citation_author" content="Berrazaga, Yossra ">
<meta name="citation_author_institution" content="Medical Oncology Department, Abderrahmen Mami Hospital, Tunisia">
<meta name="citation_author" content="Rachdi, Haifa ">
<meta name="citation_author_institution" content="Medical Oncology Department, Abderrahmen Mami Hospital, Tunisia">
<meta name="citation_author" content="Daoud, Nouha ">
<meta name="citation_author_institution" content="Medical Oncology Department, Abderrahmen Mami Hospital, Tunisia">
<meta name="citation_author" content="El Benna, Houda ">
<meta name="citation_author_institution" content="Medical Oncology Department, Abderrahmen Mami Hospital, Tunisia">
<meta name="citation_author" content="Labidi, Soumaya ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Haddaoui, Abderrazek ">
<meta name="citation_author_institution" content="Department of Medical Oncology, Military Hospital, Tunisia">
<meta name="citation_author" content="Rahal, Khaled ">
<meta name="citation_author_institution" content="Surgical Oncology Department, Salah Azaiez Institute of Cancer, Tunisia">
<meta name="citation_author" content="Benna, Farouk ">
<meta name="citation_author_institution" content="Department of Radiation Oncology, University of Tunis, Tunisia">
<meta name="citation_author" content="Boussen, Hamouda ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Abdelhak, Sonia ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Boubaker, Samir ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="dc.identifier" content="doi:10.3389/fgene.2021.674990">
<script type="application/ld+json">{"@context":"https://schema.org","@type":"ScholarlyArticle","headline":"Identification of BRCA2 Cis Double Heterozygous Breast Cancer Cases Using Whole Exome Sequencing: Phenotypic Expression and Impact on Personalized Oncology","author":[{"@type":"Person","name":"Yosr Hamdi","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia","Laboratory of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunisia"]},{"@type":"Person","name":"Maroua Boujemaa","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia"]},{"@type":"Person","name":"Najah Mighri","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia"]},{"@type":"Person","name":"Nesrine Mejri","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia","Medical Oncology Department, Abderrahmen Mami Hospital, Tunisia"]},{"@type":"Person","name":"Olfa Jaidane","affiliation":["Surgical Oncology Department, Salah Azaiez Institute of Cancer, Tunisia"]},{"@type":"Person","name":"Sonia Ben Nasr","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia","Department of Medical Oncology, Military Hospital, Tunisia"]},{"@type":"Person","name":"Hanen Bouaziz","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia","Surgical Oncology Department, Salah Azaiez Institute of Cancer, Tunisia"]},{"@type":"Person","name":"Jamel Ben Hassouna","affiliation":["Surgical Oncology Department, Salah Azaiez Institute of Cancer, Tunisia"]},{"@type":"Person","name":"Aref Zribi","affiliation":["Department of Medical Oncology, Military Hospital, Tunisia"]},{"@type":"Person","name":"Yossra Berrazaga","affiliation":["Medical Oncology Department, Abderrahmen Mami Hospital, Tunisia"]},{"@type":"Person","name":"Haifa Rachdi","affiliation":["Medical Oncology Department, Abderrahmen Mami Hospital, Tunisia"]},{"@type":"Person","name":"Nouha Daoud","affiliation":["Medical Oncology Department, Abderrahmen Mami Hospital, Tunisia"]},{"@type":"Person","name":"Houda El Benna","affiliation":["Medical Oncology Department, Abderrahmen Mami Hospital, Tunisia"]},{"@type":"Person","name":"Soumaya Labidi","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia","Medical Oncology Department, Abderrahmen Mami Hospital, Tunisia"]},{"@type":"Person","name":"Abderrazek Haddaoui","affiliation":["Department of Medical Oncology, Military Hospital, Tunisia"]},{"@type":"Person","name":"Khaled Rahal","affiliation":["Surgical Oncology Department, Salah Azaiez Institute of Cancer, Tunisia"]},{"@type":"Person","name":"Farouk Benna","affiliation":["Department of Radiation Oncology, University of Tunis, Tunisia"]},{"@type":"Person","name":"Hamouda Boussen","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia","Medical Oncology Department, Abderrahmen Mami Hospital, Tunisia"]},{"@type":"Person","name":"Sonia Abdelhak","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia"]},{"@type":"Person","name":"Samir Boubaker","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia","Laboratory of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunisia"]}],"datePublished":"2021-08-12","dateModified":"2025-11-25","publisher":{"@type":"Organization","name":"Frontiers"},"isPartOf":{"@type":"PublicationIssue","datePublished":"2021","isPartOf":{"@type":"PublicationVolume","volumeNumber":"12","isPartOf":{"@type":"Periodical","name":"Frontiers in Genetics"}}},"citation":["https://doi.org/10.3389/fgene.2021.674990"],"inLanguage":"en"}</script>
<script type="module" src="/ap-2024/_nuxt/v1IBIWh4.js" crossorigin></script>
<script id="unhead:payload" type="application/json">{"title":"Frontiers | Articles"}</script></head><body  class="body--v3"><div id="__nuxt"><!--[--><!----><div theme="purple"><nav class="Ibar"><div class="Ibar__main"><div class="Ibar__wrapper"><button class="Ibar__burger" aria-label="Open Menu" data-event="iBar-btn-openMenu"></button><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/genetics" class="Ibar__journalName" data-event="iBar-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Genetics</span></div></div></a><div class="Ibar__dropdown--aboutUs" parent-data-event="iBar"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=1&amp;fieldid=30&amp;specialtyid=0&amp;entitytype=2&amp;entityid=240" data-event="iBar-a-submit">Submit your research</a><div class="Ibar__spacer"></div><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><div><div class="Ibar__menu Ibar__menu--journal"><div class="Ibar__menu__header"><div class="Ibar__logo"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div></div><button class="Ibar__close" aria-label="Close Menu" data-event="iBarMenu-btn-closeMenu"></button></div><div class="Ibar__menu__wrapper"><div class="Ibar__menu__journal"><a href="//www.frontiersin.org/journals/genetics" data-event="iBarMenu-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Genetics</span></div></div></a><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/applied-genetic-epidemiology" data-event="iBarJournal-sections-a_id_549">Applied Genetic Epidemiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/behavioral-and-psychiatric-genetics" data-event="iBarJournal-sections-a_id_536">Behavioral and Psychiatric Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/cancer-genetics-and-oncogenomics" data-event="iBarJournal-sections-a_id_2030">Cancer Genetics and Oncogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/computational-genomics" data-event="iBarJournal-sections-a_id_551">Computational Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/cytogenomics" data-event="iBarJournal-sections-a_id_2512">Cytogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/elsi-in-science-and-genetics" data-event="iBarJournal-sections-a_id_650">ELSI in Science and Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/epigenomics-and-epigenetics" data-event="iBarJournal-sections-a_id_455">Epigenomics and Epigenetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/evolutionary-and-population-genetics" data-event="iBarJournal-sections-a_id_535">Evolutionary and Population Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genetics-of-aging" data-event="iBarJournal-sections-a_id_596">Genetics of Aging</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genetics-of-common-and-rare-diseases" data-event="iBarJournal-sections-a_id_635">Genetics of Common and Rare Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genomic-assay-technology" data-event="iBarJournal-sections-a_id_557">Genomic Assay Technology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genomics-of-plants-and-the-phytoecosystem" data-event="iBarJournal-sections-a_id_1520">Genomics of Plants and the Phytoecosystem</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/human-and-medical-genomics" data-event="iBarJournal-sections-a_id_1419">Human and Medical Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/immunogenetics" data-event="iBarJournal-sections-a_id_2237">Immunogenetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/livestock-genomics" data-event="iBarJournal-sections-a_id_241">Livestock Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/neurogenomics" data-event="iBarJournal-sections-a_id_19">Neurogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/nutritional-genomics" data-event="iBarJournal-sections-a_id_3423">Nutritional Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/pharmacogenetics-and-pharmacogenomics" data-event="iBarJournal-sections-a_id_198">Pharmacogenetics and Pharmacogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/predictive-toxicology-and-exposomics" data-event="iBarJournal-sections-a_id_556">Predictive Toxicology and Exposomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/rna" data-event="iBarJournal-sections-a_id_555">RNA</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/statistical-genetics-and-methodology" data-event="iBarJournal-sections-a_id_454">Statistical Genetics and Methodology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/stem-cell-research" data-event="iBarJournal-sections-a_id_685">Stem Cell Research</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div></div><div class="Ibar__dropdown--aboutUs" parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><!----><!----><!----><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=1&amp;fieldid=30&amp;specialtyid=0&amp;entitytype=2&amp;entityid=240" data-event="iBarMenu-a-submit">Submit your research</a></div></div></div><!--[--><div class="Ibar__journal Ibar__journal--main"><div class="Ibar__wrapper Ibar__wrapper--journal"><a href="//www.frontiersin.org/journals/genetics" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Genetics</span></div></div></a><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/applied-genetic-epidemiology" data-event="iBarJournal-sections-a_id_549">Applied Genetic Epidemiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/behavioral-and-psychiatric-genetics" data-event="iBarJournal-sections-a_id_536">Behavioral and Psychiatric Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/cancer-genetics-and-oncogenomics" data-event="iBarJournal-sections-a_id_2030">Cancer Genetics and Oncogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/computational-genomics" data-event="iBarJournal-sections-a_id_551">Computational Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/cytogenomics" data-event="iBarJournal-sections-a_id_2512">Cytogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/elsi-in-science-and-genetics" data-event="iBarJournal-sections-a_id_650">ELSI in Science and Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/epigenomics-and-epigenetics" data-event="iBarJournal-sections-a_id_455">Epigenomics and Epigenetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/evolutionary-and-population-genetics" data-event="iBarJournal-sections-a_id_535">Evolutionary and Population Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genetics-of-aging" data-event="iBarJournal-sections-a_id_596">Genetics of Aging</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genetics-of-common-and-rare-diseases" data-event="iBarJournal-sections-a_id_635">Genetics of Common and Rare Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genomic-assay-technology" data-event="iBarJournal-sections-a_id_557">Genomic Assay Technology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genomics-of-plants-and-the-phytoecosystem" data-event="iBarJournal-sections-a_id_1520">Genomics of Plants and the Phytoecosystem</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/human-and-medical-genomics" data-event="iBarJournal-sections-a_id_1419">Human and Medical Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/immunogenetics" data-event="iBarJournal-sections-a_id_2237">Immunogenetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/livestock-genomics" data-event="iBarJournal-sections-a_id_241">Livestock Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/neurogenomics" data-event="iBarJournal-sections-a_id_19">Neurogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/nutritional-genomics" data-event="iBarJournal-sections-a_id_3423">Nutritional Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/pharmacogenetics-and-pharmacogenomics" data-event="iBarJournal-sections-a_id_198">Pharmacogenetics and Pharmacogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/predictive-toxicology-and-exposomics" data-event="iBarJournal-sections-a_id_556">Predictive Toxicology and Exposomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/rna" data-event="iBarJournal-sections-a_id_555">RNA</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/statistical-genetics-and-methodology" data-event="iBarJournal-sections-a_id_454">Statistical Genetics and Methodology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/stem-cell-research" data-event="iBarJournal-sections-a_id_685">Stem Cell Research</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div></div></div><div class="Ibar__journal Ibar__journal--mix"><div class="Ibar__wrapper Ibar__wrapper--journal"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/genetics" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Genetics</span></div></div></a><div class="Ibar__spacer"></div><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/applied-genetic-epidemiology" data-event="iBarJournal-sections-a_id_549">Applied Genetic Epidemiology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/behavioral-and-psychiatric-genetics" data-event="iBarJournal-sections-a_id_536">Behavioral and Psychiatric Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/cancer-genetics-and-oncogenomics" data-event="iBarJournal-sections-a_id_2030">Cancer Genetics and Oncogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/computational-genomics" data-event="iBarJournal-sections-a_id_551">Computational Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/cytogenomics" data-event="iBarJournal-sections-a_id_2512">Cytogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/elsi-in-science-and-genetics" data-event="iBarJournal-sections-a_id_650">ELSI in Science and Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/epigenomics-and-epigenetics" data-event="iBarJournal-sections-a_id_455">Epigenomics and Epigenetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/evolutionary-and-population-genetics" data-event="iBarJournal-sections-a_id_535">Evolutionary and Population Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genetics-of-aging" data-event="iBarJournal-sections-a_id_596">Genetics of Aging</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genetics-of-common-and-rare-diseases" data-event="iBarJournal-sections-a_id_635">Genetics of Common and Rare Diseases</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genomic-assay-technology" data-event="iBarJournal-sections-a_id_557">Genomic Assay Technology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/genomics-of-plants-and-the-phytoecosystem" data-event="iBarJournal-sections-a_id_1520">Genomics of Plants and the Phytoecosystem</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/human-and-medical-genomics" data-event="iBarJournal-sections-a_id_1419">Human and Medical Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/immunogenetics" data-event="iBarJournal-sections-a_id_2237">Immunogenetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/livestock-genomics" data-event="iBarJournal-sections-a_id_241">Livestock Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/neurogenomics" data-event="iBarJournal-sections-a_id_19">Neurogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/nutritional-genomics" data-event="iBarJournal-sections-a_id_3423">Nutritional Genomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/pharmacogenetics-and-pharmacogenomics" data-event="iBarJournal-sections-a_id_198">Pharmacogenetics and Pharmacogenomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/predictive-toxicology-and-exposomics" data-event="iBarJournal-sections-a_id_556">Predictive Toxicology and Exposomics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/rna" data-event="iBarJournal-sections-a_id_555">RNA</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/statistical-genetics-and-methodology" data-event="iBarJournal-sections-a_id_454">Statistical Genetics and Methodology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/genetics/sections/stem-cell-research" data-event="iBarJournal-sections-a_id_685">Stem Cell Research</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/genetics/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/genetics/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=1&amp;fieldid=30&amp;specialtyid=0&amp;entitytype=2&amp;entityid=240" data-event="iBarJournal-a-submit"><span>Submit</span><span>your research</span></a><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><!--]--></nav><div class="ArticlePage"><!--[--><div class="Layout Layout--withAside Layout--withIbarMix"><div class="Alert Alert--info Alert--noInfo ArticleTemplateBanner"><div class="Alert__icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" class="FeedbackIcon"><path fill="#fff" d="M10 10h28v28H10z"></path><path fill="var(--blue50)" d="M24 2.88a21.12 21.12 0 1 0 0 42.24 21.12 21.12 0 0 0 0-42.24ZM22.08 13.4a.96.96 0 0 1 .96-.96h1.92a.96.96 0 0 1 .96.96v1.92a.96.96 0 0 1-.96.96h-1.92a.96.96 0 0 1-.96-.96V13.4Zm5.76 21.2a.96.96 0 0 1-.96.97h-5.76a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h.96v-7.68h-.96a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h3.84a.96.96 0 0 1 .96.96v10.56h.96a.96.96 0 0 1 .96.96v1.92Z"></path></svg></div><div class="Alert__main"><p class="Alert__message">Your new experience awaits. Try the new design now and help us make it even better</p><!--[--><button type="button" class="Button Button--outline Button--grey80 Button--small ArticleTemplateBanner__switchButton" data-event="btn-action"><span>Switch to the new experience</span></button><!--]--><!----></div><ol class="Alert__info"><!--[--><!--]--></ol></div><!----><main class="Layout__main"><!----><div class="ArticleDetails"><div class="ArticleLayoutHeader"><div class="ArticleLayoutHeader__info"><p class="ArticleLayoutHeader__info__title">ORIGINAL RESEARCH article</p><p class="ArticleLayoutHeader__info__journalDate"><span>Front. Genet.</span><span>, 12 August 2021</span></p><p class="ArticleLayoutHeader__info__journalDate"> Sec. Cancer Genetics and Oncogenomics</p><p class="ArticleLayoutHeader__info__doiVolume"><span>Volume 12 - 2021 | </span><a class="ArticleLayoutHeader__info__doi" href="https://doi.org/10.3389/fgene.2021.674990">https://doi.org/10.3389/fgene.2021.674990</a></p><!----></div><!----><!----></div><div class="ArticleDetails__main__content"><div class="ArticleDetails__main__content__main ArticleDetails__main__content__main--fullArticle"><div class="JournalAbstract"><div class="JournalAbstract__titleWrapper"><h1>Identification of <i>BRCA2 Cis</i> Double Heterozygous Breast Cancer Cases Using Whole Exome Sequencing: Phenotypic Expression and Impact on Personalized Oncology</h1><!----></div><!----></div><div class="JournalFullText"><div class="JournalAbstract">
<a id="h1" name="h1"></a>
<div class="authors"><span class="author-wrapper notranslate">
<a href="https://loop.frontiersin.org/people/887862" class="user-id-887862"><img class="pr5" src="https://loop.frontiersin.org/images/profile/887862/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="
Yosr Hamdi,&#xA;">Yosr Hamdi</a><sup>1,2</sup><sup>&#x0002A;</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/956852" class="user-id-956852"><img class="pr5" src="https://loop.frontiersin.org/images/profile/956852/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Maroua Boujemaa">Maroua Boujemaa</a><sup>1</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/958051" class="user-id-958051"><img class="pr5" src="https://loop.frontiersin.org/images/profile/958051/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Najah Mighri">Najah Mighri</a><sup>1</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1126033" class="user-id-1126033"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1126033/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Nesrine Mejri,">Nesrine Mejri</a><sup>1,3</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/957930" class="user-id-957930"><img class="pr5" src="https://loop.frontiersin.org/images/profile/957930/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Olfa Jaidane">Olfa Jaidane</a><sup>4</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/957319" class="user-id-957319"><img class="pr5" src="https://loop.frontiersin.org/images/profile/957319/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Sonia Ben Nasr,">Sonia Ben Nasr</a><sup>1,5</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1130977" class="user-id-1130977"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1130977/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Hanen Bouaziz,">Hanen Bouaziz</a><sup>1,4</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Jamel Ben Hassouna" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Jamel Ben Hassouna<sup>4</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Aref Zribi" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Aref Zribi<sup>5</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Yossra Berrazaga" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Yossra Berrazaga<sup>3</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Haifa Rachdi" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Haifa Rachdi<sup>3</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Nouha Daoud" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Nouha Daoud<sup>3</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1126178" class="user-id-1126178"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1126178/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Houda El Benna">Houda El Benna</a><sup>3</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Soumaya Labidi," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Soumaya Labidi<sup>1,3</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Abderrazek Haddaoui" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Abderrazek Haddaoui<sup>5</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Khaled Rahal" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Khaled Rahal<sup>4</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Farouk Benna" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Farouk Benna<sup>6</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1126078" class="user-id-1126078"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1126078/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Hamouda Boussen,">Hamouda Boussen</a><sup>1,3</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Sonia Abdelhak" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Sonia Abdelhak<sup>1</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Samir Boubaker," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Samir Boubaker<sup>1,2</sup></span></div>
<ul class="notes">
<li><span><sup>1</sup></span>Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, Tunisia</li>
<li><span><sup>2</sup></span>Laboratory of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunis, Tunisia</li>
<li><span><sup>3</sup></span>Medical Oncology Department, Abderrahmen Mami Hospital, Ariana, Tunisia</li>
<li><span><sup>4</sup></span>Surgical Oncology Department, Salah Azaiez Institute of Cancer, Tunis, Tunisia</li>
<li><span><sup>5</sup></span>Department of Medical Oncology, Military Hospital, Tunis, Tunisia</li>
<li><span><sup>6</sup></span>Department of Radiation Oncology, University of Tunis, Tunis, Tunisia</li>
</ul>
<p><i>BRCA1</i> and <i>BRCA2</i> are the most commonly mutated breast cancer susceptibility genes that convey a high risk of breast and ovarian cancer. Most <i>BRCA1</i> or <i>BRCA2</i> mutation carriers have inherited a single heterozygous mutation. In recent years, very rare cases with biallelic or trans double heterozygous mutations on <i>BRCA1</i> and or <i>BRCA2</i> have been identified and seem to be associated with distinctive phenotypes. Given that this genotype-phenotype correlation in cancer predisposing hereditary conditions is of relevance for oncological prevention and genetic testing, it is important to investigate these rare <i>BRCA</i> genotypes for better clinical management of <i>BRCA</i> mutation carriers. Here we present the first report on <i>Cis</i> double heterozygosity (<i>Cis</i> DH) on <i>BRCA2</i> gene identified using Whole exome sequencing (WES) in a Tunisian family with two <i>BRCA2</i> mutations namely: c.632-1G&#x0003E;A and c.1310_1313DelAAGA that are both reported as pathogenic in ClinVar database. Subsequent analysis in 300 high-risk Tunisian breast cancer families detected this <i>Cis</i> double heterozygous genotype in 8 additional individuals belonging to 5 families from the same geographic origin suggesting a founder effect. Moreover, the observed <i>Cis</i> DH seems to be associated with an early age of onset (mean age = 35.33 years) and severe phenotype of the disease with high breast cancer grade and multiple cancer cases in the family. The identification of unusual <i>BRCA</i> genotypes in this Tunisian cohort highlights the importance of performing genetic studies in under-investigated populations. This will also potentially help avoiding erroneous classifications of genetic variants in African population and therefore avoiding clinical misdiagnosis of <i>BRCA</i> related cancers. Our findings will also have an impact on the genetic testing and the clinical management of North African breast cancer patients as well as patients from different other ethnic groups in regard to several emerging target therapies such as PARP inhibitors.</p>
<div class="clear"></div>
</div>
<div class="JournalFullText">
<a id="h2" name="h2"></a><h2>Introduction</h2>
<p class="mb15">Breast cancer is the most common malignancy in women worldwide (<a href="#B45">Rojas and Stuckey, 2016</a>). Incidence and mortality rates of breast cancer differ between populations (<a href="#B5">Bray et al., 2018</a>). Moreover, remarkable diversity in epidemiological and genetic characteristics of this disease have been observed (<a href="#B49">Servick, 2014</a>). Since the mid-1990, extensive efforts have been dedicated to the analysis of <i>BRCA1</i> and <i>BRCA2</i>, the two most commonly mutated breast cancer genes. So far, about 1,800 mutations have been identified on <i>BRCA1</i> and almost 2,000 mutations on <i>BRCA2</i> (<a href="#B52">Szabo et al., 2000</a>). These mutations explain around 20&#x02013;30% of hereditary breast cancer cases and seem to be associated with different other cancers such as ovarian, prostate, colorectal, pancreatic, and melanoma (<a href="#B39">Mehrgou and Akouchekian, 2016</a>). Indeed, the identification of a <i>BRCA</i> mutation can lead to risk or mortality reduction if optimal surveillance, risk-reducing mastectomy, and risk-reducing salpingo-oophorectomy are applied (<a href="#B24">Finch et al., 2006</a>; <a href="#B16">Domchek et al., 2010</a>). In addition, cancer treatment of <i>BRCA</i> mutation carriers has advanced with the development of PARP inhibitors, which take advantage of the loss of <i>BRCA1/2</i> function in tumors (<a href="#B23">Farmer et al., 2005</a>).</p>
<p class="mb15">The vast majority of <i>BRCA1</i> and <i>BRCA2</i> mutation carriers are single heterozygous (SH) with only one mono-allelic deleterious mutation on one of these two genes. Excluding individuals of Ashkenazi descent, it is uncommon to identify carriers of two deleterious mutations either within the same gene [biallelic or double heterozygous (DH)] or in both genes [trans heterozygous (TH)]. Indeed, biallelic mutations in <i>BRCA2</i> results in childhood Fanconi anemia (FANCD1) (<a href="#B2">Alter et al., 2007</a>), which is an autosomal recessive disease resulting in developmental abnormalities, bone marrow failure, and early-onset leukemia or solid tumors. The biallelic <i>BRCA2</i> genotype has also been observed in a 31-year-old female diagnosed with colorectal cancer (<a href="#B11">Degrolard-Courcet et al., 2014</a>). Biallelic mutations in <i>BRCA1</i> are much rarer because carrying the same <i>BRCA1</i> pathogenic mutation on both alleles is widely known to be embryonic lethal (<a href="#B22">Evers and Jonkers, 2006</a>). However, <a href="#B17">Domchek et al. (2013)</a> reported a case with biallelic <i>BRCA1</i> mutations diagnosed with an ovarian cancer at age 28 with short stature, microcephaly, developmental delay, and significant toxicity from chemotherapy. Another reported case of biallelic <i>BRCA1</i> mutations was in a woman with a Fanconi anemia disorder and breast cancer at age 23 (<a href="#B47">Sawyer et al., 2015</a>). TH mutations in both <i>BRCA1</i> and <i>BRCA2</i> genes have been also reported in almost 68 cases and seem to be associated with an early age of onset and a severe disease compared to SH <i>BRCA</i> mutation carriers (<a href="#B27">Heidemann et al., 2012</a>; <a href="#B43">Rebbeck et al., 2016</a>). However, <i>Cis</i> double heterozygosity, have been reported in only two studies with controversial results (<a href="#B9">Colombo et al., 2009</a>; <a href="#B41">Pensabene et al., 2009</a>). Here we define the <i>Cis</i> DH to be the inheritance of two deleterious mutations on the same allele of a gene. To date, the phenotypic consequences of this unusual <i>BRCA</i> genotype are poorly understood.</p>
<p class="mb15">In fact, trans biallelic <i>BRCA</i> deleterious mutations, either in one gene or one allele per gene, might be expected in families with both parental lineages affected by breast and/or ovarian cancer. However, <i>Cis</i> DH most likely increases cancer occurrence in one parental bloodline, albeit, in consanguineous and endogamous populations such as the Tunisian population, <i>Cis</i> DH may increase cancer incidence in both maternal and paternal sides. Moreover, intuitively, one can anticipate that <i>Cis</i> DH is not associated with additional phenotypic consequences over and above that associated with single heterozygosity since a single mutation is sufficient to completely abolish the synthesis of a functional gene product. Contrariwise, it has been recently shown that breast and ovarian cancer risks differ depending on the position and the type of <i>BRCA1</i> and <i>BRCA2</i> mutations (<a href="#B44">Rebbeck et al., 2015</a>) meaning challenges regarding their structure and function. Thus, carrying two different mutations on the same allele may be associated with a distinctive phenotype since each mutation is located in a different domain of the BRCA protein and consequently could disturb the interaction of BRCA with several other proteins. Therefore, these altered protein-protein interactions may influence the resulting phenotype.</p>
<p class="mb0">In the current study, we aimed to present a first report on a <i>BRCA2 Cis</i> double heterozygosity in 5 Tunisian families thanks to the use of whole exome sequencing. The founder and the functional effect of the two mutations have been assessed as well as the prevalence and the phenotypic spectrum of this unusual <i>BRCA2</i> genotype.</p>
<a id="h3" name="h3"></a><h2>Materials and Methods</h2>
<h3 class="pt0">Patients</h3>
<p class="mb15">Tunisian families from different geographic origins were selected based on the following selection criteria; (1) having at least 3 breast cancer cases in first or second degree relatives at any age, (2) 2 breast cancer cases with one of them diagnosed with BC before age 40, (3) isolated breast cancer cases diagnosed before age 36, (4) one case with triple negative breast cancer (TNBC) at an age &#x02264; 40 years, (5) one case and one ovarian case diagnosed at first or second degree relatives at any age, (6) at least 2 cases with breast or ovarian cancer (at any age) and at least one case with pancreas cancer or prostate cancer at first or second degree relatives.</p>
<p class="mb15">For each participant, total genomic DNA was extracted and used as a template for exome sequencing using DNeasy blood DNA extraction Kit (Qiagen) according to the manufacturer&#x00027;s instructions. DNA purity and concentration were measured using a NanoDrop&#x02122; spectrophotometer.</p>
<p class="mb0">When possible, genomic DNA samples from other affected or unaffected family members were obtained for further validation. Written informed consent was obtained from all participants. The study was conducted according to the Declaration of Helsinki Principles. Ethical approval was obtained from the biomedical ethics committee of Institut Pasteur de Tunis (2017/16/E/H&#x000F4;pital A-M).</p>
<h3>Data Analysis</h3>
<p class="mb0">Data analysis pipeline is summarized in <a href="#F1">Figure 1</a>. Exome sequences were mapped to their location in the most recent build of the human genome (hg19/b37) using the Burrows-Wheeler Aligner (BWA) software package version 0.7.5 (<a href="#B35">Li and Durbin, 2009</a>). The subsequent SAM files were converted to BAM files using Samtools version 1.6 (<a href="#B36">Li et al., 2009</a>). Duplicate reads were removed using Picard version 2.6 (<a href="http://broadinstitute.github.io/picard/">http://broadinstitute.github.io/picard/</a>). GATK version 4.1.2 (<a href="#B55">Van der Auwera and O&#x00027;Connor, 2020</a>) was then used to recalibrate the base quality scores, as well as, for SNP and short INDEL calling. Annotation and prioritization of potential disease-causing variants were performed using VarAFT (Variant Annotation and Filtering Tool) version 2.13 (<a href="#B14">Desvignes et al., 2018</a>). To annotate variants, VarAFT uses ANNOVAR, a command line tool. INDELs and SNPs annotated were filtered according to several criteria: considering breast cancer as autosomal dominant disease, variants that were found in a homozygous state were removed. In addition, variants identified as intronic, intergenic, and synonymous were discarded. Then, assuming that causal variants are rare, we removed all variants with an allele frequency more than 1% either in ExAC version 0.3 (<a href="#B34">Lek et al., 2016</a>), 1,000 genomes 2015-08 (<a href="#B26">Genomes Project et al., 2015</a>) or ESP6500 (<a href="http://evs.gs.washington.edu/EVS/">http://evs.gs.washington.edu/EVS/</a>). We also removed all variants with no functional effect (annotated as &#x0201C;Benign&#x0201D; or &#x0201C;Tolerated&#x0201D; by the different tools used to predict the functional effect of these genetic variants). Finally, we used the literature to filter the remaining set of variants by gene function and only variants located on genes involved in cancer etiology were kept.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 1</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g001.jpg" name="figure1" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g001.jpg" alt="www.frontiersin.org" id="F1" loading="lazy">
  </picture>
</a>
<p><strong>Figure 1</strong>. Summary of the data analysis pipeline followed in the present study. Before proceeding to the alignment phase, quality control (QC1) was performed on raw sequencing data in order to ensure that the data are optimal for downstream analyses. A second quality control (QC2) was done on alignment data to reduce the alignment artifacts that could influence the quality of downstream variant calling. Subsequently, variants were filtered by keeping only heterozygous variations and discarding those with MAF &#x0003E;1% in either Exac, 1,000 genomes or ESP6500. We further removed benign or tolerated variations and focused on genes related to breast cancer susceptibility. Two pathogenic mutations were identified c.632-1G&#x0003E;A and c.1310_1313delAAGA in <i>BRCA2</i> gene.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<h3>Sanger Sequencing</h3>
<p class="mb0">Sanger sequencing technique was first used to validate the identified mutations resulting from the whole exome sequencing then to test the identified <i>BRCA2</i> variations in other family members or in other patients from our cohort. PCR reactions were performed on genomic DNA following standard protocols, followed by Sanger sequencing using an automated sequencer (ABI 3500; Applied Biosystems, Foster City, CA) and a cycle sequencing reaction kit (Big Dye Terminator kit, Applied Biosystems). Data were analyzed using BioEdit Sequence Alignment Editor Version 7.2.5. Sequencing was conducted using the following primers for exon 8 (8F: 5&#x02032;-GCCATATCTTACCACCTTGT-3&#x02032; and 8R: 5&#x02032;-CAGGTTTAGAGACTTTCTC-3&#x02032;) and exon 10 respectively (10BF: 5&#x02032;-CAGAAGCCCTTTGAGAGTGG-3&#x02032; and 10BR: 5&#x02032;-GGTACCTGAATCAGCATTTGC-3&#x02032;).</p>
<h3>Splicing Predictions</h3>
<p class="mb0">The c.632-1 G&#x0003E;A mutation is located at the splicing donor site of exon 8 of <i>BRCA2</i>.The functional effect of this mutation on splicing was evaluated using different splice-site <i>in silico</i> prediction tools: Human Splice-Finder (<a href="#B13">Desmet et al., 2009</a>) (<a href="http://www.umd.be/HSF/">http://www.umd.be/HSF/</a>) which is an online bioinformatics tool designed to predict the effects of mutations on splicing signals, Mutation Taster (<a href="#B48">Schwarz et al., 2010</a>) (<a href="http://www.mutationtaster.org/">http://www.mutationtaster.org/</a>) that evaluates disease-causing potential of sequence alterations including coding and non-coding variants and Alamut (<a href="https://www.interactive-biosoftware.com/fr/alamut-visual/">https://www.interactive-biosoftware.com/fr/alamut-visual/</a>). This latter integrates information from different public databases and several pathogenicity predictions tools to annotate variations. Human Splice-Finder and Mutation taster were used online while Alamut software was downloaded and used locally in order to predict the functional impact of the splice site variant.</p>
<h3>ClinVar Database</h3>
<p class="mb0">ClinVar (<a href="#B32">Landrum et al., 2020</a>) is a public database of reports on the relationships between human variations and phenotypes, that uses supporting evidence to classify genetic variants based on their pathogenicity. As a freely accessible public database, we used ClinVar to assess the pathogenicity of the two mutations identified on exons 8 and 10 of the BRCA2 gene.</p>
<h3>RNA Extraction and RT-PCR Product Analysis</h3>
<p class="mb15">In order to assess the impact of the c.632-1 G&#x0003E;A mutation at the RNA level, total RNA has been isolated from peripheral blood using the Trizol method (Invitrogen&#x02122;).</p>
<p class="mb15">The cDNA was synthesized using random primers and SuperScript&#x02122; II Reverse Transcriptase (Invitrogen), according to the manufacturer&#x00027;s protocol.</p>
<p class="mb15">In order to amplify the cDNA sample from two patients carrying the c.632-1G&#x0003E;A mutation and a control who is a breast cancer case that do not carry the mutation, we used four combinations of forward and reverse primer pairs flanking <i>BRCA2</i> exons 5&#x02013;10 to amplify overlapping regions of the mRNA and to cover the entire open reading frame.</p>
<p class="mb15">In order to evaluate the quality of the cDNA amplification, a PCR for a housekeeping gene <i>GAPDH</i> was conducted using the following primers (5&#x02032;-GAGTCAACGGATTTGGTCGT-3&#x02032;) and (5&#x02032;-TTGATTTTGGAGGGATCTCG-3&#x02032;).</p>
<p class="mb0">RT-PCR products were separated on agarose gel and visualized by SYBR<sup>&#x000AE;</sup> Safe staining then purified using Exo-SAP and characterized by direct sequencing.</p>
<h3>Microsatellites Genotyping and Haplotype Analysis</h3>
<p class="mb15">Haplotype analysis was carried out on 60 individuals: 11 mutation carriers, 4 relatives, 8 breast cancer non-carriers, 24 breast cancer cases with unknown <i>BRCA</i> status and 13 healthy Tunisian women from the general population.</p>
<p class="mb15">Four <i>BRCA2</i> extragenic polymorphic microsatellite markers, listed in order from centromere to telomere (D13S267, D13S171, D13S260, and D13S1246) and spanning a 6.43 Mb region around the <i>BRCA2</i> gene were studied. Characteristics of the studied region and analyzed markers are presented in <a href="#SM1">Supplementary Figure 1</a>.</p>
<p class="mb15">PCR primer sequences were obtained from the Probe NCBI database. Genotyping technique is based on a fluorescent-labeled M13(-21) universal primer. The PCR mix contained 20 &#x003BC;mol/L of each forward and FAM-M13 primer and 2 &#x003BC;mol/L of the reverse primer in a final 25 &#x003BC;L reaction. PCR amplification conditions are as follows: 94&#x000B0;C (5 min), then 35 cycles at 94&#x000B0;C (45 s)/annealing temperature (30 s)/72&#x000B0;C (1 min 30 s), and a final extension at 72&#x000B0;C for 10 min.</p>
<p class="mb15">One micro liter of the PCR product is added to 12 &#x003BC;l of formamide and 0.5 &#x003BC;l of GeneScan&#x02122; 500 ROX&#x02122; Size Standard and PCR product size was evaluated by capillary electrophoresis on ABI prism 3500 DNA Genetic Analyzer (Applied Biosystems, Foster City, CA). Data was analyzed using the GeneMapper V.5.0 software.</p>
<p class="mb0">Haplotypes were reconstructed by PHASE v.2.1 software (<a href="#B51">Stephens et al., 2001</a>), that used Bayesian methods to predict the haplotype distribution.</p>
<a id="h4" name="h4"></a><h2>Results</h2>
<p class="mb0">A 36 years old patient (BC17) consulted for a mass in the right breast. Clinical and radiological explorations concluded to a bilateral breast cancer. She had a bilateral mastectomy with right lymph node dissection. Histopathological examination concluded for the right breast to be an infiltrating ductal carcinoma, SBRIII, positive hormone receptors with 6 metastatic lymph nodes. In the left breast, there was an intraductal carcinoma. Adjuvant treatment was indicated and consisted in right loco-regional radiotherapy, chemotherapy, chemical ovarian function suppression and hormonal therapy by Tamoxifen. Eleven years later, she developed a squamous cell carcinoma of the esophagus. A radio-induced cancer was evoked and squamous cell carcinoma was confirmed. Total oesophagectomy by stripping was performed. No adjuvant treatment was indicated. One year later a recurrence of the cervical anastomosis was diagnosed and caused a severe dyspnea. Chemotherapy was rejected due to bad general conditions and the patient died of this recurrence. In addition to the severe phenotype of this patient, 9 family members have been diagnosed with breast cancer, 5 of them were diagnosed &#x02264; 45 years old. Therefore, a DNA sample of this patient was analyzed using whole exome sequencing. Results including number of reads, sample coverage, number of the different types of mutations and sequencing depth of the whole exome sequenced patient have been summarized in <a href="#T1">Table 1</a>. This analysis unexpectedly revealed two <i>BRCA2</i> mutations corresponding to the frameshift c.1310_1313DelAAGA within exon 10 and a splice site mutation c.632-1G&#x0003E;A in exon 8.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">TABLE 1</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t001.jpg" name="Table1" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t001.jpg" alt="www.frontiersin.org" id="T1" loading="lazy">
  </picture>
</a>
<p><strong>Table 1</strong>. Exome sequencing data.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb15 w100pc float_left mt15">Interestingly, both mutations have been reported as &#x0201C;pathogenic&#x0201D; in the ClinVar database.</p>
<p class="mb0">In addition, the two mutations have been confirmed by Sanger sequencing of the original DNA and of a second DNA sample extracted from a second blood sample of the same patient. These mutations were also confirmed in a relative of the patient diagnosed with pregnancy associated breast cancer at 25 years old (BC17-2). Subsequently, we searched for the 2 mutations in a cohort of 300 high risk Tunisian breast cancer families. Interestingly, 7 additional individuals belonging to 4 Tunisian families were identified as carriers of both mutations (BC6, BC39, BC95, and BC225). Pedigrees of these families are shown in <a href="#F2">Figure 2</a>. Due to the fact that a subset of Fanconi Anemia patients carry biallelic <i>BRCA2</i> mutations, it was crucial to establish whether the two mutations are found <i>in Cis</i> or <i>in Trans</i>. Beyond the index case in the BC6 family, her son, her sister and two brothers have been tested for these mutations. The son and the sister were negative for both mutations and the two brothers have been identified as carriers of the two <i>BRCA2</i> mutations. This allowed us to conclude that both mutations are found on the same allele. Furthermore, 6 individuals belonging to 5 additional families have been identified as carriers of the founder c.1310_1313DelAAGA mutation only (PEC9, PEC35, BC245, BC354-1, BC354-2, DEP13-1) including 2 unaffected carriers.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 2</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g002.jpg" name="figure2" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g002.jpg" alt="www.frontiersin.org" id="F2" loading="lazy">
  </picture>
</a>
<p><strong>Figure 2</strong>. Familial pedigrees of the 5 <i>Cis</i> double heterozygous families. Available age at diagnosis of breast cancer cases is indicated between brackets. For some cases, only age at death was available and is indicated in square brackets. BBC, Bilateral Breast Cancer.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb15 w100pc float_left mt15">The 9 carriers of this <i>Cis</i> DH <i>BRCA2</i> genotypes include 6 affected cases and 3 unaffected carriers.</p>
<p class="mb0">Epidemiological and clinico-pathological data of these <i>Cis</i> DH families are reported in <a href="#T2">Table 2</a>. The clinical phenotype correlates with the typical <i>BRCA2</i> tumor characteristics with positive estrogen and progesterone receptors and negative Her2 status. Moreover, T2 tumor size and a histological Grade III have been observed in 3 out of the 6 patients suggesting a severe phenotype for <i>Cis</i> DH <i>BRCA2</i> mutation carriers. In addition, the <i>Cis</i> DH <i>BRCA2</i> genotype seems to be associated with a significant early age of onset (mean age = 35.33 years) when compared to 48.1 in SH, 47.5 in <i>BRCA2</i> mutation carriers and 44.6 years in compound heterozygous. Furthermore, multiple breast cancer cases have been recorded in the related individuals of these <i>Cis</i> DH cases. No ovarian cancer was reported, which may not be surprising given the fact that ovarian cancer penetrance is significantly lower in <i>BRCA2</i> mutation carriers compared to <i>BRCA1</i>. Although prostate cancer is part of the <i>BRCA2</i> cancer susceptibility spectrum, no prostate cancer was reported as well. However, a brother of BC6 that has been tested positive for both mutations seems to have urological problems that may orient to a prostate pathology. One colon cancer was observed in the cousin of BC95, one brain cancer in the uncle of another case (BC225) and a renal cancer as well as a gastric cancer were diagnosed in a brother and an aunt of BC17, respectively. Even if they are not clearly <i>BRCA2</i> related carcinomas, esophageal and throat cancers were detected in 4 individuals from 3 different families (BC6, BC17, and BC225) suggesting an upper aero digestive cancer predisposition.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">TABLE 2</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t002.jpg" name="Table2" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t002.jpg" alt="www.frontiersin.org" id="T2" loading="lazy">
  </picture>
</a>
<p><strong>Table 2</strong>. Epidemiological and clinical data of <i>Cis</i> double heterozygous families.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb15 w100pc float_left mt15">Because of the rare genotype that we are investigating in this study, the number of cases reported in this study is too small to draw firm conclusions, however, there is evidences of an association between <i>Cis</i> DH and a relatively severe phenotype of the disease with early age of onset, high breast cancer grade and multiple cancer cases in the families.</p>
<p class="mb15">In addition to the identified <i>Cis</i> DH pathogenic mutations, 21 SNPs have been detected on both <i>BRCA1</i> and <i>BRCA2</i> genes including 12 exonic and 9 intronic variants (<a href="#SM1">Supplementary Table 1</a>).</p>
<p class="mb0">The co-occurrence of the two mutations on the same <i>BRCA2</i> allele raises questions about the functional significance of the splice site mutation (<a href="#F3">Figure 3</a>). Three different <i>in silico</i> prediction tools have been used to assess the functional effect of this splicing mutation (<a href="#T3">Table 3</a>). Results showed that c.632-1G&#x0003E;A seems to disturb the normal splicing by the loss of the WT acceptor site which may induce the skipping of <i>BRCA2</i>-exon 8.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 3</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g003.jpg" name="figure3" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g003.jpg" alt="www.frontiersin.org" id="F3" loading="lazy">
  </picture>
</a>
<p><strong>Figure 3</strong>. <i>BRCA2</i> sequence with the c.632-1G&#x0003E;A and c.1301-1304delAAAG mutations. Sanger chromatograms confirm <strong>(A)</strong> the presence of the c.632-1G&#x0003E;A mutation at the junction intron 7/exon 8 and <strong>(B)</strong> the c.1310_1313delAAGA (p.Lys437Ilefs) mutation in exon 10.</p>
</div>
<div class="clear"></div>
<div class="DottedLine mb15"></div>
<div class="Imageheaders">TABLE 3</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t003.jpg" name="Table3" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t003.jpg" alt="www.frontiersin.org" id="T3" loading="lazy">
  </picture>
</a>
<p><strong>Table 3</strong>. Summary of splicing predictions results.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb15 w100pc float_left mt15">Then we proceed with protein modeling as an additional functional analysis. Unfortunately, thec.632-1G&#x0003E;A splicing mutation does not appear in any regions or domains of the protein (described in uniport <a href="https://www.uniprot.org/uniprot/P51587">https://www.uniprot.org/uniprot/P51587</a>). In addition, the existing 3D structures do not cover this region and therefore we were not able to generate a 3D model of the mutant with a good confidence rate.</p>
<p class="mb0">For the RT PCR analysis, the cDNA of the <i>BRCA2</i> gene was amplified using several primer combinations flanking exons 5&#x02013;9, 5&#x02013;10, 6&#x02013;10. Although electrophoresis gel showed a specific band for the resulting cDNA, sequencing analysis did not show any sequences supporting the skipping of the <i>BRCA2</i>-exon8 hypothesis.</p>
<h3>Haplotype Analysis</h3>
<p class="mb0">To investigate a possible founder effect, haplotype analysis was performed on 60 Tunisian breast cancer cases. In detail, 8 <i>BRCA2Cis</i> DH carriers, 3 <i>BRCA2</i> SH carriers, 4 relatives, 8 non-carriers, 24 breast cancer patients with unknown <i>BRCA</i> status and 13 healthy Tunisian women were investigated using the four selected STR markers. The D13S1246 marker was inconclusive and it was then excluded from the analysis. <a href="#T4">Table 4</a> summarizes the haplotype analysis for the <i>Cis</i> DH and SH carriers. Evaluation of the informative microsatellites was performed on probands and additional family members when possible. We identified a shared haplotype between all <i>Cis</i> DH and SH <i>BRCA2</i> mutation carriers (162-233-162) and absent or very rare in the remaining controls suggesting a founder effect of these two mutations.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">TABLE 4</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t004.jpg" name="Table4" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t004.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t004.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t004.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t004.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t004.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t004.jpg" alt="www.frontiersin.org" id="T4" loading="lazy">
  </picture>
</a>
<p><strong>Table 4</strong>. Haplotype analyses in the carriers of both <i>BRCA2</i> deleterious mutations.</p>
</div>
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb0 w100pc float_left mt15">Moreover, all carriers of these two mutations are originating from the North Western and central regions of Tunisia. Of interest, <i>Cis</i> DH and SH carriers share the same haplotype suggesting that they are mostly inherited together.</p>
<a id="h5" name="h5"></a><h2>Discussion</h2>
<p class="mb15">Breast cancer is a malignancy with significant genotypic and phenotypic diversity (<a href="#B1">Almendro et al., 2014</a>). It is now well-documented that a large proportion of North African breast cancer patients are relatively young (<a href="#B10">Corbex et al., 2014</a>) with an average age at presentation of breast cancer patients a decade earlier than Caucasian individuals (<a href="#B8">Chouchane et al., 2013</a>). Recent studies showed that 11% of Tunisian breast cancer patients are under 35 years old (<a href="#B57">Zehani et al., 2009</a>). In addition, the majority of North African breast cancer patients are still diagnosed at late stages. Therefore, early disease onset and late diagnosis, both represent the main cause of high mortality among breast cancer patients in these populations. Given the fact that breast cancer in young women tends to behave more aggressively (<a href="#B3">Assi et al., 2013</a>), an early diagnosis will result in reduced treatment, effective primary prevention and additional life years gained. Therefore, understanding the epidemiology-genetic factors behind the significant high number of young breast cancer patients in North African populations will promote early detection of the disease and will have a positive impact on the survival rates of affected patients.</p>
<p class="mb15">In the present study, 6 Tunisian breast cancer patients harbor two pathogenic mutations on the same allele of <i>BRCA2</i> (c. 632-1G&#x0003E;A and c. 1310_1313 Del AAGA) have been detected using whole exome sequencing. These patients showed a significant early age of onset of the disease. Indeed, the mean age of onset was about 35.33 years in <i>Cis</i> DH, significantly younger than <i>BRCA</i> SH mutation carriers (48.1 years), <i>BRCA2</i> mutation carriers (47.5 years), and biallelic <i>BRCA</i> mutation carriers (44.6 years) (<a href="#B43">Rebbeck et al., 2016</a>) suggesting an association of this genotype with an early age of onset.</p>
<p class="mb15">Young age of onset was also observed in other unusual <i>BRCA</i> genotypes. Indeed, biallelic <i>BRCA2</i> mutations have been observed in a 31 years old female diagnosed with colorectal cancer (<a href="#B11">Degrolard-Courcet et al., 2014</a>). Biallelic mutations in <i>BRCA1</i> have been reported in a female patient with epithelial ovarian carcinoma diagnosed at age 28 years (<a href="#B17">Domchek et al., 2013</a>). Recent studies also showed that DH mutation carriers develop breast cancer at an earlier age and have more severe disease than SH cases (<a href="#B33">Lavie et al., 2011</a>; <a href="#B27">Heidemann et al., 2012</a>). Interestingly, <a href="#B9">Colombo et al. (2009)</a> reported 4 <i>BRCA2 Cis</i> DH cases with a mean age of 34.</p>
<p class="mb15">Therefore, we hypothesized that the development of early onset disease associated with co-occurrence of two deleterious mutations might be indicative of disruption of interactions between <i>BRCA2</i> and some key proteins resulting in an accumulation of DNA damages that makes the disease appear at an earlier age. In support of our hypothesis, Ashok Venkitaraman suggested that single heterozygosity in <i>BRCA</i> genes has a dosage effect sufficient to trigger low, but quantitatively significant, levels of genome instability. Alternatively, biallelic inactivation of <i>BRCA1</i> or <i>BRCA2</i> not only triggers profound chromosomal instability but also quickly leads to cell cycle arrest or apoptosis which results in an early presentation of the disease (<a href="#B56">Venkitaraman, 2019</a>). In addition, <i>Cis DH</i> breast cancer patients reported in the current study, seem to present a high histological grade and a bigger tumor size with multiple breast cancer cases in the related family members suggesting an association between <i>Cis</i> DH and the phenotypic severity. A similar phenomenon, called negative complementation or metabolic interference, occurs when two alleles at the same locus interact to give a more severe phenotype in the compound heterozygote than in either homozygote (<a href="#B28">Johnson, 1980</a>). For example, Abruptex (Abx) mutations of the Drosophila Notch gene fall into two genetic types, &#x0201C;enhancers&#x0201D; and &#x0201C;suppressors&#x0201D; of Notch. Homozygotes for either type are viable (characterized by gapping of the wing veins), yet compound enhancer/suppressor Abx heterozygotes are lethal (<a href="#B29">Kelley et al., 1987</a>).</p>
<p class="mb15">Of note, all reported patients with <i>Cis</i> DH come from a restricted geographic area suggesting a founder effect. We assume that there is no selection bias as patients from our cohort originated from different areas of Tunisia and were recruited from different oncological departments that have a national activity. Results from haplotype analysis confirmed this founder effect by the identification of a shared haplotype between all carriers of both <i>BRCA2</i> mutations, c. 1310_1313Del AAGA and c.632-1G&#x0003E;A.c.1310_1313DelAAGA is a known recurrent mutation in North African populations and has been already identified in Tunisia, Algeria and Morocco (<a href="#B7">Cherbal et al., 2012</a>). Moreover, it was found in different European patients from Denmark, France, Belgium, Spain, and Italy and it has also been identified in a Korean patient (<a href="#B15">D&#x000ED;ez et al., 2003</a>; <a href="#B53">Thomassen et al., 2008</a>; <a href="#B6">Caputo et al., 2012</a>; <a href="#B30">Kim et al., 2012</a>; <a href="#B31">Laarabi et al., 2017</a>). This mutation was also found in several male breast cancer cases (<a href="#B20">Drusedau et al., 2013</a>; <a href="#B25">Fourati et al., 2014</a>; <a href="#B50">Silvestri et al., 2020</a>). For the exon8- <i>BRCA2</i> c.632-1G&#x0003E;A mutation, it is described for the first time in Tunisia and in the North African region. It also appears to be rare in other populations since it was only reported in one patient with prostate cancer in the UK (<a href="#B21">Edwards et al., 2010</a>). Different analysis showed that there is an over-representation of mutations in <i>BRCA2&#x00027;s</i> exons 7 and 8 in FA-D1 patients (<a href="#B52">Szabo et al., 2000</a>; <a href="#B42">Rahman and Scott, 2007</a>). Furthermore, despite the high frequency of <i>BRCA2</i> truncating exon 11 mutations in familial breast cancer there is currently no known FA-D1 patient with biallelic truncating mutations in exon 11 (<a href="#B42">Rahman and Scott, 2007</a>). Interestingly, genotype-phenotype analyses of <i>BRCA2</i> breast cancer pedigrees mirror the observations in biallelic <i>BRCA2</i> mutation cases, with different cancer risks associated with monoallelic truncating mutations in exon 11 when compared with mutations located in 3&#x02032; or 5&#x02032; of this exon (<a href="#B54">Thompson et al., 2001</a>; <a href="#B37">Lubinski et al., 2004</a>).</p>
<p class="mb15">In fact, genetic disease studies on North Africans are of keen interest because of their heterogeneous and admixed populations from African and European origins. The particular structure of the Tunisian population is also due to a relatively high rate of consanguinity that reaches 98.9% in some regions (<a href="#B4">Ben Halim et al., 2015</a>). This clearly impacted the incidence rates of complex diseases as well as monogenic ones such as those predisposing to cancer (<a href="#B46">Romdhane et al., 2019</a>). Studies on the impact of consanguinity on breast cancer incidences showed controversial results. Indeed, Gilani et al. showed that consanguinity is linked to a high overall risk of breast cancer (<a href="#B38">Masood Gilani and Kamal, 2004</a>). However, other studies showed that a lower risk of breast cancer was reported in consanguineous families compared to non-consanguineous ones (<a href="#B12">Denic and Bener, 2001</a>). Here we propose that consanguinity can also affect the early onset of breast cancer and other associated phenotypes. Indeed, a long history of consanguinity that may result in a genetic mixing that may cause the co-occurrence of more than one mutation on one allele such as the <i>Cis</i> DH observed in this study and that seems to be associated with increased likelihood of breast cancer incidence and early onset of the disease. In Ashkenazi Jewish, where a relatively high risk of consanguinity has been observed, double heterozygosity in both <i>BRCA1</i> and <i>BRCA2</i> mutations is frequently observed and usually, at least one of the DH mutations is a founder mutation. In this same context, <a href="#B33">Lavie et al. (2011)</a> showed that a 1.85% prevalence of <i>BRCA1</i> and <i>BRCA2</i> DH in Ashkenazi Jewish patients with FA-D1 have a distinctively higher risk of specific cancers than patients in other Fanconi anemia complementation groups. Therefore, carrying a single mutant allele, biallelic or two monoallelic mutations are associated with a phenotypic variability, ranging from HBOC, fanconi anemia, to early age of breast cancer onset with multiple cancer cases in the family.</p>
<p class="mb15">Interestingly, the identification of these phenotype-genotype correlations will help to provide appropriate and individualized genetic counseling, risk assessment and cancer surveillance not only for index cases but also to their relatives from both parental sides. Thus, carriers of DH mutations may benefit from an earlier start of surveillance, more intensive follow up care and/or an urgent prophylactic surgery. From a therapeutic point of view, while both <i>BRCA1</i> and <i>BRCA2</i> mutations sensitize cells to PARP inhibitors, the affected gene appears to have a modulating effect on sensitivity. Indeed, <i>BRCA1</i>-defective cells demonstrate a &#x0007E;60-fold increase in sensitivity to Olaparib vs. <i>BRCA</i> wild-type cells, while the corresponding increase in sensitivity in <i>BRCA2</i>-defective cells is &#x0007E;130-fold (<a href="#B23">Farmer et al., 2005</a>). Moreover, loss of BRCA1 RING domain function appears insufficient to fully sensitize cells to PARP inhibition, while still predisposing to cancer development (<a href="#B18">Drost et al., 2011</a>, <a href="#B19">2016</a>). Given the fact that the c.632-1G&#x0003E;A mutation identified in this study is located in the N-terminal region of BRCA2 protein corresponding to the RING domain of BRCA1, and because of the financial burden of targeted therapy use in routine clinical practice, identifying patients most likely to benefit from these drugs is of great importance.</p>
<p class="mb15">Once confirmed in larger cohorts, our finding will also bring new insights to the scientific community that will either accept the <i>Cis</i> DH BRCA genotype that was largely debated, or it will help in reviewing the clinical actionability of the splicing c-632-1G&#x0003E;A <i>BRCA2</i> mutation that is still classified as pathogenic in ClinVar. Efforts made by <i>the Evidence-based Network for the Interpretation of Germline Mutant Alleles</i> (ENIGMA) in determining the clinical significance of sequence variants in <i>BRCA1, BRCA2</i>, and other known or suspected breast cancer genes represent an excellent initiative to overcome this challenge and will permit the reclassification of this mutation in order to avoid misdiagnosis and over treatment of breast cancer patients all over the world (<a href="#B40">Nielsen et al., 2018</a>).</p>
<p class="mb15">Furthermore, due to the high cost of the complete screening of the large <i>BRCA</i> genes, the screening of only recurrent or founder mutations using Sanger sequencing is a traditional genetic testing method in low and middle income countries (LMICs). This screening method is no longer concluding. Indeed, apart from the fact that this strategy may bias the frequency of <i>BRCA</i> mutations in a specific mutation, by doing so, we also risk to pass side of the double heterozygous or biallelic <i>BRCA</i> genotypes that seem to be associated with different phenotypic spectrum. This problem does not arise when using cost-efficient and sensitive new technologies such as gene panels or whole exome sequencing that extend the analysis to the whole <i>BRCA</i> and other breast cancer susceptibility genes regardless of previous identification of a specific mutation in the family.</p>
<p class="mb0">Finally, as c.1310_1313DelAAGA is a founder mutation in North African populations, our results will have an impact not only on Tunisian cancer patients but on patients from other North African countries as well as cancer cases originating from other ethnic groups.</p>
<a id="h6" name="h6"></a><h2>Conclusion</h2>
<p class="mb0">Genetic studies of under-investigated populations may lead to the identification of unusual genotypes and phenotypes that provide novel insights and avenues for research regarding the complex biological functions of the <i>BRCA</i> genes. It also increases our understanding of the clinical basis of cancer predisposition which will help moving toward a more accurate and personalized clinical management of cancer patients.</p>
<a id="h7" name="h7"></a><h2>Data Availability Statement</h2>
<p class="mb0">All pathogenic mutations identified in this study with data related to these variants have been deposited in the public database &#x0201C;ClinVar&#x0201D; under the following link <a href="https://www.ncbi.nlm.nih.gov/clinvar/submitters/507986/">https://www.ncbi.nlm.nih.gov/clinvar/submitters/507986/</a>. All remaining variations (non-pathogenic) identified within BRCA1 and BRCA2 genes have been provided in the <a href="#h14">Supplementary Material</a>. Any additional details may be made available upon request after approval of our institutional review board.</p>
<a id="h8" name="h8"></a><h2>Ethics Statement</h2>
<p class="mb0">The studies involving human participants were reviewed and approved by Biomedical Ethics Committee of Institut Pasteur de Tunis (2017/16/E/h&#x000F4;pital a-m). The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from participants for the publication of any potentially identifiable images or data included in this article.</p>
<a id="h9" name="h9"></a><h2>Author Contributions</h2>
<p class="mb0">YH prepared the study concept and design, supervised the study, did data analysis, data interpretation, drafted, and critically revised the manuscript. MB and NMi did the experiments, participated in participant recruitment, and participated in drafting and reviewing the manuscript. NMe, OJ, YH, MB, NMi, SBe, HBoua, JH, AZ, YB, HR, ND, HE, and SL contributed to data collection and clinical data analysis. SA, HBous, SBo, AH, and KR contributed to the results interpretation. SBo and SA contributed to the study concept, design and supervision. SA, SBo, and HBous critically revised the manuscript. All authors read and approved the manuscript.</p>
<a id="h10" name="h10"></a><h2>Funding</h2>
<p class="mb0">This work was supported by the Tunisian Ministry of Public Health (PEC-4-TUN), the Tunisian Ministry of Higher Education and Scientific Research (LR11IPT05 and LR16IPT05) and by the E.C. Grant agreement N&#x000B0; 295097 for FP7 project GM-NCD-Inco.</p>
<a id="h11" name="h11"></a><h2>Conflict of Interest</h2>
<p class="mb0">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<a id="h12" name="h12"></a><h2>Publisher&#x00027;s Note</h2>
<p class="mb0">All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
<a id="h13" name="h13"></a><h2>Acknowledgments</h2>
<p class="mb0">We are also grateful to all participants and their family members for their participation in the study.</p>
<a id="h14" name="h14"></a><h2>Supplementary Material</h2>
<p class="mb0" id="SM1">The Supplementary Material for this article can be found online at: <a href="https://www.frontiersin.org/articles/10.3389/fgene.2021.674990/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fgene.2021.674990/full#supplementary-material</a></p>
<a id="h15" name="h15"></a><h2>Abbreviations</h2>
<p class="mb0"><i>Cis</i> DH, <i>Cis</i> double heterozygosity; WES, Whole exome sequencing; NGS, Next Generation Sequencing; SH, single heterozygotes; TH, trans heterozygous; BC, Breast cancer; TNBC, Triple negative breast cancer; MBC, Male Breast Cancer; GC, Gastric Cancer; RC, Renal Cancer; EC, Esophageal Carcinoma; BrC, Brain Cancer; ThC, Throat Cancer; IDC, Invasive Ductal Carcinoma; DCIS, Diffuse carcinoma <i>in situ</i>; CT, Chemotherapy; RT, Radiotherapy; HT, Hormonotherapy; RB, Right breast; LB, Left breast; UOQ, Upper outer quadrant; JUQ, Junction of the upper quadrants.</p>
<a id="h16" name="h16"></a><h2>References</h2>
<div class="References">
<p class="ReferencesCopy1"><a name="B1" id="B1"></a> Almendro, V., Kim, H. J., Cheng, Y.-K., G&#x000F6;nen, M., Itzkovitz, S., Argani, P., et al. (2014). Genetic and phenotypic diversity in breast tumor metastases. <i>Cancer Res</i>. 74, 1338&#x02013;1348. doi: 10.1158/0008-5472.CAN-13-2357-T</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/24448237" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1158/0008-5472.CAN-13-2357-T" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=V.+Almendro&#x00026;author=H.+J.+Kim&#x00026;author=Y.+-K.+Cheng&#x00026;author=M.+G&#x000F6;nen&#x00026;author=S.+Itzkovitz&#x00026;author=P.+Argani+&#x00026;publication_year=2014&#x00026;title=Genetic+and+phenotypic+diversity+in+breast+tumor+metastases&#x00026;journal=Cancer+Res&#x00026;volume=74&#x00026;pages=1338-1348" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B2" id="B2"></a> Alter, B. P., Rosenberg, P. S., and Brody, L. C. (2007). Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. <i>J. Med. Genet</i>. 44, 1&#x02013;9. doi: 10.1136/jmg.2006.043257</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/16825431" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1136/jmg.2006.043257" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=B.+P.+Alter&#x00026;author=P.+S.+Rosenberg&#x00026;author=L.+C.+Brody+&#x00026;publication_year=2007&#x00026;title=Clinical+and+molecular+features+associated+with+biallelic+mutations+in+FANCD1%2FBRCA2&#x00026;journal=J.+Med.+Genet&#x00026;volume=44&#x00026;pages=1-9" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B3" id="B3"></a> Assi, H. A., Khoury, K. E., Dbouk, H., Khalil, L. E., Mouhieddine, T. H., and El Saghir, N. S. (2013). Epidemiology and prognosis of breast cancer in young women. <i>J. Thorac. Dis</i>. 5(Suppl. 1), S2&#x02013;S8. doi: 10.3978/j.issn.2072-1439.2013.05.24</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/23819024" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3978/j.issn.2072-1439.2013.05.24" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H.+A.+Assi&#x00026;author=K.+E.+Khoury&#x00026;author=H.+Dbouk&#x00026;author=L.+E.+Khalil&#x00026;author=T.+H.+Mouhieddine&#x00026;author=N.+S.+El+Saghir+&#x00026;publication_year=2013&#x00026;title=Epidemiology+and+prognosis+of+breast+cancer+in+young+women&#x00026;journal=J.+Thorac.+Dis&#x00026;volume=5&#x00026;pages=S2-S8" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B4" id="B4"></a> Ben Halim, N., Nagara, M., Regnault, B., Hsouna, S., Lasram, K., Kefi, R., et al. (2015). Estimation of recent and ancient inbreeding in a small endogamous tunisian community through genomic runs of homozygosity. <i>Ann. Hum. Genet</i>. 79, 402&#x02013;417. doi: 10.1111/ahg.12131</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/26420437" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/ahg.12131" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=N.+Ben+Halim&#x00026;author=M.+Nagara&#x00026;author=B.+Regnault&#x00026;author=S.+Hsouna&#x00026;author=K.+Lasram&#x00026;author=R.+Kefi+&#x00026;publication_year=2015&#x00026;title=Estimation+of+recent+and+ancient+inbreeding+in+a+small+endogamous+tunisian+community+through+genomic+runs+of+homozygosity&#x00026;journal=Ann.+Hum.+Genet&#x00026;volume=79&#x00026;pages=402-417" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B5" id="B5"></a> Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <i>CA Cancer J. Clin</i>. 68, 394&#x02013;424. doi: 10.3322/caac.21492</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/32767693" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3322/caac.21492" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=F.+Bray&#x00026;author=J.+Ferlay&#x00026;author=I.+Soerjomataram&#x00026;author=R.+L.+Siegel&#x00026;author=L.+A.+Torre&#x00026;author=A.+Jemal+&#x00026;publication_year=2018&#x00026;title=Global+cancer+statistics+2018%3A+GLOBOCAN+estimates+of+incidence+and+mortality+worldwide+for+36+cancers+in+185+countries&#x00026;journal=CA+Cancer+J.+Clin&#x00026;volume=68&#x00026;pages=394-424" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B6" id="B6"></a> Caputo, S., Benboudjema, L., Sinilnikova, O., Rouleau, E., Beroud, C., Lidereau, R., et al. (2012). Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases. <i>Nucleic Acids Res</i>. 40(Database issue), D992&#x02013;1002. doi: 10.1093/nar/gkr1160</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/22144684" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/nar/gkr1160" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S.+Caputo&#x00026;author=L.+Benboudjema&#x00026;author=O.+Sinilnikova&#x00026;author=E.+Rouleau&#x00026;author=C.+Beroud&#x00026;author=R.+Lidereau+&#x00026;publication_year=2012&#x00026;title=Description+and+analysis+of+genetic+variants+in+French+hereditary+breast+and+ovarian+cancer+families+recorded+in+the+UMD-BRCA1%2FBRCA2+databases&#x00026;journal=Nucleic+Acids+Res&#x00026;volume=40&#x00026;pages=D992-1002" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B7" id="B7"></a> Cherbal, F., Bakour, R., Adane, S., and Boualga, K. (2012). BRCA1 and BRCA2 germline mutation spectrum in hereditary breast/ovarian cancer families from Maghrebian countries. <i>Breast Dis</i>. 34, 1&#x02013;8. doi: 10.3233/BD-130348</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/23697973" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3233/BD-130348" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=F.+Cherbal&#x00026;author=R.+Bakour&#x00026;author=S.+Adane&#x00026;author=K.+Boualga+&#x00026;publication_year=2012&#x00026;title=BRCA1+and+BRCA2+germline+mutation+spectrum+in+hereditary+breast%2Fovarian+cancer+families+from+Maghrebian+countries&#x00026;journal=Breast+Dis&#x00026;volume=34&#x00026;pages=1-8" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B8" id="B8"></a> Chouchane, L., Boussen, H., and Sastry, K. S. R. (2013). Breast cancer in Arab populations: molecular characteristics and disease management implications. <i>Lancet Oncol</i>. 14:e417&#x02013;e24. doi: 10.1016/S1470-2045(13)70165-7</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/23993386" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/S1470-2045(13)70165-7" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L.+Chouchane&#x00026;author=H.+Boussen&#x00026;author=K.+S.+R.+Sastry+&#x00026;publication_year=2013&#x00026;title=Breast+cancer+in+Arab+populations%3A+molecular+characteristics+and+disease+management+implications&#x00026;journal=Lancet+Oncol&#x00026;volume=14&#x00026;pages=e417-e24" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B9" id="B9"></a> Colombo, M., Ripamonti, C., Pensotti, V., Foglia, C., Peissel, B., Pierotti, M., et al. (2009). An unusual BRCA2 allele carrying two splice site mutations. <i>Ann. Oncol</i>. 20, 1143&#x02013;1144. doi: 10.1093/annonc/mdp241</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/19423647" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/annonc/mdp241" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M.+Colombo&#x00026;author=C.+Ripamonti&#x00026;author=V.+Pensotti&#x00026;author=C.+Foglia&#x00026;author=B.+Peissel&#x00026;author=M.+Pierotti+&#x00026;publication_year=2009&#x00026;title=An+unusual+BRCA2+allele+carrying+two+splice+site+mutations&#x00026;journal=Ann.+Oncol&#x00026;volume=20&#x00026;pages=1143-1144" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B10" id="B10"></a> Corbex, M., Bouzbid, S., and Boffetta, P. (2014). Features of breast cancer in developing countries, examples from North-Africa. <i>Eur. J. Cancer</i> 50, 1808&#x02013;1818. doi: 10.1016/j.ejca.2014.03.016</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/24767469" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.ejca.2014.03.016" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M.+Corbex&#x00026;author=S.+Bouzbid&#x00026;author=P.+Boffetta+&#x00026;publication_year=2014&#x00026;title=Features+of+breast+cancer+in+developing+countries,+examples+from+North-Africa&#x00026;journal=Eur.+J.+Cancer&#x00026;volume=50&#x00026;pages=1808-1818" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B11" id="B11"></a> Degrolard-Courcet, E., Sokolowska, J., Padeano, M.-M., Guiu, S., Bronner, M., Chery, C., et al. (2014). Development of primary early-onset colorectal cancers due to biallelic mutations of the FANCD1/BRCA2 gene. <i>Euro. J. Human Genet</i>. 22, 979&#x02013;987. doi: 10.1038/ejhg.2013.278</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/24301060" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/ejhg.2013.278" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=E.+Degrolard-Courcet&#x00026;author=J.+Sokolowska&#x00026;author=M.+-M.+Padeano&#x00026;author=S.+Guiu&#x00026;author=M.+Bronner&#x00026;author=C.+Chery+&#x00026;publication_year=2014&#x00026;title=Development+of+primary+early-onset+colorectal+cancers+due+to+biallelic+mutations+of+the+FANCD1%2FBRCA2+gene&#x00026;journal=Euro.+J.+Human+Genet&#x00026;volume=22&#x00026;pages=979-987" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B12" id="B12"></a> Denic, S., and Bener, A. (2001). Consanguinity decreases risk of breast cancer&#x02013;cervical cancer unaffected. <i>Br. J. Cancer</i> 85, 1675&#x02013;1679. doi: 10.1054/bjoc.2001.2131</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/11742487" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1054/bjoc.2001.2131" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S.+Denic&#x00026;author=A.+Bener+&#x00026;publication_year=2001&#x00026;title=Consanguinity+decreases+risk+of+breast+cancer&#x02013;cervical+cancer+unaffected&#x00026;journal=Br.+J.+Cancer&#x00026;volume=85&#x00026;pages=1675-1679" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B13" id="B13"></a> Desmet, F. O., Hamroun, D., Lalande, M., Collod-Beroud, G., Claustres, M., and Beroud, C. (2009). Human splicing finder: an online bioinformatics tool to predict splicing signals. <i>Nucleic Acids Res</i>. 37:e67. doi: 10.1093/nar/gkp215</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/19339519" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/nar/gkp215" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=F.+O.+Desmet&#x00026;author=D.+Hamroun&#x00026;author=M.+Lalande&#x00026;author=G.+Collod-Beroud&#x00026;author=M.+Claustres&#x00026;author=C.+Beroud+&#x00026;publication_year=2009&#x00026;title=Human+splicing+finder%3A+an+online+bioinformatics+tool+to+predict+splicing+signals&#x00026;journal=Nucleic+Acids+Res&#x00026;volume=37&#x00026;pages=e67" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B14" id="B14"></a> Desvignes, J.-P., Bartoli, M., Delague, V., Krahn, M., Miltgen, M., B&#x000E9;roud, C., et al. (2018). VarAFT: a variant annotation and filtration system for human next generation sequencing data. <i>Nucleic Acids Res</i>. 46, W545&#x02013;W553. doi: 10.1093/nar/gky471</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/29860484" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/nar/gky471" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J.+-P.+Desvignes&#x00026;author=M.+Bartoli&#x00026;author=V.+Delague&#x00026;author=M.+Krahn&#x00026;author=M.+Miltgen&#x00026;author=C.+B&#x000E9;roud+&#x00026;publication_year=2018&#x00026;title=VarAFT%3A+a+variant+annotation+and+filtration+system+for+human+next+generation+sequencing+data&#x00026;journal=Nucleic+Acids+Res&#x00026;volume=46&#x00026;pages=W545-W553" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B15" id="B15"></a> D&#x000ED;ez, O., Osorio, A., Dur&#x000E1;n, M., Martinez-Ferrandis, J. I., Hoya, M., dl Salazar, R., et al. (2003). Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. <i>Hum. Mutat</i>. 22, 301&#x02013;312. doi: 10.1002/humu.10260</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/12955716" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.10260" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=O.+D&#x000ED;ez&#x00026;author=A.+Osorio&#x00026;author=M.+Dur&#x000E1;n&#x00026;author=J.+I.+Martinez-Ferrandis&#x00026;author=M.+Hoya&#x00026;author=R.+dl+Salazar+&#x00026;publication_year=2003&#x00026;title=Analysis+of+BRCA1+and+BRCA2+genes+in+Spanish+breast%2Fovarian+cancer+patients%3A+a+high+proportion+of+mutations+unique+to+Spain+and+evidence+of+founder+effects&#x00026;journal=Hum.+Mutat&#x00026;volume=22&#x00026;pages=301-312" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B16" id="B16"></a> Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, H. T., Isaacs, C., et al. (2010). Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. <i>JAMA</i> 304, 967&#x02013;975. doi: 10.1001/jama.2010.1237</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/20810374" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1001/jama.2010.1237" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S.+M.+Domchek&#x00026;author=T.+M.+Friebel&#x00026;author=C.+F.+Singer&#x00026;author=D.+G.+Evans&#x00026;author=H.+T.+Lynch&#x00026;author=C.+Isaacs+&#x00026;publication_year=2010&#x00026;title=Association+of+risk-reducing+surgery+in+BRCA1+or+BRCA2+mutation+carriers+with+cancer+risk+and+mortality&#x00026;journal=JAMA&#x00026;volume=304&#x00026;pages=967-975" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B17" id="B17"></a> Domchek, S. M., Tang, J., Stopfer, J., Lilli, D. R., Hamel, N., Tischkowitz, M., et al. (2013). Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. <i>Cancer Discov</i>. 3, 399&#x02013;405. doi: 10.1158/2159-8290.CD-12-0421</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/23269703" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1158/2159-8290.CD-12-0421" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S.+M.+Domchek&#x00026;author=J.+Tang&#x00026;author=J.+Stopfer&#x00026;author=D.+R.+Lilli&#x00026;author=N.+Hamel&#x00026;author=M.+Tischkowitz+&#x00026;publication_year=2013&#x00026;title=Biallelic+deleterious+BRCA1+mutations+in+a+woman+with+early-onset+ovarian+cancer&#x00026;journal=Cancer+Discov&#x00026;volume=3&#x00026;pages=399-405" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B18" id="B18"></a> Drost, R., Bouwman, P., Rottenberg, S., Boon, U., Schut, E., Klarenbeek, S., et al. (2011). BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. <i>Cancer Cell</i>. 20, 797&#x02013;809. doi: 10.1016/j.ccr.2011.11.014</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/22172724" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.ccr.2011.11.014" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R.+Drost&#x00026;author=P.+Bouwman&#x00026;author=S.+Rottenberg&#x00026;author=U.+Boon&#x00026;author=E.+Schut&#x00026;author=S.+Klarenbeek+&#x00026;publication_year=2011&#x00026;title=BRCA1+RING+function+is+essential+for+tumor+suppression+but+dispensable+for+therapy+resistance&#x00026;journal=Cancer+Cell&#x00026;volume=20&#x00026;pages=797-809" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B19" id="B19"></a> Drost, R., Dhillon, K. K., Van Der Gulden, H., Van Der Heijden, I., Brandsma, I., Cruz, C., et al. (2016). BRCA1 185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. <i>J. Clin. Invest</i>. 126, 2903&#x02013;2918. doi: 10.1172/JCI70196</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/27454287" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1172/JCI70196" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R.+Drost&#x00026;author=K.+K.+Dhillon&#x00026;author=H.+Van+Der+Gulden&#x00026;author=I.+Van+Der+Heijden&#x00026;author=I.+Brandsma&#x00026;author=C.+Cruz+&#x00026;publication_year=2016&#x00026;title=BRCA1+185delAG+tumors+may+acquire+therapy+resistance+through+expression+of+RING-less+BRCA1&#x00026;journal=J.+Clin.+Invest&#x00026;volume=126&#x00026;pages=2903-2918" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B20" id="B20"></a> Drusedau, M., Dreesen, J. C., Derks-Smeets, I., Coonen, E., van Golde, R., van Echten-Arends, J., et al. (2013). PGD for hereditary breast and ovarian cancer: the route to universal tests for BRCA1 and BRCA2 mutation carriers. <i>Eur. J. Hum. Genet</i>. 21, 1361&#x02013;1368. doi: 10.1038/ejhg.2013.50</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/23531862" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/ejhg.2013.50" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M.+Drusedau&#x00026;author=J.+C.+Dreesen&#x00026;author=I.+Derks-Smeets&#x00026;author=E.+Coonen&#x00026;author=R.+van+Golde&#x00026;author=J.+van+Echten-Arends+&#x00026;publication_year=2013&#x00026;title=PGD+for+hereditary+breast+and+ovarian+cancer%3A+the+route+to+universal+tests+for+BRCA1+and+BRCA2+mutation+carriers&#x00026;journal=Eur.+J.+Hum.+Genet&#x00026;volume=21&#x00026;pages=1361-1368" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B21" id="B21"></a> Edwards, S. M., Evans, D. G. R., Hope, Q., Norman, A., Barbachano, Y., Bullock, S., et al. (2010). Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. <i>Br. J. Cancer</i> 103, 918&#x02013;924. doi: 10.1038/sj.bjc.6605822</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/20736950" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/sj.bjc.6605822" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S.+M.+Edwards&#x00026;author=D.+G.+R.+Evans&#x00026;author=Q.+Hope&#x00026;author=A.+Norman&#x00026;author=Y.+Barbachano&#x00026;author=S.+Bullock+&#x00026;publication_year=2010&#x00026;title=Prostate+cancer+in+BRCA2+germline+mutation+carriers+is+associated+with+poorer+prognosis&#x00026;journal=Br.+J.+Cancer&#x00026;volume=103&#x00026;pages=918-924" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B22" id="B22"></a> Evers, B., and Jonkers, J. (2006). Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. <i>Oncogene</i>. 25, 5885&#x02013;5897. doi: 10.1038/sj.onc.1209871</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/16998503" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/sj.onc.1209871" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=B.+Evers&#x00026;author=J.+Jonkers+&#x00026;publication_year=2006&#x00026;title=Mouse+models+of+BRCA1+and+BRCA2+deficiency%3A+past+lessons,+current+understanding+and+future+prospects&#x00026;journal=Oncogene&#x00026;volume=25&#x00026;pages=5885-5897" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B23" id="B23"></a> Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. <i>Nature</i> 434, 917&#x02013;921. doi: 10.1038/nature03445</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/15829967" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nature03445" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H.+Farmer&#x00026;author=N.+McCabe&#x00026;author=C.+J.+Lord&#x00026;author=A.+N.+Tutt&#x00026;author=D.+A.+Johnson&#x00026;author=T.+B.+Richardson+&#x00026;publication_year=2005&#x00026;title=Targeting+the+DNA+repair+defect+in+BRCA+mutant+cells+as+a+therapeutic+strategy&#x00026;journal=Nature&#x00026;volume=434&#x00026;pages=917-921" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B24" id="B24"></a> Finch, A., Beiner, M., Lubinski, J., Lynch, H. T., Moller, P., Rosen, B., et al. (2006). Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. <i>JAMA</i> 296, 185&#x02013;192. doi: 10.1001/jama.296.2.185</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/16835424" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1001/jama.296.2.185" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A.+Finch&#x00026;author=M.+Beiner&#x00026;author=J.+Lubinski&#x00026;author=H.+T.+Lynch&#x00026;author=P.+Moller&#x00026;author=B.+Rosen+&#x00026;publication_year=2006&#x00026;title=Salpingo-oophorectomy+and+the+risk+of+ovarian,+fallopian+tube,+and+peritoneal+cancers+in+women+with+a+BRCA1+or+BRCA2+mutation&#x00026;journal=JAMA&#x00026;volume=296&#x00026;pages=185-192" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B25" id="B25"></a> Fourati, A., Louchez, M. M., Fournier, J., Gamoudi, A., Rahal, K., El May, M. V., et al. (2014). Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer. <i>Bull. Cancer</i> 101, E36&#x02013;E40. doi: 10.1684/bdc.2014.2049</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/25418591" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1684/bdc.2014.2049" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A.+Fourati&#x00026;author=M.+M.+Louchez&#x00026;author=J.+Fournier&#x00026;author=A.+Gamoudi&#x00026;author=K.+Rahal&#x00026;author=M.+V.+El+May+&#x00026;publication_year=2014&#x00026;title=Screening+for+common+mutations+in+BRCA1+and+BRCA2+genes%3A+interest+in+genetic+testing+of+Tunisian+families+with+breast+and%2For+ovarian+cancer&#x00026;journal=Bull.+Cancer&#x00026;volume=101&#x00026;pages=E36-E40" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B26" id="B26"></a> Genomes Project, C., Auton, A., Brooks, L. D., Durbin, R. M., Garrison, E. P., Kang, H. M., et al. (2015). A global reference for human genetic variation. <i>Nature</i> 526, 68&#x02013;74. doi: 10.1038/nature15393</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/26432245" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nature15393" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C.+Genomes+Project&#x00026;author=A.+Auton&#x00026;author=L.+D.+Brooks&#x00026;author=R.+M.+Durbin&#x00026;author=E.+P.+Garrison&#x00026;author=H.+M.+Kang+&#x00026;publication_year=2015&#x00026;title=A+global+reference+for+human+genetic+variation&#x00026;journal=Nature&#x00026;volume=526&#x00026;pages=68-74" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B27" id="B27"></a> Heidemann, S., Fischer, C., Engel, C., Fischer, B., Harder, L., Schlegelberger, B., et al. (2012). Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management. <i>Breast Cancer Res. Treat</i>. 134, 1229&#x02013;1239. doi: 10.1007/s10549-012-2050-4</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/22535016" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10549-012-2050-4" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S.+Heidemann&#x00026;author=C.+Fischer&#x00026;author=C.+Engel&#x00026;author=B.+Fischer&#x00026;author=L.+Harder&#x00026;author=B.+Schlegelberger+&#x00026;publication_year=2012&#x00026;title=Double+heterozygosity+for+mutations+in+BRCA1+and+BRCA2+in+German+breast+cancer+patients%3A+implications+on+test+strategies+and+clinical+management&#x00026;journal=Breast+Cancer+Res.+Treat&#x00026;volume=134&#x00026;pages=1229-1239" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B28" id="B28"></a> Johnson, W. G. (1980). Metabolic interference and the&#x0002B;- heterozygote. a hypothetical form of simple inheritance which is neither dominant nor recessive. <i>Am. J. Hum. Genet</i>. 32:374.</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/6770678" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?author=W.+G.+Johnson+&#x00026;publication_year=1980&#x00026;title=Metabolic+interference+and+the+-+heterozygote.+a+hypothetical+form+of+simple+inheritance+which+is+neither+dominant+nor+recessive&#x00026;journal=Am.+J.+Hum.+Genet&#x00026;volume=32&#x00026;pages=374" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B29" id="B29"></a> Kelley, M. R., Kidd, S., Deutsch, W. A., and Young, M. W. (1987). Mutations altering the structure of epidermal growth factor-like coding sequences at the Drosophila Notch locus. <i>Cell</i>. 51, 539&#x02013;548. doi: 10.1016/0092-8674(87)90123-1</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/3119223" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/0092-8674(87)90123-1" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M.+R.+Kelley&#x00026;author=S.+Kidd&#x00026;author=W.+A.+Deutsch&#x00026;author=M.+W.+Young+&#x00026;publication_year=1987&#x00026;title=Mutations+altering+the+structure+of+epidermal+growth+factor-like+coding+sequences+at+the+Drosophila+Notch+locus&#x00026;journal=Cell&#x00026;volume=51&#x00026;pages=539-548" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B30" id="B30"></a> Kim, H., Cho, D. Y., Choi, D. H., Choi, S. Y., Shin, I., Park, W., et al. (2012). Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer. <i>Breast Cancer Res. Treat</i>. 134, 1315&#x02013;1326. doi: 10.1007/s10549-012-2159-5</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/22798144" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10549-012-2159-5" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H.+Kim&#x00026;author=D.+Y.+Cho&#x00026;author=D.+H.+Choi&#x00026;author=S.+Y.+Choi&#x00026;author=I.+Shin&#x00026;author=W.+Park+&#x00026;publication_year=2012&#x00026;title=Characteristics+and+spectrum+of+BRCA1+and+BRCA2+mutations+in+3,922+Korean+patients+with+breast+and+ovarian+cancer&#x00026;journal=Breast+Cancer+Res.+Treat&#x00026;volume=134&#x00026;pages=1315-1326" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B31" id="B31"></a> Laarabi, F. Z., Ratbi, I., Elalaoui, S. C., Mezzouar, L., Doubaj, Y., Bouguenouch, L., et al. (2017). High frequency of the recurrent c. 1310_1313delAAGA BRCA2 mutation in the North-East of Morocco and implication for hereditary breast-ovarian cancer prevention and control. <i>BMC Res. Notes</i> 10:188. doi: 10.1186/s13104-017-2511-2</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/28577564" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s13104-017-2511-2" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=F.+Z.+Laarabi&#x00026;author=I.+Ratbi&#x00026;author=S.+C.+Elalaoui&#x00026;author=L.+Mezzouar&#x00026;author=Y.+Doubaj&#x00026;author=L.+Bouguenouch+&#x00026;publication_year=2017&#x00026;title=High+frequency+of+the+recurrent+c.+1310_1313delAAGA+BRCA2+mutation+in+the+North-East+of+Morocco+and+implication+for+hereditary+breast-ovarian+cancer+prevention+and+control&#x00026;journal=BMC+Res.+Notes&#x00026;volume=10&#x00026;pages=188" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B32" id="B32"></a> Landrum, M. J., Chitipiralla, S., Brown, G. R., Chen, C., Gu, B., Hart, J., et al. (2020). ClinVar: improvements to accessing data. <i>Nucleic Acids Res</i>. 48(D1), D835&#x02013;D844. doi: 10.1093/nar/gkz972</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/31777943" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/nar/gkz972" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M.+J.+Landrum&#x00026;author=S.+Chitipiralla&#x00026;author=G.+R.+Brown&#x00026;author=C.+Chen&#x00026;author=B.+Gu&#x00026;author=J.+Hart+&#x00026;publication_year=2020&#x00026;title=ClinVar%3A+improvements+to+accessing+data&#x00026;journal=Nucleic+Acids+Res&#x00026;volume=48&#x00026;pages=D835-D844" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B33" id="B33"></a> Lavie, O., Narod, S., Lejbkowicz, F., Dishon, S., Goldberg, Y., Gemer, O., et al. (2011). Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population. <i>Ann. Oncol</i>. 22, 964&#x02013;966. doi: 10.1093/annonc/mdq460</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/20924075" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/annonc/mdq460" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=O.+Lavie&#x00026;author=S.+Narod&#x00026;author=F.+Lejbkowicz&#x00026;author=S.+Dishon&#x00026;author=Y.+Goldberg&#x00026;author=O.+Gemer+&#x00026;publication_year=2011&#x00026;title=Double+heterozygosity+in+the+BRCA1+and+BRCA2+genes+in+the+Jewish+population&#x00026;journal=Ann.+Oncol&#x00026;volume=22&#x00026;pages=964-966" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B34" id="B34"></a> Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., et al. (2016). Analysis of protein-coding genetic variation in 60,706 humans. <i>Nature</i> 536, 285&#x02013;291. doi: 10.1038/nature19057</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/27535533" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nature19057" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M.+Lek&#x00026;author=K.+J.+Karczewski&#x00026;author=E.+V.+Minikel&#x00026;author=K.+E.+Samocha&#x00026;author=E.+Banks&#x00026;author=T.+Fennell+&#x00026;publication_year=2016&#x00026;title=Analysis+of+protein-coding+genetic+variation+in+60,706+humans&#x00026;journal=Nature&#x00026;volume=536&#x00026;pages=285-291" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B35" id="B35"></a> Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. <i>Bioinformatics</i> 25, 1754&#x02013;1760. doi: 10.1093/bioinformatics/btp324</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/19451168" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/bioinformatics/btp324" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H.+Li&#x00026;author=R.+Durbin+&#x00026;publication_year=2009&#x00026;title=Fast+and+accurate+short+read+alignment+with+Burrows-Wheeler+transform&#x00026;journal=Bioinformatics&#x00026;volume=25&#x00026;pages=1754-1760" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B36" id="B36"></a> Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., et al. (2009). The Sequence alignment/Map format and SAMtools. <i>Bioinformatics</i> 25, 2078&#x02013;2079. doi: 10.1093/bioinformatics/btp352</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/19505943" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/bioinformatics/btp352" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H.+Li&#x00026;author=B.+Handsaker&#x00026;author=A.+Wysoker&#x00026;author=T.+Fennell&#x00026;author=J.+Ruan&#x00026;author=N.+Homer+&#x00026;publication_year=2009&#x00026;title=The+Sequence+alignment%2FMap+format+and+SAMtools&#x00026;journal=Bioinformatics&#x00026;volume=25&#x00026;pages=2078-2079" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B37" id="B37"></a> Lubinski, J., Phelan, C. M., Ghadirian, P., Lynch, H. T., Garber, J., Weber, B., et al. (2004). Cancer variation associated with the position of the mutation in the BRCA2 gene. <i>Fam. Cancer</i> 3, 1&#x02013;10. doi: 10.1023/B:FAME.0000026816.32400.45</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/15131399" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1023/B:FAME.0000026816.32400.45" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J.+Lubinski&#x00026;author=C.+M.+Phelan&#x00026;author=P.+Ghadirian&#x00026;author=H.+T.+Lynch&#x00026;author=J.+Garber&#x00026;author=B.+Weber+&#x00026;publication_year=2004&#x00026;title=Cancer+variation+associated+with+the+position+of+the+mutation+in+the+BRCA2+gene&#x00026;journal=Fam.+Cancer&#x00026;volume=3&#x00026;pages=1-10" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B38" id="B38"></a> Masood Gilani, G., and Kamal, S. (2004). Risk factors for breast cancer in Pakistani women aged less than 45 years. <i>Ann. Hum. Biol</i>. 31, 398&#x02013;407. doi: 10.1080/0301446042000226763</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/15513691" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1080/0301446042000226763" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=G.+Masood+Gilani&#x00026;author=S.+Kamal+&#x00026;publication_year=2004&#x00026;title=Risk+factors+for+breast+cancer+in+Pakistani+women+aged+less+than+45+years&#x00026;journal=Ann.+Hum.+Biol&#x00026;volume=31&#x00026;pages=398-407" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B39" id="B39"></a> Mehrgou, A., and Akouchekian, M. (2016). The importance of BRCA1 and BRCA2 genes mutations in breast cancer development. <i>Med. J. Islam. Repub. Iran</i>. 30:369.</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/27493913" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?author=A.+Mehrgou&#x00026;author=M.+Akouchekian+&#x00026;publication_year=2016&#x00026;title=The+importance+of+BRCA1+and+BRCA2+genes+mutations+in+breast+cancer+development&#x00026;journal=Med.+J.+Islam.+Repub.+Iran&#x00026;volume=30&#x00026;pages=369" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B40" id="B40"></a> Nielsen, S. M., Eccles, D. M., Romero, I. L., Al-Mulla, F., Balmana, J., Biancolella, M., et al. (2018). Genetic testing and clinical management practices for variants in non-BRCA1/2 breast (and breast/ovarian) cancer susceptibility genes: an international survey by the evidence-based network for the interpretation of germline mutant alleles (ENIGMA) clinical working group. <i>JCO Precision Oncol</i>. 2:PO.18.00091. doi: 10.1200/PO.18.00091</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/31517176" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1200/PO.18.00091" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S.+M.+Nielsen&#x00026;author=D.+M.+Eccles&#x00026;author=I.+L.+Romero&#x00026;author=F.+Al-Mulla&#x00026;author=J.+Balmana&#x00026;author=M.+Biancolella+&#x00026;publication_year=2018&#x00026;title=Genetic+testing+and+clinical+management+practices+for+variants+in+non-BRCA1%2F2+breast+(and+breast%2Fovarian)+cancer+susceptibility+genes%3A+an+international+survey+by+the+evidence-based+network+for+the+interpretation+of+germline+mutant+alleles+(ENIGMA)+clinical+working+group&#x00026;journal=JCO+Precision+Oncol&#x00026;volume=2&#x00026;pages=PO.18.00091" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B41" id="B41"></a> Pensabene, M., Spagnoletti, I., Capuano, I., Condello, C., Pepe, S., Contegiacomo, A., et al. (2009). Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling. <i>Ann. Oncol</i>. 20, 874&#x02013;878. doi: 10.1093/annonc/mdn724</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/19179552" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/annonc/mdn724" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M.+Pensabene&#x00026;author=I.+Spagnoletti&#x00026;author=I.+Capuano&#x00026;author=C.+Condello&#x00026;author=S.+Pepe&#x00026;author=A.+Contegiacomo+&#x00026;publication_year=2009&#x00026;title=Two+mutations+of+BRCA2+gene+at+exon+and+splicing+site+in+a+woman+who+underwent+oncogenetic+counseling&#x00026;journal=Ann.+Oncol&#x00026;volume=20&#x00026;pages=874-878" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B42" id="B42"></a> Rahman, N., and Scott, R. H. (2007). Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players. <i>Human Mol. Genet</i>. 16, R60&#x02013;R66. doi: 10.1093/hmg/ddm026</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/17613548" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/hmg/ddm026" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=N.+Rahman&#x00026;author=R.+H.+Scott+&#x00026;publication_year=2007&#x00026;title=Cancer+genes+associated+with+phenotypes+in+monoallelic+and+biallelic+mutation+carriers%3A+new+lessons+from+old+players&#x00026;journal=Human+Mol.+Genet&#x00026;volume=16&#x00026;pages=R60-R66" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B43" id="B43"></a> Rebbeck, T. R., Friebel, T. M., Mitra, N., Wan, F., Chen, S., Andrulis, I. L., et al. (2016). Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. <i>Breast Cancer Res</i>. 18:112. doi: 10.1186/s13058-016-0768-3</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/27836010" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s13058-016-0768-3" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=T.+R.+Rebbeck&#x00026;author=T.+M.+Friebel&#x00026;author=N.+Mitra&#x00026;author=F.+Wan&#x00026;author=S.+Chen&#x00026;author=I.+L.+Andrulis+&#x00026;publication_year=2016&#x00026;title=Inheritance+of+deleterious+mutations+at+both+BRCA1+and+BRCA2+in+an+international+sample+of+32,295+women&#x00026;journal=Breast+Cancer+Res&#x00026;volume=18&#x00026;pages=112" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B44" id="B44"></a> Rebbeck, T. R., Mitra, N., Wan, F., Sinilnikova, O. M., Healey, S., McGuffog, L., et al. (2015). Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. <i>JAMA</i> 313, 1347&#x02013;1361. doi: 10.1001/jama.2014.5985</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/25849179" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1001/jama.2014.5985" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=T.+R.+Rebbeck&#x00026;author=N.+Mitra&#x00026;author=F.+Wan&#x00026;author=O.+M.+Sinilnikova&#x00026;author=S.+Healey&#x00026;author=L.+McGuffog+&#x00026;publication_year=2015&#x00026;title=Association+of+type+and+location+of+BRCA1+and+BRCA2+mutations+with+risk+of+breast+and+ovarian+cancer&#x00026;journal=JAMA&#x00026;volume=313&#x00026;pages=1347-1361" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B45" id="B45"></a> Rojas, K., and Stuckey, A. (2016). Breast cancer epidemiology and risk factors. <i>Clin. Obstet. Gynecol</i>. 59, 651&#x02013;672. doi: 10.1097/GRF.0000000000000239</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/27681694" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1097/GRF.0000000000000239" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=K.+Rojas&#x00026;author=A.+Stuckey+&#x00026;publication_year=2016&#x00026;title=Breast+cancer+epidemiology+and+risk+factors&#x00026;journal=Clin.+Obstet.+Gynecol&#x00026;volume=59&#x00026;pages=651-672" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B46" id="B46"></a> Romdhane, L., Mezzi, N., Hamdi, Y., El-Kamah, G., Barakat, A., and Abdelhak, S. (2019). Consanguinity and inbreeding in health and disease in North African populations. <i>Annu. Rev. Genomics Hum. Genet</i>. 20, 155&#x02013;179. doi: 10.1146/annurev-genom-083118-014954</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/31039041" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1146/annurev-genom-083118-014954" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L.+Romdhane&#x00026;author=N.+Mezzi&#x00026;author=Y.+Hamdi&#x00026;author=G.+El-Kamah&#x00026;author=A.+Barakat&#x00026;author=S.+Abdelhak+&#x00026;publication_year=2019&#x00026;title=Consanguinity+and+inbreeding+in+health+and+disease+in+North+African+populations&#x00026;journal=Annu.+Rev.+Genomics+Hum.+Genet&#x00026;volume=20&#x00026;pages=155-179" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B47" id="B47"></a> Sawyer, S. L., Tian, L., K&#x000E4;hk&#x000F6;nen, M., Schwartzentruber, J., Kircher, M., Majewski, J., et al. (2015). Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. <i>Cancer Discov</i>. 5, 135&#x02013;142. doi: 10.1158/2159-8290.CD-14-1156</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/25472942" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1158/2159-8290.CD-14-1156" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S.+L.+Sawyer&#x00026;author=L.+Tian&#x00026;author=M.+K&#x000E4;hk&#x000F6;nen&#x00026;author=J.+Schwartzentruber&#x00026;author=M.+Kircher&#x00026;author=J.+Majewski+&#x00026;publication_year=2015&#x00026;title=Biallelic+mutations+in+BRCA1+cause+a+new+Fanconi+anemia+subtype&#x00026;journal=Cancer+Discov&#x00026;volume=5&#x00026;pages=135-142" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B48" id="B48"></a> Schwarz, J. M., Rodelsperger, C., Schuelke, M., and Seelow, D. (2010). MutationTaster evaluates disease-causing potential of sequence alterations. <i>Nat. Methods</i> 7, 575&#x02013;576. doi: 10.1038/nmeth0810-575</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/20676075" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nmeth0810-575" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J.+M.+Schwarz&#x00026;author=C.+Rodelsperger&#x00026;author=M.+Schuelke&#x00026;author=D.+Seelow+&#x00026;publication_year=2010&#x00026;title=MutationTaster+evaluates+disease-causing+potential+of+sequence+alterations&#x00026;journal=Nat.+Methods&#x00026;volume=7&#x00026;pages=575-576" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B49" id="B49"></a> Servick, K. (2014). Breast cancer: a world of differences. <i>Am. Assoc. Adv. Sci</i>. doi: 10.1126/science.343.6178.1452</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/24675948" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1126/science.343.6178.1452" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=K.+Servick+&#x00026;publication_year=2014&#x00026;title=Breast+cancer%3A+a+world+of+differences&#x00026;journal=Am.+Assoc.+Adv.+Sci" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B50" id="B50"></a> Silvestri, V., Leslie, G., Barnes, D. R., Group, C., Agnarsson, B. A., Aittomaki, K., et al. (2020). Characterization of the cancer spectrum in men with germline BRCA1 and BRCA2 pathogenic variants: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). <i>JAMA Oncol</i>. 6, 1218&#x02013;1230. doi: 10.1001/jamaoncol.2020.2134</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/32614418" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1001/jamaoncol.2020.2134" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=V.+Silvestri&#x00026;author=G.+Leslie&#x00026;author=D.+R.+Barnes&#x00026;author=C.+Group&#x00026;author=B.+A.+Agnarsson&#x00026;author=K.+Aittomaki+&#x00026;publication_year=2020&#x00026;title=Characterization+of+the+cancer+spectrum+in+men+with+germline+BRCA1+and+BRCA2+pathogenic+variants%3A+results+from+the+consortium+of+investigators+of+modifiers+of+BRCA1%2F2+(CIMBA)&#x00026;journal=JAMA+Oncol&#x00026;volume=6&#x00026;pages=1218-1230" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B51" id="B51"></a> Stephens, M., Smith, N. J., and Donnelly, P. (2001). A new statistical method for haplotype reconstruction from population data. <i>Am. J. Human Genet</i>. 68, 978&#x02013;989. doi: 10.1086/319501</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/11254454" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1086/319501" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M.+Stephens&#x00026;author=N.+J.+Smith&#x00026;author=P.+Donnelly+&#x00026;publication_year=2001&#x00026;title=A+new+statistical+method+for+haplotype+reconstruction+from+population+data&#x00026;journal=Am.+J.+Human+Genet&#x00026;volume=68&#x00026;pages=978-989" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B52" id="B52"></a> Szabo, C., Masiello, A., Ryan, J. F., Consortium, B., and Brody, L. C. (2000). The breast cancer information core: database design, structure, and scope. <i>Hum. Mutat</i>. 16, 123&#x02013;131. doi: 10.1002/1098-1004(200008)16:2&#x0003C;123::AID-HUMU4&#x0003E;3.0.CO;2-Y</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/10923033" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/1098-1004(200008)16:2&#x0003C;123::AID-HUMU4&#x0003E;3.0.CO;2-Y" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C.+Szabo&#x00026;author=A.+Masiello&#x00026;author=J.+F.+Ryan&#x00026;author=B.+Consortium&#x00026;author=L.+C.+Brody+&#x00026;publication_year=2000&#x00026;title=The+breast+cancer+information+core%3A+database+design,+structure,+and+scope&#x00026;journal=Hum.+Mutat&#x00026;volume=16&#x00026;pages=123-131" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B53" id="B53"></a> Thomassen, M., Hansen, T. V., Borg, A., Lianee, H. T., Wikman, F., Pedersen, I. S., et al. (2008). BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer. <i>Acta Oncol</i>. 47, 772&#x02013;777. doi: 10.1080/02841860802004974</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/18465347" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1080/02841860802004974" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M.+Thomassen&#x00026;author=T.+V.+Hansen&#x00026;author=A.+Borg&#x00026;author=H.+T.+Lianee&#x00026;author=F.+Wikman&#x00026;author=I.+S.+Pedersen+&#x00026;publication_year=2008&#x00026;title=BRCA1+and+BRCA2+mutations+in+Danish+families+with+hereditary+breast+and%2For+ovarian+cancer&#x00026;journal=Acta+Oncol&#x00026;volume=47&#x00026;pages=772-777" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B54" id="B54"></a> Thompson, D., Easton, D., and Breast Cancer Linkage, C. (2001). Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. <i>Am. J. Hum. Genet</i>. 68, 410&#x02013;419. doi: 10.1086/318181</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/11170890" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1086/318181" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=D.+Thompson&#x00026;author=D.+Easton&#x00026;author=C.+Breast+Cancer+Linkage+&#x00026;publication_year=2001&#x00026;title=Variation+in+cancer+risks,+by+mutation+position,+in+BRCA2+mutation+carriers&#x00026;journal=Am.+J.+Hum.+Genet&#x00026;volume=68&#x00026;pages=410-419" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B55" id="B55"></a> Van der Auwera, G., and O&#x00027;Connor, B. (2020). <i>Genomics in the Cloud: Using Docker</i>, GATK, and WDL in Terra. O&#x00027;Reilly Media.</p>
<p class="ReferencesCopy2"><a href="http://scholar.google.com/scholar_lookup?author=G.+Van+der+Auwera&#x00026;author=B.+O&#x00027;Connor+&#x00026;publication_year=2020&#x00026;title=Genomics+in+the+Cloud%3A+Using+Docker" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B56" id="B56"></a> Venkitaraman, A. R. (2019). How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility? <i>DNA Repair</i>. 81:102668. doi: 10.1016/j.dnarep.2019.102668</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/31337537" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.dnarep.2019.102668" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A.+R.+Venkitaraman+&#x00026;publication_year=2019&#x00026;title=How+do+mutations+affecting+the+breast+cancer+genes+BRCA1+and+BRCA2+cause+cancer+susceptibility%3F&#x00026;journal=DNA+Repair&#x00026;volume=81&#x00026;pages=102668" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B57" id="B57"></a> Zehani, S., Maalej, M., Hsairi, M., Hechiche, M., Romdhane, B., Boussen, H., et al. (2009). Breast cancer in Tunisia: epidemiologic characteristics and trends in incidence. <i>Tunis. Med</i>. 87, 417&#x02013;425.</p>
<p class="ReferencesCopy2"><a href="https://pubmed.ncbi.nlm.nih.gov/20063673" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?author=S.+Zehani&#x00026;author=M.+Maalej&#x00026;author=M.+Hsairi&#x00026;author=M.+Hechiche&#x00026;author=B.+Romdhane&#x00026;author=H.+Boussen+&#x00026;publication_year=2009&#x00026;title=Breast+cancer+in+Tunisia%3A+epidemiologic+characteristics+and+trends+in+incidence&#x00026;journal=Tunis.+Med&#x00026;volume=87&#x00026;pages=417-425" target="_blank">Google Scholar</a></p>
</div>
</div>
<div class="thinLineM20"></div>
<div class="AbstractSummary">
<p><span>Keywords:</span> breast cancer susceptibility, whole exome sequencing, <i>Cis</i> double heterozygosity, BRCA2 mutations, early age of onset, phenotype genotype correlation</p>
<p><span>Citation:</span> Hamdi Y, Boujemaa M, Mighri N, Mejri N, Jaidane O, Ben Nasr S, Bouaziz H, Hassouna JB, Zribi A, Berrazaga Y, Rachdi H, Daoud N, El Benna H, Labidi S, Haddaoui A, Rahal K, Benna F, Boussen H, Abdelhak S and Boubaker S (2021) Identification of <i>BRCA2 Cis</i> Double Heterozygous Breast Cancer Cases Using Whole Exome Sequencing: Phenotypic Expression and Impact on Personalized Oncology. <i>Front. Genet.</i> 12:674990. doi: 10.3389/fgene.2021.674990</p>
<p id="timestamps"><span>Received:</span> 17 April 2021; <span>Accepted:</span> 08 July 2021;<br> <span>Published:</span> 12 August 2021.</p>
<div><p>Edited by:</p> <a href="http://loop.frontiersin.org/people/48619/overview">Mehdi Pirooznia</a>, National Heart, Lung, and Blood Institute (NHLBI), United States</div>
<div><p>Reviewed by:</p> <a href="http://loop.frontiersin.org/people/955227/overview">Stephen R. Piccolo</a>, Brigham Young University, United States<br> <a href="http://loop.frontiersin.org/people/795534/overview">Deli Liu</a>, Weill Cornell Medicine, United States</div>
<p><span>Copyright</span> &#x000A9; 2021 Hamdi, Boujemaa, Mighri, Mejri, Jaidane, Ben Nasr, Bouaziz, Hassouna, Zribi, Berrazaga, Rachdi, Daoud, El Benna, Labidi, Haddaoui, Rahal, Benna, Boussen, Abdelhak and Boubaker. This is an open-access article distributed under the terms of the <a rel="license" href="http://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License (CC BY)</a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
<p><span>&#x0002A;Correspondence:</span> Yosr Hamdi, <a id="encmail">eW9zci5oYW1kaUBwYXN0ZXVyLnRu</a></p>
<div class="clear"></div>
</div></div></div><p class="AbstractSummary__disclaimer"><span>Disclaimer: </span> All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. </p></div></div><!----></main><aside class="Layout__aside"><div class="ArticleDetails__wrapper"><div class="ArticleDetails__aside"><div class="ArticleDetails__aside__responsiveButtons"><div class="ActionsDropDown" id="FloatingButtonsEl"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--icon ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fgene.2021.674990" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="ArticleDetails__aside__responsiveButtons__items"><span></span><div class="ArticleDetailsShare__responsive"><button class="ArticleDetailsShare__trigger" aria-label="Open share options"></button><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div></div><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeIconButton ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><!----></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Export citation</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div></div></div><div class="TotalViews"><div class="TotalViews__data"><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">4,8K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Total views</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">1,5K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Downloads</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">2</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Citations</div></div></div><div class="ImpactMetricsInfoPopover"><button aria-label="Open impact metrics info" class="ImpactMetricsInfoPopover__button"></button><div class="ImpactMetricsInfoPopover__tooltip"><button aria-label="Close impact metrics info" class="ImpactMetricsInfoPopover__tooltip__closeButton"></button><div class="ImpactMetricsInfoPopover__tooltip__text"> Citation numbers are available from Dimensions </div></div></div></div><div class="TotalViews__viewImpactLink"><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View article impact" href="http://loop-impact.frontiersin.org/impact/article/674990#totalviews/views" target="_blank" data-event="customLink-link-a_viewArticleImpact"><span>View article impact</span></a></span></div><div class="TotalViews__altmetric"><div data-badge-popover="bottom" data-badge-type="donut" data-doi="10.3389/fgene.2021.674990" data-condensed="true" data-link-target="new" class="altmetric-embed"></div><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View altmetric score" href="https://www.altmetric.com/details/doi/10.3389/fgene.2021.674990" target="_blank" data-event="customLink-link-a_viewAltmetricScore"><span>View altmetric score</span></a></span></div></div><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Edited by</div><!--[--><a href="https://loop.frontiersin.org/people/48619/overview" data-event="editorInfo-a-mehdiPirooznia" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">M</span><span class="notranslate">P</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Mehdi  Pirooznia</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Johnson &amp; Johnson, United States</div></div></a><!--]--></div></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Reviewed by</div><!--[--><a href="https://loop.frontiersin.org/people/795534/overview" data-event="editorInfo-a-deliLiu" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">D</span><span class="notranslate">L</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Deli  Liu</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Weill Cornell Medicine, Cornell University, United States</div></div></a><a href="https://loop.frontiersin.org/people/955227/overview" data-event="editorInfo-a-stephenRPiccolo" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">S</span><span class="notranslate">R</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Stephen  R Piccolo</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Brigham Young University, United States</div></div></a><!--]--></div></div><div class="ArticleDetailsGlossary ArticleDetailsGlossary--open"><button class="ArticleDetailsGlossary__header"><div class="ArticleDetailsGlossary__header__title">Table of contents</div><div class="ArticleDetailsGlossary__header__arrow"></div></button><div class="ArticleDetailsGlossary__content"><ul class="flyoutJournal">
<li><a href="#h1">Abstract</a></li>
<li><a href="#h2">Introduction</a></li>
<li><a href="#h3">Materials and Methods</a></li>
<li><a href="#h4">Results</a></li>
<li><a href="#h5">Discussion</a></li>
<li><a href="#h6">Conclusion</a></li>
<li><a href="#h7">Data Availability Statement</a></li>
<li><a href="#h8">Ethics Statement</a></li>
<li><a href="#h9">Author Contributions</a></li>
<li><a href="#h10">Funding</a></li>
<li><a href="#h11">Conflict of Interest</a></li>
<li><a href="#h12">Publisher&#x00027;s Note</a></li>
<li><a href="#h13">Acknowledgments</a></li>
<li><a href="#h14">Supplementary Material</a></li>
<li><a href="#h15">Abbreviations</a></li>
<li><a href="#h16">References</a></li>
</ul></div></div><span></span><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeOutline ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Export citation</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="CheckForUpdates"><button data-target="crossmark" class="CheckForUpdates__link" data-event="checkForUpdates-btn-openModal"><img class="CheckForUpdates__link__img" src="/ap-2024/images/crossmark.svg" alt="Crossmark icon"><div class="CheckForUpdates__link__text">Check for updates</div></button></div><div class="AnnouncementCard"><p class="AnnouncementCard__title">Frontiers&#39; impact</p><article class="CardA"><div class="CardA__wrapper CardA__wrapper--vertical"><figure class="FrontiersImage CardA__img"><picture class="FrontiersImage"><!--[--><source srcset="https://images-provider.frontiersin.org/api/ipx/w=440&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 563px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=320x400&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1024px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=268x280&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1441px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><!--]--><img src="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" class="is-inside-mask" alt loading="eager"></picture><!----></figure><div class="CardA__info"><!--[--><h2 class="CardA__title">Articles published with Frontiers have received 12 million total citations</h2><p class="CardA__text">Your research is the real superpower - learn how we maximise its impact through our leading community journals</p><br><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--small Link--icon Link--chevronRight Link--right" aria-label="Explore our impact metrics" href="https://www.frontiersin.org/about/impact" target="_self" data-event="customLink-linkType-a_exploreOurImpactMe"><span>Explore our impact metrics</span></a></span><!--]--></div></div></article></div><!----><!----></div><div><div class="Modal Modal--noFooter"><button aria-label="Close modal" class="Modal__overlay" data-event="modal-overlay-close"></button><div class="Modal__container"><div class="Modal__header"><p class="Modal__title">Supplementary Material</p><button aria-label="Close modal" class="Modal__close" data-event="modal-button-close"></button></div><div class="Modal__body"><!--[--><div class="SupplementalData"><ul class="SupplementalData__list"><!--[--><!--]--></ul></div><!--]--><!----></div><!----><!----></div></div></div><div><div class="FloatingButtons"><!----><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--iconDownload ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Download</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fgene.2021.674990" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><!----></div></div></div></aside></div><div class=""><!----></div><!--]--></div><!----><footer class="Footer"><div class="Footer__wrapper"><div class="Footer__sections"><ul class="Accordion"><!--[--><!--[--><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Guidelines</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/guidelines/author-guidelines" target="_self" data-event="footer-block_0-a_authorGuidelines">Author guidelines</a></li><li><a href="https://www.frontiersin.org/for-authors/author-services" target="_self" data-event="footer-block_0-a_servicesForAuthors">Services for authors</a></li><li><a href="https://www.frontiersin.org/guidelines/policies-and-publication-ethics" target="_self" data-event="footer-block_0-a_policiesAndPublicationE">Policies and publication ethics</a></li><li><a href="https://www.frontiersin.org/guidelines/editor-guidelines" target="_self" data-event="footer-block_0-a_editorGuidelines">Editor guidelines</a></li><li><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="footer-block_0-a_feePolicy">Fee policy</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Explore</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/articles" target="_self" data-event="footer-block_1-a_articles">Articles</a></li><li><a href="https://www.frontiersin.org/research-topics" target="_self" data-event="footer-block_1-a_researchTopics">Research Topics </a></li><li><a href="https://www.frontiersin.org/journals" target="_self" data-event="footer-block_1-a_journals">Journals</a></li><li><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="footer-block_1-a_howWePublish">How we publish</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Outreach</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://forum.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForum">Frontiers Forum </a></li><li><a href="https://policylabs.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersPolicyLabs">Frontiers Policy Labs </a></li><li><a href="https://kids.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForYoungMinds">Frontiers for Young Minds</a></li><li><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="footer-block_2-a_frontiersPlanetPrize">Frontiers Planet Prize</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Connect</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://helpcenter.frontiersin.org" target="_blank" data-event="footer-block_3-a_helpCenter">Help center</a></li><li><a href="https://subscription-management.frontiersin.org/emails/preferences#block0" target="_blank" data-event="footer-block_3-a_emailsAndAlerts">Emails and alerts </a></li><li><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="footer-block_3-a_contactUs">Contact us </a></li><li><a href="https://www.frontiersin.org/submission/submit" target="_self" data-event="footer-block_3-a_submit">Submit</a></li><li><a href="https://careers.frontiersin.org/" target="_blank" data-event="footer-block_3-a_careerOpportunities">Career opportunities</a></li><!--]--></ul><!--]--></div></li><!--]--><!--]--></ul><div class="Footer__socialLinks"><div class="Footer__socialLinks__title">Follow us</div><!--[--><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--facebook Link--right" aria-label="Frontiers Facebook" href="https://www.facebook.com/Frontiersin" target="_blank" data-event="footer-facebook-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--twitter Link--right" aria-label="Frontiers Twitter" href="https://twitter.com/frontiersin" target="_blank" data-event="footer-twitter-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--linkedin Link--right" aria-label="Frontiers LinkedIn" href="https://www.linkedin.com/company/frontiers" target="_blank" data-event="footer-linkedIn-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--instagram Link--right" aria-label="Frontiers Instagram" href="https://www.instagram.com/frontiersin_" target="_blank" data-event="footer-instagram-a_true"><span></span></a></span><!--]--></div></div><div class="Footer__copyright"><div><span> 2025 Frontiers Media SA. All rights reserved.</span></div><div><a href="https://www.frontiersin.org/legal/privacy-policy" target="_blank">Privacy policy</a><span>|</span><a href="https://www.frontiersin.org/legal/terms-and-conditions" target="_blank">Terms and conditions</a></div></div></div></footer><div class="SnackbarWrapper"><div class="SnackbarManager"><!--[--><!--]--></div></div></div><noscript><iframe
            src="https://tag-manager.frontiersin.org/ns.html?id=GTM-M322FV2&gtm_auth=owVbWxfaJr21yQv1fe1cAQ&gtm_preview=env-1&gtm_cookies_win=x"
            height="0"
            width="0"
            style="display: none; visibility: hidden">
          </iframe></noscript><!--]--></div><div id="teleports"></div><script type="application/json" id="__NUXT_DATA__" data-ssr="true">[["ShallowReactive",1],{"data":2,"state":4,"once":10,"_errors":11,"serverRendered":13,"path":14,"pinia":15},["ShallowReactive",3],{},["Reactive",5],{"$ssite-config":6},{"env":7,"name":8,"url":9},"production","Frontiers articles","https://article-pages-2024.frontiersin.org/",["Set"],["ShallowReactive",12],{},true,"/journals/genetics/articles/10.3389/fgene.2021.674990/full",["Reactive",16],{"main":17,"user":514,"article":515,"articleHub":953,"mainHeader":957},{"ibar":18,"footer":276,"newsletterComponent":-1,"snackbarItem":358,"toggleShowSnackbar":359,"contentfulJournal":360,"graphJournal":414,"settingsFeaturesSwitchers":418,"templateToggleBanner":419,"tenantConfig":479},{"tenantLogo":19,"journalLogo":19,"aboutUs":20,"submitUrl":113,"showSubmitButton":13,"journal":114,"sectionTerm":207,"aboutJournal":208,"mainLinks":257,"journalLinks":264,"helpCenterLink":273},"",[21,38,47,71,87],{"title":22,"links":23},"Who we are",[24,29,32,35],{"text":25,"url":26,"target":27,"ariaLabel":28},"Mission and values","https://www.frontiersin.org/about/mission","_self",null,{"text":30,"url":31,"target":27,"ariaLabel":28},"History","https://www.frontiersin.org/about/history",{"text":33,"url":34,"target":27,"ariaLabel":28},"Leadership","https://www.frontiersin.org/about/leadership",{"text":36,"url":37,"target":27,"ariaLabel":28},"Awards","https://www.frontiersin.org/about/awards",{"title":39,"links":40},"Impact and progress",[41,44],{"text":42,"url":43,"target":27,"ariaLabel":28},"Frontiers' impact","https://www.frontiersin.org/about/impact",{"text":45,"url":46,"target":27,"ariaLabel":28},"Our annual reports","https://www.frontiersin.org/about/annual-reports",{"title":48,"links":49},"Publishing model",[50,53,56,59,62,65,68],{"text":51,"url":52,"target":27,"ariaLabel":28},"How we publish","https://www.frontiersin.org/about/how-we-publish",{"text":54,"url":55,"target":27,"ariaLabel":28},"Open access","https://www.frontiersin.org/about/open-access",{"text":57,"url":58,"target":27,"ariaLabel":28},"Peer review","https://www.frontiersin.org/about/peer-review",{"text":60,"url":61,"target":27,"ariaLabel":28},"Research integrity","https://www.frontiersin.org/about/research-integrity",{"text":63,"url":64,"target":27,"ariaLabel":28},"Research Topics","https://www.frontiersin.org/about/research-topics",{"text":66,"url":67,"target":27,"ariaLabel":28},"FAIR Data Management","https://www.frontiersin.org/about/fair-data-management",{"text":69,"url":70,"target":27,"ariaLabel":28},"Fee policy","https://www.frontiersin.org/about/fee-policy",{"title":72,"links":73},"Services",[74,78,81,84],{"text":75,"url":76,"target":77,"ariaLabel":28},"Societies","https://publishingpartnerships.frontiersin.org/","_blank",{"text":79,"url":80,"target":27,"ariaLabel":28},"National consortia","https://www.frontiersin.org/open-access-agreements/consortia",{"text":82,"url":83,"target":27,"ariaLabel":28},"Institutional partnerships","https://www.frontiersin.org/about/open-access-agreements",{"text":85,"url":86,"target":27,"ariaLabel":28},"Collaborators","https://www.frontiersin.org/about/collaborators",{"title":88,"links":89},"More from Frontiers",[90,94,97,101,105,109],{"text":91,"url":92,"target":77,"ariaLabel":93},"Frontiers Forum","https://forum.frontiersin.org/","this link will take you to the Frontiers Forum website",{"text":95,"url":96,"target":27,"ariaLabel":28},"Frontiers Planet Prize","https://www.frontiersin.org/about/frontiers-planet-prize",{"text":98,"url":99,"target":77,"ariaLabel":100},"Press office","https://pressoffice.frontiersin.org/","this link will take you to the Frontiers press office website",{"text":102,"url":103,"target":27,"ariaLabel":104},"Sustainability","https://www.frontiersin.org/about/sustainability","link to information about Frontiers' sustainability",{"text":106,"url":107,"target":77,"ariaLabel":108},"Career opportunities","https://careers.frontiersin.org/","this link will take you to the Frontiers careers website",{"text":110,"url":111,"target":27,"ariaLabel":112},"Contact us","https://www.frontiersin.org/about/contact","this link will take you to the help pages to contact our support team","https://www.frontiersin.org/submission/submit?domainid=1&fieldid=30&specialtyid=0&entitytype=2&entityid=240",{"id":115,"name":116,"slug":117,"sections":118},240,"Frontiers in Genetics","genetics",[119,123,127,131,135,139,143,147,151,155,159,163,167,171,175,179,183,187,191,195,199,203],{"id":120,"name":121,"slug":122},549,"Applied Genetic Epidemiology","applied-genetic-epidemiology",{"id":124,"name":125,"slug":126},536,"Behavioral and Psychiatric Genetics","behavioral-and-psychiatric-genetics",{"id":128,"name":129,"slug":130},2030,"Cancer Genetics and Oncogenomics","cancer-genetics-and-oncogenomics",{"id":132,"name":133,"slug":134},551,"Computational Genomics","computational-genomics",{"id":136,"name":137,"slug":138},2512,"Cytogenomics","cytogenomics",{"id":140,"name":141,"slug":142},650,"ELSI in Science and Genetics","elsi-in-science-and-genetics",{"id":144,"name":145,"slug":146},455,"Epigenomics and Epigenetics","epigenomics-and-epigenetics",{"id":148,"name":149,"slug":150},535,"Evolutionary and Population Genetics","evolutionary-and-population-genetics",{"id":152,"name":153,"slug":154},596,"Genetics of Aging","genetics-of-aging",{"id":156,"name":157,"slug":158},635,"Genetics of Common and Rare Diseases","genetics-of-common-and-rare-diseases",{"id":160,"name":161,"slug":162},557,"Genomic Assay Technology","genomic-assay-technology",{"id":164,"name":165,"slug":166},1520,"Genomics of Plants and the Phytoecosystem","genomics-of-plants-and-the-phytoecosystem",{"id":168,"name":169,"slug":170},1419,"Human and Medical Genomics","human-and-medical-genomics",{"id":172,"name":173,"slug":174},2237,"Immunogenetics","immunogenetics",{"id":176,"name":177,"slug":178},241,"Livestock Genomics","livestock-genomics",{"id":180,"name":181,"slug":182},19,"Neurogenomics","neurogenomics",{"id":184,"name":185,"slug":186},3423,"Nutritional Genomics","nutritional-genomics",{"id":188,"name":189,"slug":190},198,"Pharmacogenetics and Pharmacogenomics","pharmacogenetics-and-pharmacogenomics",{"id":192,"name":193,"slug":194},556,"Predictive Toxicology and Exposomics","predictive-toxicology-and-exposomics",{"id":196,"name":197,"slug":198},555,"RNA","rna",{"id":200,"name":201,"slug":202},454,"Statistical Genetics and Methodology","statistical-genetics-and-methodology",{"id":204,"name":205,"slug":206},685,"Stem Cell Research","stem-cell-research","Sections",[209,233],{"title":210,"links":211},"Scope",[212,215,218,221,224,227,230],{"text":213,"url":214,"target":27,"ariaLabel":28},"Field chief editors","https://www.frontiersin.org/journals/genetics/about#about-editors",{"text":216,"url":217,"target":27,"ariaLabel":28},"Mission & scope","https://www.frontiersin.org/journals/genetics/about#about-scope",{"text":219,"url":220,"target":27,"ariaLabel":28},"Facts","https://www.frontiersin.org/journals/genetics/about#about-facts",{"text":222,"url":223,"target":27,"ariaLabel":28},"Journal sections","https://www.frontiersin.org/journals/genetics/about#about-submission",{"text":225,"url":226,"target":27,"ariaLabel":28},"Open access statement","https://www.frontiersin.org/journals/genetics/about#about-open",{"text":228,"url":229,"target":27,"ariaLabel":28},"Copyright statement","https://www.frontiersin.org/journals/genetics/about#copyright-statement",{"text":231,"url":232,"target":27,"ariaLabel":28},"Quality","https://www.frontiersin.org/journals/genetics/about#about-quality",{"title":234,"links":235},"For authors",[236,239,242,245,248,251,254],{"text":237,"url":238,"target":27,"ariaLabel":28},"Why submit?","https://www.frontiersin.org/journals/genetics/for-authors/why-submit",{"text":240,"url":241,"target":27,"ariaLabel":28},"Article types","https://www.frontiersin.org/journals/genetics/for-authors/article-types",{"text":243,"url":244,"target":27,"ariaLabel":28},"Author guidelines","https://www.frontiersin.org/journals/genetics/for-authors/author-guidelines",{"text":246,"url":247,"target":27,"ariaLabel":28},"Editor guidelines","https://www.frontiersin.org/journals/genetics/for-authors/editor-guidelines",{"text":249,"url":250,"target":27,"ariaLabel":28},"Publishing fees","https://www.frontiersin.org/journals/genetics/for-authors/publishing-fees",{"text":252,"url":253,"target":27,"ariaLabel":28},"Submission checklist","https://www.frontiersin.org/journals/genetics/for-authors/submission-checklist",{"text":255,"url":256,"target":27,"ariaLabel":28},"Contact editorial office","https://www.frontiersin.org/journals/genetics/for-authors/contact-editorial-office",[258,261],{"text":259,"url":260,"target":27,"ariaLabel":28},"All journals","https://www.frontiersin.org/journals",{"text":262,"url":263,"target":27,"ariaLabel":28},"All articles","https://www.frontiersin.org/articles",[265,268,270],{"text":266,"url":267,"target":27,"ariaLabel":28},"Articles","articles",{"text":63,"url":269,"target":27,"ariaLabel":28},"research-topics",{"text":271,"url":272,"target":27,"ariaLabel":28},"Editorial board","editors",{"text":274,"url":275,"target":77,"ariaLabel":274},"Help center","https://helpcenter.frontiersin.org",{"blocks":277,"socialLinks":331,"copyright":355,"termsAndConditionsUrl":356,"privacyPolicyUrl":357},[278,292,302,316],{"title":279,"links":280},"Guidelines",[281,283,286,289,291],{"text":243,"url":282,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/author-guidelines",{"text":284,"url":285,"target":27,"ariaLabel":28},"Services for authors","https://www.frontiersin.org/for-authors/author-services",{"text":287,"url":288,"target":27,"ariaLabel":28},"Policies and publication ethics","https://www.frontiersin.org/guidelines/policies-and-publication-ethics",{"text":246,"url":290,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/editor-guidelines",{"text":69,"url":70,"target":27,"ariaLabel":28},{"title":293,"links":294},"Explore",[295,296,299,301],{"text":266,"url":263,"target":27,"ariaLabel":28},{"text":297,"url":298,"target":27,"ariaLabel":28},"Research Topics ","https://www.frontiersin.org/research-topics",{"text":300,"url":260,"target":27,"ariaLabel":28},"Journals",{"text":51,"url":52,"target":27,"ariaLabel":28},{"title":303,"links":304},"Outreach",[305,308,311,315],{"text":306,"url":92,"target":77,"ariaLabel":307},"Frontiers Forum ","Frontiers Forum website",{"text":309,"url":310,"target":77,"ariaLabel":28},"Frontiers Policy Labs ","https://policylabs.frontiersin.org/",{"text":312,"url":313,"target":77,"ariaLabel":314},"Frontiers for Young Minds","https://kids.frontiersin.org/","Frontiers for Young Minds journal",{"text":95,"url":96,"target":27,"ariaLabel":28},{"title":317,"links":318},"Connect",[319,320,324,327,330],{"text":274,"url":275,"target":77,"ariaLabel":274},{"text":321,"url":322,"target":77,"ariaLabel":323},"Emails and alerts ","https://subscription-management.frontiersin.org/emails/preferences#block0","Subscribe to Frontiers emails",{"text":325,"url":111,"target":27,"ariaLabel":326},"Contact us ","Subscribe to newsletter",{"text":328,"url":329,"target":27,"ariaLabel":28},"Submit","https://www.frontiersin.org/submission/submit",{"text":106,"url":107,"target":77,"ariaLabel":28},[332,340,345,350],{"link":333,"type":336,"color":337,"icon":338,"size":339,"hiddenText":13},{"text":334,"url":335,"target":77,"ariaLabel":334},"Frontiers Facebook","https://www.facebook.com/Frontiersin","Link","Grey","Facebook","Medium",{"link":341,"type":336,"color":337,"icon":344,"size":339,"hiddenText":13},{"text":342,"url":343,"target":77,"ariaLabel":28},"Frontiers Twitter","https://twitter.com/frontiersin","Twitter",{"link":346,"type":336,"color":337,"icon":349,"size":339,"hiddenText":13},{"text":347,"url":348,"target":77,"ariaLabel":28},"Frontiers LinkedIn","https://www.linkedin.com/company/frontiers","LinkedIn",{"link":351,"type":336,"color":337,"icon":354,"size":339,"hiddenText":13},{"text":352,"url":353,"target":77,"ariaLabel":28},"Frontiers Instagram","https://www.instagram.com/frontiersin_","Instagram","Frontiers Media SA. All rights reserved.","https://www.frontiersin.org/legal/terms-and-conditions","https://www.frontiersin.org/legal/privacy-policy",{},false,{"__typename":361,"identifier":115,"name":116,"slug":117,"banner":362,"description":407,"mission":408,"palette":409,"impactFactor":410,"citeScore":411,"citations":412,"showTagline":28,"twitter":413},"Journal",[363],{"id":364,"src":365,"name":366,"type":367,"width":368,"height":369,"idHash":370,"archive":371,"brandId":372,"limited":371,"fileSize":373,"isPublic":374,"original":375,"copyright":19,"extension":376,"thumbnails":378,"dateCreated":386,"description":19,"orientation":387,"userCreated":388,"watermarked":371,"dateModified":386,"datePublished":389,"ecsArchiveFiles":390,"propertyOptions":391,"property_Channel":396,"property_Sub-Type":398,"property_Asset_Type":400,"activeOriginalFocusPoint":402,"property_Office_Department":405},"12AFEC62-10F2-4A9B-900C8422E4B53D54","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/webimage-A09D2065-D257-435D-987C43E79D7FBDFD.png","FGENE_Main Visual_Purple_Website","image",6016,4016,"3b54103c3aad636f",0,"22C10171-81B3-4DA6-99342F272A32E8BB",10275124,1,"https://brand.frontiersin.org/m/3b54103c3aad636f/original/FGENE_Main-Visual_Purple_Website.jpg",[377],"jpg",{"mini":379,"thul":380,"webimage":365,"Guidelines":381,"WebsiteJpg_XL":382,"WebsiteWebP_L":383,"WebsiteWebP_M":384,"WebsiteWebP_XL":385},"https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/mini-8741E412-02C1-4126-84DDA81B97389D5E.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/thul-D176A038-2FDA-438D-B9A7E98CF3926BBE.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/511D4207-6085-4D24-9E5E56EBCA9EBCD2/Guidelines-FGENE_Main Visual_Purple_Website.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/511D4207-6085-4D24-9E5E56EBCA9EBCD2/WebsiteJpg_XL-FGENE_Main Visual_Purple_Website.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/511D4207-6085-4D24-9E5E56EBCA9EBCD2/WebsiteWebP_L-FGENE_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/511D4207-6085-4D24-9E5E56EBCA9EBCD2/WebsiteWebP_M-FGENE_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/12AFEC62-10F2-4A9B-900C8422E4B53D54/511D4207-6085-4D24-9E5E56EBCA9EBCD2/WebsiteWebP_XL-FGENE_Main Visual_Purple_Website.webp","2022-06-27T09:59:48Z","landscape","Caroline Sutter","2022-06-27T09:27:09Z",[],[392,393,394,395],"414FB2D4-2283-43FD-BE14E534ECA67928","6C18119B-14BD-4951-B437696F4357BD33","7C692885-DB25-4858-B1FB4FF47B241E9B","D88C0047-EC30-4506-A7DF28A4D765E1CF",[397],"frontiersin_org",[399],"Main_Visual",[401],"Photography",{"x":403,"y":404},3008,2008,[406],"Publishing","Explore research from the world's most cited genetics and heredity journal, advancing our understanding of genes from humans to plants and other model organisms.","\u003Cp>Frontiers in Genetics publishes research on genes and genomes relating to all the domains of life, from humans to livestock, and plants to other model organisms.\u003C/p>\n\n\u003Cp>Led by Field Chief Editor Enrico Domenici (Department of Cellular, Computational and Integrated Biology, University of Trento, Italy) Frontiers in Genetics is indexed in PubMed Central (PMC) and Scopus, among others, and explores the full spectrum of genetic and genomic research, encompassing fundamental studies and their clinical applications, while also embracing methodological advancements and exploring their applications and implications. Topics of interest include, but are not limited to:\u003C/p>\n\n\u003Cdiv> &bull; how genes or genomes relate to traits and humanpathophysiology\u003C/div>\n\u003Cdiv> &bull; advances in genomic data technology and analysis\u003C/div>\n\u003Cdiv> &bull; gene flow among species and populations\u003C/div>\n\u003Cdiv> &bull; livestock genome research Interactions between organisms, theirenvironment, and xenobiotics\u003C/div>\n\u003Cdiv> &bull; molecular and cellular genetics\u003C/div>\n\u003Cdiv> &bull; societal implicationsof genetic research.\u003C/div>\n\u003Cbr>\n\u003Cp>Submissions that emphasize advancement in the understanding of the function and variability of the genome, the use of genetic and genomic tools, and the analysis of the genetic underpinnings of biological processes are of particular interest to this journal.\u003Cp>\n\u003Cp>Furthermore, the journal actively welcomes submissions which support and advance the UNs Sustainable Development Goals (SDGs), notably SDG 3: good health and well-being.\u003C/p>\n\u003Cp>Manuscripts that focus solely on clinical outcomes, patient management, or therapeutic interventions without a clear genetic or genomic component are not suitable for publication in this journal. Studies that are purely epidemiological or observational, without a foundation in genetic or genomic mechanisms, are also not within the scope of this journal. Manuscripts consisting solely of bioinformatics, computational analyses of public data which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo) or are not highly innovative are not suitable for publication in this journal. Please refer to the \u003Ca href=\"https://www.frontiersin.org/guidelines/policies-and-publication-ethics#standards-for-research-methodology:~:text=complaints%20and%20allegations.-,Standards%20for%20research%20methodology,-Experiments\">Frontiers Standards for research methodology policy\u003C/a>, for more information.\u003C/p>\n\u003Cp>Frontiers in Genetics is committed to advancing developments in the field of genetics and genomics by allowing unrestricted access to articles, and communicating scientific knowledge to both researchers and the public, to enable the scientific breakthroughs of the future.\u003C/p>","purple","3.7","5.2","277710","@FrontGenetics",{"id":115,"name":116,"slug":117,"abbreviation":415,"isOnline":13,"isOpenForSubmissions":13,"citeScore":416,"impactFactor":417},"fgene",6.2,2.8,{"displayTitlePillLabels":13,"displayRelatedArticlesBox":13,"showEditors":13,"showReviewers":13,"showLoopImpactLink":13,"enableFigshare":359},{"isPublic":13,"allowCompanyUsers":359,"whiteListEmails":420,"enableAllJournals":13,"whiteListJournals":442},[421,422,423,424,425,426,427,428,429,426,430,431,432,433,434,435,436,437,438,439,440,441],"Y2FybG9zLmxvcmNhQGZyb250aWVyc2luLm9yZw==","ZGFuaWVsLmx1ekBmcm9udGllcnNpbi5vcmc=","bGF1cmEudGVuYUBmcm9udGllcnNpbi5vcmc=","cmFmYWVsLnJpYW5jaG9AZnJvbnRpZXJzaW4ub3Jn","amFtZXMuc21hbGxib25lQGZyb250aWVyc2luLm9yZw==","ZnJhbi5tb3Jlbm9AZnJvbnRpZXJzaW4ub3Jn","c2FtdWVsLmZlcm5hbmRlekBmcm9udGllcnNpbi5vcmc=","YmFyYmFyYS5jYXJjYW5naXVAZnJvbnRpZXJzaW4ub3Jn","aXZhbi5zYW50YW1hcmlhQGZyb250aWVyc2luLm9yZw==","aHVlLnRyYW5AZnJvbnRpZXJzaW4ub3Jn","Z29uY2Fsby52YXJnYXNAZnJvbnRpZXJzaW4ub3Jn","bHVjaWUuc2VubkBmcm9udGllcnNpbi5vcmc=","bG9ybi5mcmFzZXJAZnJvbnRpZXJzaW4ub3Jn","ZWxzYS5jYXJyb25AZnJvbnRpZXJzaW4ub3Jn","bWFhcnRlbi52YW5kaWpja0Bmcm9udGllcnNpbi5vcmc=","YmluZGh1LmtyaXNobmFuQGZyb250aWVyc2luLm9yZw==","bWF0dGhldy5hdHR3YXRlcnNAZnJvbnRpZXJzaW4ub3Jn","Z2l1bGlhLnZhbHNlY2NoaUBmcm9udGllcnNpbi5vcmc=","ZmFiaWFuLmRlbGxhbW9ydGVAZnJvbnRpZXJzaW4ub3Jn","dmlqYXlhbi5wcEBwaXRzb2x1dGlvbnMuY29t","Z3VpbGxhdW1lLnNldXJhdEBmcm9udGllcnNpbi5vcmc=",[443,444,445,446,447,448,374,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478],2232,1729,2357,2456,2176,2333,1843,602,106,616,310,657,3123,1468,2137,628,1566,2726,2086,1490,451,141,1335,2655,1238,604,698,1547,176,1440,403,1239,755,2136,609,1534,{"spaceId":374,"name":374,"availableJournalPages":480,"announcement":484},[267,272,269,481,482,483],"volumes","about","community-reviewers",{"__typename":485,"sys":486,"preHeader":42,"title":488,"description":489,"image":490,"link":512},"Announcement",{"id":487},"5ITtnTtQgAzPPGH6rX0AlM","Articles published with Frontiers have received 12 million total citations","Your research is the real superpower - learn how we maximise its impact through our leading community journals",[491],{"archive":371,"brandId":372,"copyright":28,"dateCreated":492,"dateModified":493,"datePublished":494,"description":28,"extension":495,"fileSize":497,"height":498,"id":499,"isPublic":371,"limited":371,"name":500,"orientation":387,"original":28,"thumbnails":501,"type":367,"watermarked":371,"width":508,"videoPreviewURLs":509,"tags":510,"textMetaproperties":511,"src":502},"2025-06-18T12:58:01Z","2025-06-18T14:15:34Z","2025-06-18T12:57:32Z",[496],"png",1365026,920,"7C5269C4-3C83-4591-951A74D15B95DAEA","Impact metrics banner for article pages",{"webimage":502,"thul":503,"mini":504,"WebsiteWebP_L":505,"WebsiteWebP_M":506,"Guidelines":507},"https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/thul-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/mini-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_L/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_M/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/Guidelines/Impact-metrics-banner-for-article-pages.png",1600,[],[],[],{"text":513,"url":43,"target":27,"ariaLabel":28},"Explore our impact metrics",{"loggedUserInfo":-1},{"currentArticle":516,"isPreviewPage":359,"hasSupplementalData":359,"showCrossmarkWidget":13,"articleTemplate":752,"currentArticlePageMetaInfo":753,"xmlParsedArticleContent":-1,"xmlParsingError":-1},{"id":517,"doi":518,"title":519,"acceptanceDate":520,"receptionDate":521,"publicationDate":522,"lastModifiedDate":523,"isPublished":13,"abstract":524,"researchTopic":28,"articleType":525,"stage":528,"keywords":530,"authors":537,"editors":679,"reviewers":689,"journal":707,"section":714,"impactMetrics":716,"volume":720,"articleVolume":721,"relatedArticles":722,"isPublishedV2":359,"contents":723,"files":727},674990,"10.3389/fgene.2021.674990","Identification of BRCA2 Cis Double Heterozygous Breast Cancer Cases Using Whole Exome Sequencing: Phenotypic Expression and Impact on Personalized Oncology",["Date","2021-07-08T10:35:52.000Z"],["Date","2021-04-17T14:39:18.000Z"],["Date","2021-08-12T00:00:00.000Z"],["Date","2025-11-25T04:33:14.646Z"],"BRCA1 and BRCA2 are the most commonly mutated breast cancer susceptibility genes that convey a high risk of breast and ovarian cancer. Most BRCA1 or BRCA2 mutation carriers have inherited a single heterozygous mutation. In recent years, very rare cases with biallelic or trans double heterozygous mutations on BRCA1 and or BRCA2 have been identified and seem to be associated with distinctive phenotypes. Given that this genotype-phenotype correlation in cancer-predisposing hereditary conditions is of relevance for oncological prevention and genetic testing, it is important to investigate these rare BRCA genotypes for better clinical management of BRCA mutation carriers. Here we present the first report on Cis double heterozygosity (Cis DH) on BRCA2 gene identified using Whole exome sequencing (WES) in a Tunisian family with two BRCA2 mutations namely: c.632-1G>A and c.1310_1313DelAAGA that are both reported as pathogenic in ClinVar database. Subsequent analysis in 300 high-risk Tunisian breast cancer families detected this Cis double heterozygous genotype in 8 additional individuals belonging to 5 families from the same geographic origin suggesting a founder effect. Moreover, the observed Cis DH seems to be associated with an early age of onset (mean age = 35.33 years) and severe phenotype of the disease with high breast cancer grade and multiple cancer cases in the family. The identification of unusual BRCA genotypes in this Tunisian cohort highlights the importance of performing genetic studies in under-investigated populations. This will also potentially help to avoid erroneous classifications of genetic variants in African population and therefore avoiding clinical misdiagnosis of BRCA related cancers.  Our findings will also have an impact on the genetic testing and the clinical management of North African breast cancer patients as well as patients from different other ethnic groups in regard to several emerging target therapies such as PARP inhibitors.",{"id":526,"name":527},24,"Original Research",{"id":529,"name":19},18,[531,532,533,534,535,536],"Breast cancer susceptibility","whole exome sequencing","Cis double heterozygosity","BRCA2 mutations","Early age of onset","Phenotype genotype correlation",[538,549,556,563,572,580,589,597,603,609,615,621,627,634,641,647,653,660,668,672],{"id":539,"firstName":540,"middleName":19,"lastName":541,"givenNames":542,"isCorresponding":359,"isProfilePublic":13,"userId":539,"email":-1,"affiliations":543},887862,"Yosr","Hamdi","Yosr ",[544,547],{"organizationName":545,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},"Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar","Tunisia",{"organizationName":548,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},"Laboratory of Human and Experimental Pathology, Institut Pasteur de Tunis",{"id":550,"firstName":551,"middleName":19,"lastName":552,"givenNames":553,"isCorresponding":359,"isProfilePublic":13,"userId":550,"email":-1,"affiliations":554},956852,"Maroua","Boujemaa","Maroua ",[555],{"organizationName":545,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":557,"firstName":558,"middleName":19,"lastName":559,"givenNames":560,"isCorresponding":359,"isProfilePublic":13,"userId":557,"email":-1,"affiliations":561},958051,"Najah","Mighri","Najah ",[562],{"organizationName":545,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":564,"firstName":565,"middleName":19,"lastName":566,"givenNames":567,"isCorresponding":359,"isProfilePublic":13,"userId":564,"email":-1,"affiliations":568},1126033,"Nesrine","Mejri","Nesrine ",[569,570],{"organizationName":545,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":571,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},"Medical Oncology Department, Abderrahmen Mami Hospital",{"id":573,"firstName":574,"middleName":19,"lastName":575,"givenNames":576,"isCorresponding":359,"isProfilePublic":13,"userId":573,"email":-1,"affiliations":577},957930,"Olfa","Jaidane","Olfa ",[578],{"organizationName":579,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},"Surgical Oncology Department, Salah Azaiez Institute of Cancer",{"id":581,"firstName":582,"middleName":19,"lastName":583,"givenNames":584,"isCorresponding":359,"isProfilePublic":13,"userId":581,"email":-1,"affiliations":585},957319,"Sonia","Ben Nasr","Sonia ",[586,587],{"organizationName":545,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":588,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},"Department of Medical Oncology, Military Hospital",{"id":590,"firstName":591,"middleName":19,"lastName":592,"givenNames":593,"isCorresponding":359,"isProfilePublic":13,"userId":590,"email":-1,"affiliations":594},1130977,"Hanen","Bouaziz","Hanen ",[595,596],{"organizationName":545,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":579,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":371,"firstName":598,"middleName":19,"lastName":599,"givenNames":600,"isCorresponding":359,"isProfilePublic":359,"userId":371,"email":-1,"affiliations":601},"Jamel Ben","Hassouna","Jamel Ben ",[602],{"organizationName":579,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":371,"firstName":604,"middleName":19,"lastName":605,"givenNames":606,"isCorresponding":359,"isProfilePublic":359,"userId":371,"email":-1,"affiliations":607},"Aref","Zribi","Aref ",[608],{"organizationName":588,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":371,"firstName":610,"middleName":19,"lastName":611,"givenNames":612,"isCorresponding":359,"isProfilePublic":359,"userId":371,"email":-1,"affiliations":613},"Yossra","Berrazaga","Yossra ",[614],{"organizationName":571,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":371,"firstName":616,"middleName":19,"lastName":617,"givenNames":618,"isCorresponding":359,"isProfilePublic":359,"userId":371,"email":-1,"affiliations":619},"Haifa","Rachdi","Haifa ",[620],{"organizationName":571,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":371,"firstName":622,"middleName":19,"lastName":623,"givenNames":624,"isCorresponding":359,"isProfilePublic":359,"userId":371,"email":-1,"affiliations":625},"Nouha","Daoud","Nouha ",[626],{"organizationName":571,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":628,"firstName":629,"middleName":19,"lastName":630,"givenNames":631,"isCorresponding":359,"isProfilePublic":13,"userId":628,"email":-1,"affiliations":632},1126178,"Houda","El Benna","Houda ",[633],{"organizationName":571,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":371,"firstName":635,"middleName":19,"lastName":636,"givenNames":637,"isCorresponding":359,"isProfilePublic":359,"userId":371,"email":-1,"affiliations":638},"Soumaya","Labidi","Soumaya ",[639,640],{"organizationName":545,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":571,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":371,"firstName":642,"middleName":19,"lastName":643,"givenNames":644,"isCorresponding":359,"isProfilePublic":359,"userId":371,"email":-1,"affiliations":645},"Abderrazek","Haddaoui","Abderrazek ",[646],{"organizationName":588,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":371,"firstName":648,"middleName":19,"lastName":649,"givenNames":650,"isCorresponding":359,"isProfilePublic":359,"userId":371,"email":-1,"affiliations":651},"Khaled","Rahal","Khaled ",[652],{"organizationName":579,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":371,"firstName":654,"middleName":19,"lastName":655,"givenNames":656,"isCorresponding":359,"isProfilePublic":359,"userId":371,"email":-1,"affiliations":657},"Farouk","Benna","Farouk ",[658],{"organizationName":659,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},"Department of Radiation Oncology, University of Tunis",{"id":661,"firstName":662,"middleName":19,"lastName":663,"givenNames":664,"isCorresponding":359,"isProfilePublic":13,"userId":661,"email":-1,"affiliations":665},1126078,"Hamouda","Boussen","Hamouda ",[666,667],{"organizationName":545,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":571,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":371,"firstName":582,"middleName":19,"lastName":669,"givenNames":584,"isCorresponding":359,"isProfilePublic":359,"userId":371,"email":-1,"affiliations":670},"Abdelhak",[671],{"organizationName":545,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"id":371,"firstName":673,"middleName":19,"lastName":674,"givenNames":675,"isCorresponding":359,"isProfilePublic":359,"userId":371,"email":-1,"affiliations":676},"Samir","Boubaker","Samir ",[677,678],{"organizationName":545,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":548,"countryName":546,"cityName":19,"stateName":19,"zipCode":19},[680],{"id":681,"firstName":682,"middleName":19,"lastName":683,"givenNames":684,"isCorresponding":359,"isProfilePublic":13,"userId":681,"email":-1,"affiliations":685},48619,"Mehdi","Pirooznia","Mehdi ",[686],{"organizationName":687,"countryName":688,"cityName":19,"stateName":19,"zipCode":19},"Johnson & Johnson","United States",[690,698],{"id":691,"firstName":692,"middleName":19,"lastName":693,"givenNames":694,"isCorresponding":359,"isProfilePublic":13,"userId":691,"email":-1,"affiliations":695},795534,"Deli","Liu","Deli ",[696],{"organizationName":697,"countryName":688,"cityName":19,"stateName":19,"zipCode":19},"Weill Cornell Medicine, Cornell University",{"id":699,"firstName":700,"middleName":701,"lastName":702,"givenNames":703,"isCorresponding":359,"isProfilePublic":13,"userId":699,"email":-1,"affiliations":704},955227,"Stephen","R","Piccolo","Stephen  R",[705],{"organizationName":706,"countryName":688,"cityName":19,"stateName":19,"zipCode":19},"Brigham Young University",{"id":115,"slug":117,"name":116,"shortName":708,"electronicISSN":709,"field":710,"specialtyId":28,"journalSectionPaths":712},"Front. Genet.","1664-8021",{"id":711,"domainId":374},30,[713],{"section":714},{"id":128,"name":129,"slug":130,"specialtyId":715},2437,{"views":717,"downloads":718,"citations":719},4812,1541,2,12,"Volume 12 - 2021",[],{"titleHtml":724,"fullTextHtml":725,"menuHtml":726},"Identification of \u003Ci>BRCA2 Cis\u003C/i> Double Heterozygous Breast Cancer Cases Using Whole Exome Sequencing: Phenotypic Expression and Impact on Personalized Oncology","\u003Cdiv class=\"JournalAbstract\">\n\u003Ca id=\"h1\" name=\"h1\">\u003C/a>\n\u003Cdiv class=\"authors\">\u003Cspan class=\"author-wrapper notranslate\">\n\u003Ca href=\"https://loop.frontiersin.org/people/887862\" class=\"user-id-887862\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/887862/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"\nYosr Hamdi,&#xA;\">Yosr Hamdi\u003C/a>\u003Csup>1,2\u003C/sup>\u003Csup>&#x0002A;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/956852\" class=\"user-id-956852\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/956852/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Maroua Boujemaa\">Maroua Boujemaa\u003C/a>\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/958051\" class=\"user-id-958051\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/958051/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Najah Mighri\">Najah Mighri\u003C/a>\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1126033\" class=\"user-id-1126033\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1126033/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Nesrine Mejri,\">Nesrine Mejri\u003C/a>\u003Csup>1,3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/957930\" class=\"user-id-957930\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/957930/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Olfa Jaidane\">Olfa Jaidane\u003C/a>\u003Csup>4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/957319\" class=\"user-id-957319\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/957319/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Sonia Ben Nasr,\">Sonia Ben Nasr\u003C/a>\u003Csup>1,5\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1130977\" class=\"user-id-1130977\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1130977/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Hanen Bouaziz,\">Hanen Bouaziz\u003C/a>\u003Csup>1,4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Jamel Ben Hassouna\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Jamel Ben Hassouna\u003Csup>4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Aref Zribi\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Aref Zribi\u003Csup>5\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Yossra Berrazaga\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Yossra Berrazaga\u003Csup>3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Haifa Rachdi\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Haifa Rachdi\u003Csup>3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Nouha Daoud\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Nouha Daoud\u003Csup>3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1126178\" class=\"user-id-1126178\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1126178/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Houda El Benna\">Houda El Benna\u003C/a>\u003Csup>3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Soumaya Labidi,\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Soumaya Labidi\u003Csup>1,3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Abderrazek Haddaoui\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Abderrazek Haddaoui\u003Csup>5\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Khaled Rahal\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Khaled Rahal\u003Csup>4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Farouk Benna\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Farouk Benna\u003Csup>6\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1126078\" class=\"user-id-1126078\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1126078/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Hamouda Boussen,\">Hamouda Boussen\u003C/a>\u003Csup>1,3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Sonia Abdelhak\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Sonia Abdelhak\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Samir Boubaker,\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Samir Boubaker\u003Csup>1,2\u003C/sup>\u003C/span>\u003C/div>\n\u003Cul class=\"notes\">\n\u003Cli>\u003Cspan>\u003Csup>1\u003C/sup>\u003C/span>Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, Tunisia\u003C/li>\n\u003Cli>\u003Cspan>\u003Csup>2\u003C/sup>\u003C/span>Laboratory of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunis, Tunisia\u003C/li>\n\u003Cli>\u003Cspan>\u003Csup>3\u003C/sup>\u003C/span>Medical Oncology Department, Abderrahmen Mami Hospital, Ariana, Tunisia\u003C/li>\n\u003Cli>\u003Cspan>\u003Csup>4\u003C/sup>\u003C/span>Surgical Oncology Department, Salah Azaiez Institute of Cancer, Tunis, Tunisia\u003C/li>\n\u003Cli>\u003Cspan>\u003Csup>5\u003C/sup>\u003C/span>Department of Medical Oncology, Military Hospital, Tunis, Tunisia\u003C/li>\n\u003Cli>\u003Cspan>\u003Csup>6\u003C/sup>\u003C/span>Department of Radiation Oncology, University of Tunis, Tunis, Tunisia\u003C/li>\n\u003C/ul>\n\u003Cp>\u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> are the most commonly mutated breast cancer susceptibility genes that convey a high risk of breast and ovarian cancer. Most \u003Ci>BRCA1\u003C/i> or \u003Ci>BRCA2\u003C/i> mutation carriers have inherited a single heterozygous mutation. In recent years, very rare cases with biallelic or trans double heterozygous mutations on \u003Ci>BRCA1\u003C/i> and or \u003Ci>BRCA2\u003C/i> have been identified and seem to be associated with distinctive phenotypes. Given that this genotype-phenotype correlation in cancer predisposing hereditary conditions is of relevance for oncological prevention and genetic testing, it is important to investigate these rare \u003Ci>BRCA\u003C/i> genotypes for better clinical management of \u003Ci>BRCA\u003C/i> mutation carriers. Here we present the first report on \u003Ci>Cis\u003C/i> double heterozygosity (\u003Ci>Cis\u003C/i> DH) on \u003Ci>BRCA2\u003C/i> gene identified using Whole exome sequencing (WES) in a Tunisian family with two \u003Ci>BRCA2\u003C/i> mutations namely: c.632-1G&#x0003E;A and c.1310_1313DelAAGA that are both reported as pathogenic in ClinVar database. Subsequent analysis in 300 high-risk Tunisian breast cancer families detected this \u003Ci>Cis\u003C/i> double heterozygous genotype in 8 additional individuals belonging to 5 families from the same geographic origin suggesting a founder effect. Moreover, the observed \u003Ci>Cis\u003C/i> DH seems to be associated with an early age of onset (mean age = 35.33 years) and severe phenotype of the disease with high breast cancer grade and multiple cancer cases in the family. The identification of unusual \u003Ci>BRCA\u003C/i> genotypes in this Tunisian cohort highlights the importance of performing genetic studies in under-investigated populations. This will also potentially help avoiding erroneous classifications of genetic variants in African population and therefore avoiding clinical misdiagnosis of \u003Ci>BRCA\u003C/i> related cancers. Our findings will also have an impact on the genetic testing and the clinical management of North African breast cancer patients as well as patients from different other ethnic groups in regard to several emerging target therapies such as PARP inhibitors.\u003C/p>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003C/div>\n\u003Cdiv class=\"JournalFullText\">\n\u003Ca id=\"h2\" name=\"h2\">\u003C/a>\u003Ch2>Introduction\u003C/h2>\n\u003Cp class=\"mb15\">Breast cancer is the most common malignancy in women worldwide (\u003Ca href=\"#B45\">Rojas and Stuckey, 2016\u003C/a>). Incidence and mortality rates of breast cancer differ between populations (\u003Ca href=\"#B5\">Bray et al., 2018\u003C/a>). Moreover, remarkable diversity in epidemiological and genetic characteristics of this disease have been observed (\u003Ca href=\"#B49\">Servick, 2014\u003C/a>). Since the mid-1990, extensive efforts have been dedicated to the analysis of \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i>, the two most commonly mutated breast cancer genes. So far, about 1,800 mutations have been identified on \u003Ci>BRCA1\u003C/i> and almost 2,000 mutations on \u003Ci>BRCA2\u003C/i> (\u003Ca href=\"#B52\">Szabo et al., 2000\u003C/a>). These mutations explain around 20&#x02013;30% of hereditary breast cancer cases and seem to be associated with different other cancers such as ovarian, prostate, colorectal, pancreatic, and melanoma (\u003Ca href=\"#B39\">Mehrgou and Akouchekian, 2016\u003C/a>). Indeed, the identification of a \u003Ci>BRCA\u003C/i> mutation can lead to risk or mortality reduction if optimal surveillance, risk-reducing mastectomy, and risk-reducing salpingo-oophorectomy are applied (\u003Ca href=\"#B24\">Finch et al., 2006\u003C/a>; \u003Ca href=\"#B16\">Domchek et al., 2010\u003C/a>). In addition, cancer treatment of \u003Ci>BRCA\u003C/i> mutation carriers has advanced with the development of PARP inhibitors, which take advantage of the loss of \u003Ci>BRCA1/2\u003C/i> function in tumors (\u003Ca href=\"#B23\">Farmer et al., 2005\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">The vast majority of \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> mutation carriers are single heterozygous (SH) with only one mono-allelic deleterious mutation on one of these two genes. Excluding individuals of Ashkenazi descent, it is uncommon to identify carriers of two deleterious mutations either within the same gene [biallelic or double heterozygous (DH)] or in both genes [trans heterozygous (TH)]. Indeed, biallelic mutations in \u003Ci>BRCA2\u003C/i> results in childhood Fanconi anemia (FANCD1) (\u003Ca href=\"#B2\">Alter et al., 2007\u003C/a>), which is an autosomal recessive disease resulting in developmental abnormalities, bone marrow failure, and early-onset leukemia or solid tumors. The biallelic \u003Ci>BRCA2\u003C/i> genotype has also been observed in a 31-year-old female diagnosed with colorectal cancer (\u003Ca href=\"#B11\">Degrolard-Courcet et al., 2014\u003C/a>). Biallelic mutations in \u003Ci>BRCA1\u003C/i> are much rarer because carrying the same \u003Ci>BRCA1\u003C/i> pathogenic mutation on both alleles is widely known to be embryonic lethal (\u003Ca href=\"#B22\">Evers and Jonkers, 2006\u003C/a>). However, \u003Ca href=\"#B17\">Domchek et al. (2013)\u003C/a> reported a case with biallelic \u003Ci>BRCA1\u003C/i> mutations diagnosed with an ovarian cancer at age 28 with short stature, microcephaly, developmental delay, and significant toxicity from chemotherapy. Another reported case of biallelic \u003Ci>BRCA1\u003C/i> mutations was in a woman with a Fanconi anemia disorder and breast cancer at age 23 (\u003Ca href=\"#B47\">Sawyer et al., 2015\u003C/a>). TH mutations in both \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> genes have been also reported in almost 68 cases and seem to be associated with an early age of onset and a severe disease compared to SH \u003Ci>BRCA\u003C/i> mutation carriers (\u003Ca href=\"#B27\">Heidemann et al., 2012\u003C/a>; \u003Ca href=\"#B43\">Rebbeck et al., 2016\u003C/a>). However, \u003Ci>Cis\u003C/i> double heterozygosity, have been reported in only two studies with controversial results (\u003Ca href=\"#B9\">Colombo et al., 2009\u003C/a>; \u003Ca href=\"#B41\">Pensabene et al., 2009\u003C/a>). Here we define the \u003Ci>Cis\u003C/i> DH to be the inheritance of two deleterious mutations on the same allele of a gene. To date, the phenotypic consequences of this unusual \u003Ci>BRCA\u003C/i> genotype are poorly understood.\u003C/p>\n\u003Cp class=\"mb15\">In fact, trans biallelic \u003Ci>BRCA\u003C/i> deleterious mutations, either in one gene or one allele per gene, might be expected in families with both parental lineages affected by breast and/or ovarian cancer. However, \u003Ci>Cis\u003C/i> DH most likely increases cancer occurrence in one parental bloodline, albeit, in consanguineous and endogamous populations such as the Tunisian population, \u003Ci>Cis\u003C/i> DH may increase cancer incidence in both maternal and paternal sides. Moreover, intuitively, one can anticipate that \u003Ci>Cis\u003C/i> DH is not associated with additional phenotypic consequences over and above that associated with single heterozygosity since a single mutation is sufficient to completely abolish the synthesis of a functional gene product. Contrariwise, it has been recently shown that breast and ovarian cancer risks differ depending on the position and the type of \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> mutations (\u003Ca href=\"#B44\">Rebbeck et al., 2015\u003C/a>) meaning challenges regarding their structure and function. Thus, carrying two different mutations on the same allele may be associated with a distinctive phenotype since each mutation is located in a different domain of the BRCA protein and consequently could disturb the interaction of BRCA with several other proteins. Therefore, these altered protein-protein interactions may influence the resulting phenotype.\u003C/p>\n\u003Cp class=\"mb0\">In the current study, we aimed to present a first report on a \u003Ci>BRCA2 Cis\u003C/i> double heterozygosity in 5 Tunisian families thanks to the use of whole exome sequencing. The founder and the functional effect of the two mutations have been assessed as well as the prevalence and the phenotypic spectrum of this unusual \u003Ci>BRCA2\u003C/i> genotype.\u003C/p>\n\u003Ca id=\"h3\" name=\"h3\">\u003C/a>\u003Ch2>Materials and Methods\u003C/h2>\n\u003Ch3 class=\"pt0\">Patients\u003C/h3>\n\u003Cp class=\"mb15\">Tunisian families from different geographic origins were selected based on the following selection criteria; (1) having at least 3 breast cancer cases in first or second degree relatives at any age, (2) 2 breast cancer cases with one of them diagnosed with BC before age 40, (3) isolated breast cancer cases diagnosed before age 36, (4) one case with triple negative breast cancer (TNBC) at an age &#x02264; 40 years, (5) one case and one ovarian case diagnosed at first or second degree relatives at any age, (6) at least 2 cases with breast or ovarian cancer (at any age) and at least one case with pancreas cancer or prostate cancer at first or second degree relatives.\u003C/p>\n\u003Cp class=\"mb15\">For each participant, total genomic DNA was extracted and used as a template for exome sequencing using DNeasy blood DNA extraction Kit (Qiagen) according to the manufacturer&#x00027;s instructions. DNA purity and concentration were measured using a NanoDrop&#x02122; spectrophotometer.\u003C/p>\n\u003Cp class=\"mb0\">When possible, genomic DNA samples from other affected or unaffected family members were obtained for further validation. Written informed consent was obtained from all participants. The study was conducted according to the Declaration of Helsinki Principles. Ethical approval was obtained from the biomedical ethics committee of Institut Pasteur de Tunis (2017/16/E/H&#x000F4;pital A-M).\u003C/p>\n\u003Ch3>Data Analysis\u003C/h3>\n\u003Cp class=\"mb0\">Data analysis pipeline is summarized in \u003Ca href=\"#F1\">Figure 1\u003C/a>. Exome sequences were mapped to their location in the most recent build of the human genome (hg19/b37) using the Burrows-Wheeler Aligner (BWA) software package version 0.7.5 (\u003Ca href=\"#B35\">Li and Durbin, 2009\u003C/a>). The subsequent SAM files were converted to BAM files using Samtools version 1.6 (\u003Ca href=\"#B36\">Li et al., 2009\u003C/a>). Duplicate reads were removed using Picard version 2.6 (\u003Ca href=\"http://broadinstitute.github.io/picard/\">http://broadinstitute.github.io/picard/\u003C/a>). GATK version 4.1.2 (\u003Ca href=\"#B55\">Van der Auwera and O&#x00027;Connor, 2020\u003C/a>) was then used to recalibrate the base quality scores, as well as, for SNP and short INDEL calling. Annotation and prioritization of potential disease-causing variants were performed using VarAFT (Variant Annotation and Filtering Tool) version 2.13 (\u003Ca href=\"#B14\">Desvignes et al., 2018\u003C/a>). To annotate variants, VarAFT uses ANNOVAR, a command line tool. INDELs and SNPs annotated were filtered according to several criteria: considering breast cancer as autosomal dominant disease, variants that were found in a homozygous state were removed. In addition, variants identified as intronic, intergenic, and synonymous were discarded. Then, assuming that causal variants are rare, we removed all variants with an allele frequency more than 1% either in ExAC version 0.3 (\u003Ca href=\"#B34\">Lek et al., 2016\u003C/a>), 1,000 genomes 2015-08 (\u003Ca href=\"#B26\">Genomes Project et al., 2015\u003C/a>) or ESP6500 (\u003Ca href=\"http://evs.gs.washington.edu/EVS/\">http://evs.gs.washington.edu/EVS/\u003C/a>). We also removed all variants with no functional effect (annotated as &#x0201C;Benign&#x0201D; or &#x0201C;Tolerated&#x0201D; by the different tools used to predict the functional effect of these genetic variants). Finally, we used the literature to filter the remaining set of variants by gene function and only variants located on genes involved in cancer etiology were kept.\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">FIGURE 1\u003C/div>\n\u003Cdiv class=\"FigureDesc\">\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g001.jpg\" name=\"figure1\" target=\"_blank\">\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g001.jpg\" alt=\"www.frontiersin.org\" id=\"F1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cstrong>Figure 1\u003C/strong>. Summary of the data analysis pipeline followed in the present study. Before proceeding to the alignment phase, quality control (QC1) was performed on raw sequencing data in order to ensure that the data are optimal for downstream analyses. A second quality control (QC2) was done on alignment data to reduce the alignment artifacts that could influence the quality of downstream variant calling. Subsequently, variants were filtered by keeping only heterozygous variations and discarding those with MAF &#x0003E;1% in either Exac, 1,000 genomes or ESP6500. We further removed benign or tolerated variations and focused on genes related to breast cancer susceptibility. Two pathogenic mutations were identified c.632-1G&#x0003E;A and c.1310_1313delAAGA in \u003Ci>BRCA2\u003C/i> gene.\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Ch3>Sanger Sequencing\u003C/h3>\n\u003Cp class=\"mb0\">Sanger sequencing technique was first used to validate the identified mutations resulting from the whole exome sequencing then to test the identified \u003Ci>BRCA2\u003C/i> variations in other family members or in other patients from our cohort. PCR reactions were performed on genomic DNA following standard protocols, followed by Sanger sequencing using an automated sequencer (ABI 3500; Applied Biosystems, Foster City, CA) and a cycle sequencing reaction kit (Big Dye Terminator kit, Applied Biosystems). Data were analyzed using BioEdit Sequence Alignment Editor Version 7.2.5. Sequencing was conducted using the following primers for exon 8 (8F: 5&#x02032;-GCCATATCTTACCACCTTGT-3&#x02032; and 8R: 5&#x02032;-CAGGTTTAGAGACTTTCTC-3&#x02032;) and exon 10 respectively (10BF: 5&#x02032;-CAGAAGCCCTTTGAGAGTGG-3&#x02032; and 10BR: 5&#x02032;-GGTACCTGAATCAGCATTTGC-3&#x02032;).\u003C/p>\n\u003Ch3>Splicing Predictions\u003C/h3>\n\u003Cp class=\"mb0\">The c.632-1 G&#x0003E;A mutation is located at the splicing donor site of exon 8 of \u003Ci>BRCA2\u003C/i>.The functional effect of this mutation on splicing was evaluated using different splice-site \u003Ci>in silico\u003C/i> prediction tools: Human Splice-Finder (\u003Ca href=\"#B13\">Desmet et al., 2009\u003C/a>) (\u003Ca href=\"http://www.umd.be/HSF/\">http://www.umd.be/HSF/\u003C/a>) which is an online bioinformatics tool designed to predict the effects of mutations on splicing signals, Mutation Taster (\u003Ca href=\"#B48\">Schwarz et al., 2010\u003C/a>) (\u003Ca href=\"http://www.mutationtaster.org/\">http://www.mutationtaster.org/\u003C/a>) that evaluates disease-causing potential of sequence alterations including coding and non-coding variants and Alamut (\u003Ca href=\"https://www.interactive-biosoftware.com/fr/alamut-visual/\">https://www.interactive-biosoftware.com/fr/alamut-visual/\u003C/a>). This latter integrates information from different public databases and several pathogenicity predictions tools to annotate variations. Human Splice-Finder and Mutation taster were used online while Alamut software was downloaded and used locally in order to predict the functional impact of the splice site variant.\u003C/p>\n\u003Ch3>ClinVar Database\u003C/h3>\n\u003Cp class=\"mb0\">ClinVar (\u003Ca href=\"#B32\">Landrum et al., 2020\u003C/a>) is a public database of reports on the relationships between human variations and phenotypes, that uses supporting evidence to classify genetic variants based on their pathogenicity. As a freely accessible public database, we used ClinVar to assess the pathogenicity of the two mutations identified on exons 8 and 10 of the BRCA2 gene.\u003C/p>\n\u003Ch3>RNA Extraction and RT-PCR Product Analysis\u003C/h3>\n\u003Cp class=\"mb15\">In order to assess the impact of the c.632-1 G&#x0003E;A mutation at the RNA level, total RNA has been isolated from peripheral blood using the Trizol method (Invitrogen&#x02122;).\u003C/p>\n\u003Cp class=\"mb15\">The cDNA was synthesized using random primers and SuperScript&#x02122; II Reverse Transcriptase (Invitrogen), according to the manufacturer&#x00027;s protocol.\u003C/p>\n\u003Cp class=\"mb15\">In order to amplify the cDNA sample from two patients carrying the c.632-1G&#x0003E;A mutation and a control who is a breast cancer case that do not carry the mutation, we used four combinations of forward and reverse primer pairs flanking \u003Ci>BRCA2\u003C/i> exons 5&#x02013;10 to amplify overlapping regions of the mRNA and to cover the entire open reading frame.\u003C/p>\n\u003Cp class=\"mb15\">In order to evaluate the quality of the cDNA amplification, a PCR for a housekeeping gene \u003Ci>GAPDH\u003C/i> was conducted using the following primers (5&#x02032;-GAGTCAACGGATTTGGTCGT-3&#x02032;) and (5&#x02032;-TTGATTTTGGAGGGATCTCG-3&#x02032;).\u003C/p>\n\u003Cp class=\"mb0\">RT-PCR products were separated on agarose gel and visualized by SYBR\u003Csup>&#x000AE;\u003C/sup> Safe staining then purified using Exo-SAP and characterized by direct sequencing.\u003C/p>\n\u003Ch3>Microsatellites Genotyping and Haplotype Analysis\u003C/h3>\n\u003Cp class=\"mb15\">Haplotype analysis was carried out on 60 individuals: 11 mutation carriers, 4 relatives, 8 breast cancer non-carriers, 24 breast cancer cases with unknown \u003Ci>BRCA\u003C/i> status and 13 healthy Tunisian women from the general population.\u003C/p>\n\u003Cp class=\"mb15\">Four \u003Ci>BRCA2\u003C/i> extragenic polymorphic microsatellite markers, listed in order from centromere to telomere (D13S267, D13S171, D13S260, and D13S1246) and spanning a 6.43 Mb region around the \u003Ci>BRCA2\u003C/i> gene were studied. Characteristics of the studied region and analyzed markers are presented in \u003Ca href=\"#SM1\">Supplementary Figure 1\u003C/a>.\u003C/p>\n\u003Cp class=\"mb15\">PCR primer sequences were obtained from the Probe NCBI database. Genotyping technique is based on a fluorescent-labeled M13(-21) universal primer. The PCR mix contained 20 &#x003BC;mol/L of each forward and FAM-M13 primer and 2 &#x003BC;mol/L of the reverse primer in a final 25 &#x003BC;L reaction. PCR amplification conditions are as follows: 94&#x000B0;C (5 min), then 35 cycles at 94&#x000B0;C (45 s)/annealing temperature (30 s)/72&#x000B0;C (1 min 30 s), and a final extension at 72&#x000B0;C for 10 min.\u003C/p>\n\u003Cp class=\"mb15\">One micro liter of the PCR product is added to 12 &#x003BC;l of formamide and 0.5 &#x003BC;l of GeneScan&#x02122; 500 ROX&#x02122; Size Standard and PCR product size was evaluated by capillary electrophoresis on ABI prism 3500 DNA Genetic Analyzer (Applied Biosystems, Foster City, CA). Data was analyzed using the GeneMapper V.5.0 software.\u003C/p>\n\u003Cp class=\"mb0\">Haplotypes were reconstructed by PHASE v.2.1 software (\u003Ca href=\"#B51\">Stephens et al., 2001\u003C/a>), that used Bayesian methods to predict the haplotype distribution.\u003C/p>\n\u003Ca id=\"h4\" name=\"h4\">\u003C/a>\u003Ch2>Results\u003C/h2>\n\u003Cp class=\"mb0\">A 36 years old patient (BC17) consulted for a mass in the right breast. Clinical and radiological explorations concluded to a bilateral breast cancer. She had a bilateral mastectomy with right lymph node dissection. Histopathological examination concluded for the right breast to be an infiltrating ductal carcinoma, SBRIII, positive hormone receptors with 6 metastatic lymph nodes. In the left breast, there was an intraductal carcinoma. Adjuvant treatment was indicated and consisted in right loco-regional radiotherapy, chemotherapy, chemical ovarian function suppression and hormonal therapy by Tamoxifen. Eleven years later, she developed a squamous cell carcinoma of the esophagus. A radio-induced cancer was evoked and squamous cell carcinoma was confirmed. Total oesophagectomy by stripping was performed. No adjuvant treatment was indicated. One year later a recurrence of the cervical anastomosis was diagnosed and caused a severe dyspnea. Chemotherapy was rejected due to bad general conditions and the patient died of this recurrence. In addition to the severe phenotype of this patient, 9 family members have been diagnosed with breast cancer, 5 of them were diagnosed &#x02264; 45 years old. Therefore, a DNA sample of this patient was analyzed using whole exome sequencing. Results including number of reads, sample coverage, number of the different types of mutations and sequencing depth of the whole exome sequenced patient have been summarized in \u003Ca href=\"#T1\">Table 1\u003C/a>. This analysis unexpectedly revealed two \u003Ci>BRCA2\u003C/i> mutations corresponding to the frameshift c.1310_1313DelAAGA within exon 10 and a splice site mutation c.632-1G&#x0003E;A in exon 8.\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">TABLE 1\u003C/div>\n\u003Cdiv class=\"FigureDesc\">\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t001.jpg\" name=\"Table1\" target=\"_blank\">\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t001.jpg\" alt=\"www.frontiersin.org\" id=\"T1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cstrong>Table 1\u003C/strong>. Exome sequencing data.\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cp class=\"mb15 w100pc float_left mt15\">Interestingly, both mutations have been reported as &#x0201C;pathogenic&#x0201D; in the ClinVar database.\u003C/p>\n\u003Cp class=\"mb0\">In addition, the two mutations have been confirmed by Sanger sequencing of the original DNA and of a second DNA sample extracted from a second blood sample of the same patient. These mutations were also confirmed in a relative of the patient diagnosed with pregnancy associated breast cancer at 25 years old (BC17-2). Subsequently, we searched for the 2 mutations in a cohort of 300 high risk Tunisian breast cancer families. Interestingly, 7 additional individuals belonging to 4 Tunisian families were identified as carriers of both mutations (BC6, BC39, BC95, and BC225). Pedigrees of these families are shown in \u003Ca href=\"#F2\">Figure 2\u003C/a>. Due to the fact that a subset of Fanconi Anemia patients carry biallelic \u003Ci>BRCA2\u003C/i> mutations, it was crucial to establish whether the two mutations are found \u003Ci>in Cis\u003C/i> or \u003Ci>in Trans\u003C/i>. Beyond the index case in the BC6 family, her son, her sister and two brothers have been tested for these mutations. The son and the sister were negative for both mutations and the two brothers have been identified as carriers of the two \u003Ci>BRCA2\u003C/i> mutations. This allowed us to conclude that both mutations are found on the same allele. Furthermore, 6 individuals belonging to 5 additional families have been identified as carriers of the founder c.1310_1313DelAAGA mutation only (PEC9, PEC35, BC245, BC354-1, BC354-2, DEP13-1) including 2 unaffected carriers.\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">FIGURE 2\u003C/div>\n\u003Cdiv class=\"FigureDesc\">\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g002.jpg\" name=\"figure2\" target=\"_blank\">\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g002.jpg\" alt=\"www.frontiersin.org\" id=\"F2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cstrong>Figure 2\u003C/strong>. Familial pedigrees of the 5 \u003Ci>Cis\u003C/i> double heterozygous families. Available age at diagnosis of breast cancer cases is indicated between brackets. For some cases, only age at death was available and is indicated in square brackets. BBC, Bilateral Breast Cancer.\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cp class=\"mb15 w100pc float_left mt15\">The 9 carriers of this \u003Ci>Cis\u003C/i> DH \u003Ci>BRCA2\u003C/i> genotypes include 6 affected cases and 3 unaffected carriers.\u003C/p>\n\u003Cp class=\"mb0\">Epidemiological and clinico-pathological data of these \u003Ci>Cis\u003C/i> DH families are reported in \u003Ca href=\"#T2\">Table 2\u003C/a>. The clinical phenotype correlates with the typical \u003Ci>BRCA2\u003C/i> tumor characteristics with positive estrogen and progesterone receptors and negative Her2 status. Moreover, T2 tumor size and a histological Grade III have been observed in 3 out of the 6 patients suggesting a severe phenotype for \u003Ci>Cis\u003C/i> DH \u003Ci>BRCA2\u003C/i> mutation carriers. In addition, the \u003Ci>Cis\u003C/i> DH \u003Ci>BRCA2\u003C/i> genotype seems to be associated with a significant early age of onset (mean age = 35.33 years) when compared to 48.1 in SH, 47.5 in \u003Ci>BRCA2\u003C/i> mutation carriers and 44.6 years in compound heterozygous. Furthermore, multiple breast cancer cases have been recorded in the related individuals of these \u003Ci>Cis\u003C/i> DH cases. No ovarian cancer was reported, which may not be surprising given the fact that ovarian cancer penetrance is significantly lower in \u003Ci>BRCA2\u003C/i> mutation carriers compared to \u003Ci>BRCA1\u003C/i>. Although prostate cancer is part of the \u003Ci>BRCA2\u003C/i> cancer susceptibility spectrum, no prostate cancer was reported as well. However, a brother of BC6 that has been tested positive for both mutations seems to have urological problems that may orient to a prostate pathology. One colon cancer was observed in the cousin of BC95, one brain cancer in the uncle of another case (BC225) and a renal cancer as well as a gastric cancer were diagnosed in a brother and an aunt of BC17, respectively. Even if they are not clearly \u003Ci>BRCA2\u003C/i> related carcinomas, esophageal and throat cancers were detected in 4 individuals from 3 different families (BC6, BC17, and BC225) suggesting an upper aero digestive cancer predisposition.\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">TABLE 2\u003C/div>\n\u003Cdiv class=\"FigureDesc\">\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t002.jpg\" name=\"Table2\" target=\"_blank\">\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t002.jpg\" alt=\"www.frontiersin.org\" id=\"T2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cstrong>Table 2\u003C/strong>. Epidemiological and clinical data of \u003Ci>Cis\u003C/i> double heterozygous families.\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cp class=\"mb15 w100pc float_left mt15\">Because of the rare genotype that we are investigating in this study, the number of cases reported in this study is too small to draw firm conclusions, however, there is evidences of an association between \u003Ci>Cis\u003C/i> DH and a relatively severe phenotype of the disease with early age of onset, high breast cancer grade and multiple cancer cases in the families.\u003C/p>\n\u003Cp class=\"mb15\">In addition to the identified \u003Ci>Cis\u003C/i> DH pathogenic mutations, 21 SNPs have been detected on both \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> genes including 12 exonic and 9 intronic variants (\u003Ca href=\"#SM1\">Supplementary Table 1\u003C/a>).\u003C/p>\n\u003Cp class=\"mb0\">The co-occurrence of the two mutations on the same \u003Ci>BRCA2\u003C/i> allele raises questions about the functional significance of the splice site mutation (\u003Ca href=\"#F3\">Figure 3\u003C/a>). Three different \u003Ci>in silico\u003C/i> prediction tools have been used to assess the functional effect of this splicing mutation (\u003Ca href=\"#T3\">Table 3\u003C/a>). Results showed that c.632-1G&#x0003E;A seems to disturb the normal splicing by the loss of the WT acceptor site which may induce the skipping of \u003Ci>BRCA2\u003C/i>-exon 8.\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">FIGURE 3\u003C/div>\n\u003Cdiv class=\"FigureDesc\">\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g003.jpg\" name=\"figure3\" target=\"_blank\">\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g003.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g003.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g003.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g003.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g003.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g003.jpg\" alt=\"www.frontiersin.org\" id=\"F3\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cstrong>Figure 3\u003C/strong>. \u003Ci>BRCA2\u003C/i> sequence with the c.632-1G&#x0003E;A and c.1301-1304delAAAG mutations. Sanger chromatograms confirm \u003Cstrong>(A)\u003C/strong> the presence of the c.632-1G&#x0003E;A mutation at the junction intron 7/exon 8 and \u003Cstrong>(B)\u003C/strong> the c.1310_1313delAAGA (p.Lys437Ilefs) mutation in exon 10.\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003Cdiv class=\"DottedLine mb15\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">TABLE 3\u003C/div>\n\u003Cdiv class=\"FigureDesc\">\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t003.jpg\" name=\"Table3\" target=\"_blank\">\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t003.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t003.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t003.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t003.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t003.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t003.jpg\" alt=\"www.frontiersin.org\" id=\"T3\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cstrong>Table 3\u003C/strong>. Summary of splicing predictions results.\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cp class=\"mb15 w100pc float_left mt15\">Then we proceed with protein modeling as an additional functional analysis. Unfortunately, thec.632-1G&#x0003E;A splicing mutation does not appear in any regions or domains of the protein (described in uniport \u003Ca href=\"https://www.uniprot.org/uniprot/P51587\">https://www.uniprot.org/uniprot/P51587\u003C/a>). In addition, the existing 3D structures do not cover this region and therefore we were not able to generate a 3D model of the mutant with a good confidence rate.\u003C/p>\n\u003Cp class=\"mb0\">For the RT PCR analysis, the cDNA of the \u003Ci>BRCA2\u003C/i> gene was amplified using several primer combinations flanking exons 5&#x02013;9, 5&#x02013;10, 6&#x02013;10. Although electrophoresis gel showed a specific band for the resulting cDNA, sequencing analysis did not show any sequences supporting the skipping of the \u003Ci>BRCA2\u003C/i>-exon8 hypothesis.\u003C/p>\n\u003Ch3>Haplotype Analysis\u003C/h3>\n\u003Cp class=\"mb0\">To investigate a possible founder effect, haplotype analysis was performed on 60 Tunisian breast cancer cases. In detail, 8 \u003Ci>BRCA2Cis\u003C/i> DH carriers, 3 \u003Ci>BRCA2\u003C/i> SH carriers, 4 relatives, 8 non-carriers, 24 breast cancer patients with unknown \u003Ci>BRCA\u003C/i> status and 13 healthy Tunisian women were investigated using the four selected STR markers. The D13S1246 marker was inconclusive and it was then excluded from the analysis. \u003Ca href=\"#T4\">Table 4\u003C/a> summarizes the haplotype analysis for the \u003Ci>Cis\u003C/i> DH and SH carriers. Evaluation of the informative microsatellites was performed on probands and additional family members when possible. We identified a shared haplotype between all \u003Ci>Cis\u003C/i> DH and SH \u003Ci>BRCA2\u003C/i> mutation carriers (162-233-162) and absent or very rare in the remaining controls suggesting a founder effect of these two mutations.\u003C/p>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cdiv class=\"Imageheaders\">TABLE 4\u003C/div>\n\u003Cdiv class=\"FigureDesc\">\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t004.jpg\" name=\"Table4\" target=\"_blank\">\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t004.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t004.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t004.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t004.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t004.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-t004.jpg\" alt=\"www.frontiersin.org\" id=\"T4\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\n\u003Cp>\u003Cstrong>Table 4\u003C/strong>. Haplotype analyses in the carriers of both \u003Ci>BRCA2\u003C/i> deleterious mutations.\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003Cdiv class=\"DottedLine\">\u003C/div>\n\u003Cp class=\"mb0 w100pc float_left mt15\">Moreover, all carriers of these two mutations are originating from the North Western and central regions of Tunisia. Of interest, \u003Ci>Cis\u003C/i> DH and SH carriers share the same haplotype suggesting that they are mostly inherited together.\u003C/p>\n\u003Ca id=\"h5\" name=\"h5\">\u003C/a>\u003Ch2>Discussion\u003C/h2>\n\u003Cp class=\"mb15\">Breast cancer is a malignancy with significant genotypic and phenotypic diversity (\u003Ca href=\"#B1\">Almendro et al., 2014\u003C/a>). It is now well-documented that a large proportion of North African breast cancer patients are relatively young (\u003Ca href=\"#B10\">Corbex et al., 2014\u003C/a>) with an average age at presentation of breast cancer patients a decade earlier than Caucasian individuals (\u003Ca href=\"#B8\">Chouchane et al., 2013\u003C/a>). Recent studies showed that 11% of Tunisian breast cancer patients are under 35 years old (\u003Ca href=\"#B57\">Zehani et al., 2009\u003C/a>). In addition, the majority of North African breast cancer patients are still diagnosed at late stages. Therefore, early disease onset and late diagnosis, both represent the main cause of high mortality among breast cancer patients in these populations. Given the fact that breast cancer in young women tends to behave more aggressively (\u003Ca href=\"#B3\">Assi et al., 2013\u003C/a>), an early diagnosis will result in reduced treatment, effective primary prevention and additional life years gained. Therefore, understanding the epidemiology-genetic factors behind the significant high number of young breast cancer patients in North African populations will promote early detection of the disease and will have a positive impact on the survival rates of affected patients.\u003C/p>\n\u003Cp class=\"mb15\">In the present study, 6 Tunisian breast cancer patients harbor two pathogenic mutations on the same allele of \u003Ci>BRCA2\u003C/i> (c. 632-1G&#x0003E;A and c. 1310_1313 Del AAGA) have been detected using whole exome sequencing. These patients showed a significant early age of onset of the disease. Indeed, the mean age of onset was about 35.33 years in \u003Ci>Cis\u003C/i> DH, significantly younger than \u003Ci>BRCA\u003C/i> SH mutation carriers (48.1 years), \u003Ci>BRCA2\u003C/i> mutation carriers (47.5 years), and biallelic \u003Ci>BRCA\u003C/i> mutation carriers (44.6 years) (\u003Ca href=\"#B43\">Rebbeck et al., 2016\u003C/a>) suggesting an association of this genotype with an early age of onset.\u003C/p>\n\u003Cp class=\"mb15\">Young age of onset was also observed in other unusual \u003Ci>BRCA\u003C/i> genotypes. Indeed, biallelic \u003Ci>BRCA2\u003C/i> mutations have been observed in a 31 years old female diagnosed with colorectal cancer (\u003Ca href=\"#B11\">Degrolard-Courcet et al., 2014\u003C/a>). Biallelic mutations in \u003Ci>BRCA1\u003C/i> have been reported in a female patient with epithelial ovarian carcinoma diagnosed at age 28 years (\u003Ca href=\"#B17\">Domchek et al., 2013\u003C/a>). Recent studies also showed that DH mutation carriers develop breast cancer at an earlier age and have more severe disease than SH cases (\u003Ca href=\"#B33\">Lavie et al., 2011\u003C/a>; \u003Ca href=\"#B27\">Heidemann et al., 2012\u003C/a>). Interestingly, \u003Ca href=\"#B9\">Colombo et al. (2009)\u003C/a> reported 4 \u003Ci>BRCA2 Cis\u003C/i> DH cases with a mean age of 34.\u003C/p>\n\u003Cp class=\"mb15\">Therefore, we hypothesized that the development of early onset disease associated with co-occurrence of two deleterious mutations might be indicative of disruption of interactions between \u003Ci>BRCA2\u003C/i> and some key proteins resulting in an accumulation of DNA damages that makes the disease appear at an earlier age. In support of our hypothesis, Ashok Venkitaraman suggested that single heterozygosity in \u003Ci>BRCA\u003C/i> genes has a dosage effect sufficient to trigger low, but quantitatively significant, levels of genome instability. Alternatively, biallelic inactivation of \u003Ci>BRCA1\u003C/i> or \u003Ci>BRCA2\u003C/i> not only triggers profound chromosomal instability but also quickly leads to cell cycle arrest or apoptosis which results in an early presentation of the disease (\u003Ca href=\"#B56\">Venkitaraman, 2019\u003C/a>). In addition, \u003Ci>Cis DH\u003C/i> breast cancer patients reported in the current study, seem to present a high histological grade and a bigger tumor size with multiple breast cancer cases in the related family members suggesting an association between \u003Ci>Cis\u003C/i> DH and the phenotypic severity. A similar phenomenon, called negative complementation or metabolic interference, occurs when two alleles at the same locus interact to give a more severe phenotype in the compound heterozygote than in either homozygote (\u003Ca href=\"#B28\">Johnson, 1980\u003C/a>). For example, Abruptex (Abx) mutations of the Drosophila Notch gene fall into two genetic types, &#x0201C;enhancers&#x0201D; and &#x0201C;suppressors&#x0201D; of Notch. Homozygotes for either type are viable (characterized by gapping of the wing veins), yet compound enhancer/suppressor Abx heterozygotes are lethal (\u003Ca href=\"#B29\">Kelley et al., 1987\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">Of note, all reported patients with \u003Ci>Cis\u003C/i> DH come from a restricted geographic area suggesting a founder effect. We assume that there is no selection bias as patients from our cohort originated from different areas of Tunisia and were recruited from different oncological departments that have a national activity. Results from haplotype analysis confirmed this founder effect by the identification of a shared haplotype between all carriers of both \u003Ci>BRCA2\u003C/i> mutations, c. 1310_1313Del AAGA and c.632-1G&#x0003E;A.c.1310_1313DelAAGA is a known recurrent mutation in North African populations and has been already identified in Tunisia, Algeria and Morocco (\u003Ca href=\"#B7\">Cherbal et al., 2012\u003C/a>). Moreover, it was found in different European patients from Denmark, France, Belgium, Spain, and Italy and it has also been identified in a Korean patient (\u003Ca href=\"#B15\">D&#x000ED;ez et al., 2003\u003C/a>; \u003Ca href=\"#B53\">Thomassen et al., 2008\u003C/a>; \u003Ca href=\"#B6\">Caputo et al., 2012\u003C/a>; \u003Ca href=\"#B30\">Kim et al., 2012\u003C/a>; \u003Ca href=\"#B31\">Laarabi et al., 2017\u003C/a>). This mutation was also found in several male breast cancer cases (\u003Ca href=\"#B20\">Drusedau et al., 2013\u003C/a>; \u003Ca href=\"#B25\">Fourati et al., 2014\u003C/a>; \u003Ca href=\"#B50\">Silvestri et al., 2020\u003C/a>). For the exon8- \u003Ci>BRCA2\u003C/i> c.632-1G&#x0003E;A mutation, it is described for the first time in Tunisia and in the North African region. It also appears to be rare in other populations since it was only reported in one patient with prostate cancer in the UK (\u003Ca href=\"#B21\">Edwards et al., 2010\u003C/a>). Different analysis showed that there is an over-representation of mutations in \u003Ci>BRCA2&#x00027;s\u003C/i> exons 7 and 8 in FA-D1 patients (\u003Ca href=\"#B52\">Szabo et al., 2000\u003C/a>; \u003Ca href=\"#B42\">Rahman and Scott, 2007\u003C/a>). Furthermore, despite the high frequency of \u003Ci>BRCA2\u003C/i> truncating exon 11 mutations in familial breast cancer there is currently no known FA-D1 patient with biallelic truncating mutations in exon 11 (\u003Ca href=\"#B42\">Rahman and Scott, 2007\u003C/a>). Interestingly, genotype-phenotype analyses of \u003Ci>BRCA2\u003C/i> breast cancer pedigrees mirror the observations in biallelic \u003Ci>BRCA2\u003C/i> mutation cases, with different cancer risks associated with monoallelic truncating mutations in exon 11 when compared with mutations located in 3&#x02032; or 5&#x02032; of this exon (\u003Ca href=\"#B54\">Thompson et al., 2001\u003C/a>; \u003Ca href=\"#B37\">Lubinski et al., 2004\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">In fact, genetic disease studies on North Africans are of keen interest because of their heterogeneous and admixed populations from African and European origins. The particular structure of the Tunisian population is also due to a relatively high rate of consanguinity that reaches 98.9% in some regions (\u003Ca href=\"#B4\">Ben Halim et al., 2015\u003C/a>). This clearly impacted the incidence rates of complex diseases as well as monogenic ones such as those predisposing to cancer (\u003Ca href=\"#B46\">Romdhane et al., 2019\u003C/a>). Studies on the impact of consanguinity on breast cancer incidences showed controversial results. Indeed, Gilani et al. showed that consanguinity is linked to a high overall risk of breast cancer (\u003Ca href=\"#B38\">Masood Gilani and Kamal, 2004\u003C/a>). However, other studies showed that a lower risk of breast cancer was reported in consanguineous families compared to non-consanguineous ones (\u003Ca href=\"#B12\">Denic and Bener, 2001\u003C/a>). Here we propose that consanguinity can also affect the early onset of breast cancer and other associated phenotypes. Indeed, a long history of consanguinity that may result in a genetic mixing that may cause the co-occurrence of more than one mutation on one allele such as the \u003Ci>Cis\u003C/i> DH observed in this study and that seems to be associated with increased likelihood of breast cancer incidence and early onset of the disease. In Ashkenazi Jewish, where a relatively high risk of consanguinity has been observed, double heterozygosity in both \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> mutations is frequently observed and usually, at least one of the DH mutations is a founder mutation. In this same context, \u003Ca href=\"#B33\">Lavie et al. (2011)\u003C/a> showed that a 1.85% prevalence of \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> DH in Ashkenazi Jewish patients with FA-D1 have a distinctively higher risk of specific cancers than patients in other Fanconi anemia complementation groups. Therefore, carrying a single mutant allele, biallelic or two monoallelic mutations are associated with a phenotypic variability, ranging from HBOC, fanconi anemia, to early age of breast cancer onset with multiple cancer cases in the family.\u003C/p>\n\u003Cp class=\"mb15\">Interestingly, the identification of these phenotype-genotype correlations will help to provide appropriate and individualized genetic counseling, risk assessment and cancer surveillance not only for index cases but also to their relatives from both parental sides. Thus, carriers of DH mutations may benefit from an earlier start of surveillance, more intensive follow up care and/or an urgent prophylactic surgery. From a therapeutic point of view, while both \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> mutations sensitize cells to PARP inhibitors, the affected gene appears to have a modulating effect on sensitivity. Indeed, \u003Ci>BRCA1\u003C/i>-defective cells demonstrate a &#x0007E;60-fold increase in sensitivity to Olaparib vs. \u003Ci>BRCA\u003C/i> wild-type cells, while the corresponding increase in sensitivity in \u003Ci>BRCA2\u003C/i>-defective cells is &#x0007E;130-fold (\u003Ca href=\"#B23\">Farmer et al., 2005\u003C/a>). Moreover, loss of BRCA1 RING domain function appears insufficient to fully sensitize cells to PARP inhibition, while still predisposing to cancer development (\u003Ca href=\"#B18\">Drost et al., 2011\u003C/a>, \u003Ca href=\"#B19\">2016\u003C/a>). Given the fact that the c.632-1G&#x0003E;A mutation identified in this study is located in the N-terminal region of BRCA2 protein corresponding to the RING domain of BRCA1, and because of the financial burden of targeted therapy use in routine clinical practice, identifying patients most likely to benefit from these drugs is of great importance.\u003C/p>\n\u003Cp class=\"mb15\">Once confirmed in larger cohorts, our finding will also bring new insights to the scientific community that will either accept the \u003Ci>Cis\u003C/i> DH BRCA genotype that was largely debated, or it will help in reviewing the clinical actionability of the splicing c-632-1G&#x0003E;A \u003Ci>BRCA2\u003C/i> mutation that is still classified as pathogenic in ClinVar. Efforts made by \u003Ci>the Evidence-based Network for the Interpretation of Germline Mutant Alleles\u003C/i> (ENIGMA) in determining the clinical significance of sequence variants in \u003Ci>BRCA1, BRCA2\u003C/i>, and other known or suspected breast cancer genes represent an excellent initiative to overcome this challenge and will permit the reclassification of this mutation in order to avoid misdiagnosis and over treatment of breast cancer patients all over the world (\u003Ca href=\"#B40\">Nielsen et al., 2018\u003C/a>).\u003C/p>\n\u003Cp class=\"mb15\">Furthermore, due to the high cost of the complete screening of the large \u003Ci>BRCA\u003C/i> genes, the screening of only recurrent or founder mutations using Sanger sequencing is a traditional genetic testing method in low and middle income countries (LMICs). This screening method is no longer concluding. Indeed, apart from the fact that this strategy may bias the frequency of \u003Ci>BRCA\u003C/i> mutations in a specific mutation, by doing so, we also risk to pass side of the double heterozygous or biallelic \u003Ci>BRCA\u003C/i> genotypes that seem to be associated with different phenotypic spectrum. This problem does not arise when using cost-efficient and sensitive new technologies such as gene panels or whole exome sequencing that extend the analysis to the whole \u003Ci>BRCA\u003C/i> and other breast cancer susceptibility genes regardless of previous identification of a specific mutation in the family.\u003C/p>\n\u003Cp class=\"mb0\">Finally, as c.1310_1313DelAAGA is a founder mutation in North African populations, our results will have an impact not only on Tunisian cancer patients but on patients from other North African countries as well as cancer cases originating from other ethnic groups.\u003C/p>\n\u003Ca id=\"h6\" name=\"h6\">\u003C/a>\u003Ch2>Conclusion\u003C/h2>\n\u003Cp class=\"mb0\">Genetic studies of under-investigated populations may lead to the identification of unusual genotypes and phenotypes that provide novel insights and avenues for research regarding the complex biological functions of the \u003Ci>BRCA\u003C/i> genes. It also increases our understanding of the clinical basis of cancer predisposition which will help moving toward a more accurate and personalized clinical management of cancer patients.\u003C/p>\n\u003Ca id=\"h7\" name=\"h7\">\u003C/a>\u003Ch2>Data Availability Statement\u003C/h2>\n\u003Cp class=\"mb0\">All pathogenic mutations identified in this study with data related to these variants have been deposited in the public database &#x0201C;ClinVar&#x0201D; under the following link \u003Ca href=\"https://www.ncbi.nlm.nih.gov/clinvar/submitters/507986/\">https://www.ncbi.nlm.nih.gov/clinvar/submitters/507986/\u003C/a>. All remaining variations (non-pathogenic) identified within BRCA1 and BRCA2 genes have been provided in the \u003Ca href=\"#h14\">Supplementary Material\u003C/a>. Any additional details may be made available upon request after approval of our institutional review board.\u003C/p>\n\u003Ca id=\"h8\" name=\"h8\">\u003C/a>\u003Ch2>Ethics Statement\u003C/h2>\n\u003Cp class=\"mb0\">The studies involving human participants were reviewed and approved by Biomedical Ethics Committee of Institut Pasteur de Tunis (2017/16/E/h&#x000F4;pital a-m). The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from participants for the publication of any potentially identifiable images or data included in this article.\u003C/p>\n\u003Ca id=\"h9\" name=\"h9\">\u003C/a>\u003Ch2>Author Contributions\u003C/h2>\n\u003Cp class=\"mb0\">YH prepared the study concept and design, supervised the study, did data analysis, data interpretation, drafted, and critically revised the manuscript. MB and NMi did the experiments, participated in participant recruitment, and participated in drafting and reviewing the manuscript. NMe, OJ, YH, MB, NMi, SBe, HBoua, JH, AZ, YB, HR, ND, HE, and SL contributed to data collection and clinical data analysis. SA, HBous, SBo, AH, and KR contributed to the results interpretation. SBo and SA contributed to the study concept, design and supervision. SA, SBo, and HBous critically revised the manuscript. All authors read and approved the manuscript.\u003C/p>\n\u003Ca id=\"h10\" name=\"h10\">\u003C/a>\u003Ch2>Funding\u003C/h2>\n\u003Cp class=\"mb0\">This work was supported by the Tunisian Ministry of Public Health (PEC-4-TUN), the Tunisian Ministry of Higher Education and Scientific Research (LR11IPT05 and LR16IPT05) and by the E.C. Grant agreement N&#x000B0; 295097 for FP7 project GM-NCD-Inco.\u003C/p>\n\u003Ca id=\"h11\" name=\"h11\">\u003C/a>\u003Ch2>Conflict of Interest\u003C/h2>\n\u003Cp class=\"mb0\">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\u003C/p>\n\u003Ca id=\"h12\" name=\"h12\">\u003C/a>\u003Ch2>Publisher&#x00027;s Note\u003C/h2>\n\u003Cp class=\"mb0\">All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.\u003C/p>\n\u003Ca id=\"h13\" name=\"h13\">\u003C/a>\u003Ch2>Acknowledgments\u003C/h2>\n\u003Cp class=\"mb0\">We are also grateful to all participants and their family members for their participation in the study.\u003C/p>\n\u003Ca id=\"h14\" name=\"h14\">\u003C/a>\u003Ch2>Supplementary Material\u003C/h2>\n\u003Cp class=\"mb0\" id=\"SM1\">The Supplementary Material for this article can be found online at: \u003Ca href=\"https://www.frontiersin.org/articles/10.3389/fgene.2021.674990/full#supplementary-material\">https://www.frontiersin.org/articles/10.3389/fgene.2021.674990/full#supplementary-material\u003C/a>\u003C/p>\n\u003Ca id=\"h15\" name=\"h15\">\u003C/a>\u003Ch2>Abbreviations\u003C/h2>\n\u003Cp class=\"mb0\">\u003Ci>Cis\u003C/i> DH, \u003Ci>Cis\u003C/i> double heterozygosity; WES, Whole exome sequencing; NGS, Next Generation Sequencing; SH, single heterozygotes; TH, trans heterozygous; BC, Breast cancer; TNBC, Triple negative breast cancer; MBC, Male Breast Cancer; GC, Gastric Cancer; RC, Renal Cancer; EC, Esophageal Carcinoma; BrC, Brain Cancer; ThC, Throat Cancer; IDC, Invasive Ductal Carcinoma; DCIS, Diffuse carcinoma \u003Ci>in situ\u003C/i>; CT, Chemotherapy; RT, Radiotherapy; HT, Hormonotherapy; RB, Right breast; LB, Left breast; UOQ, Upper outer quadrant; JUQ, Junction of the upper quadrants.\u003C/p>\n\u003Ca id=\"h16\" name=\"h16\">\u003C/a>\u003Ch2>References\u003C/h2>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B1\" id=\"B1\">\u003C/a> Almendro, V., Kim, H. J., Cheng, Y.-K., G&#x000F6;nen, M., Itzkovitz, S., Argani, P., et al. (2014). Genetic and phenotypic diversity in breast tumor metastases. \u003Ci>Cancer Res\u003C/i>. 74, 1338&#x02013;1348. doi: 10.1158/0008-5472.CAN-13-2357-T\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24448237\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1158/0008-5472.CAN-13-2357-T\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=V.+Almendro&#x00026;author=H.+J.+Kim&#x00026;author=Y.+-K.+Cheng&#x00026;author=M.+G&#x000F6;nen&#x00026;author=S.+Itzkovitz&#x00026;author=P.+Argani+&#x00026;publication_year=2014&#x00026;title=Genetic+and+phenotypic+diversity+in+breast+tumor+metastases&#x00026;journal=Cancer+Res&#x00026;volume=74&#x00026;pages=1338-1348\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B2\" id=\"B2\">\u003C/a> Alter, B. P., Rosenberg, P. S., and Brody, L. C. (2007). Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. \u003Ci>J. Med. Genet\u003C/i>. 44, 1&#x02013;9. doi: 10.1136/jmg.2006.043257\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16825431\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1136/jmg.2006.043257\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=B.+P.+Alter&#x00026;author=P.+S.+Rosenberg&#x00026;author=L.+C.+Brody+&#x00026;publication_year=2007&#x00026;title=Clinical+and+molecular+features+associated+with+biallelic+mutations+in+FANCD1%2FBRCA2&#x00026;journal=J.+Med.+Genet&#x00026;volume=44&#x00026;pages=1-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B3\" id=\"B3\">\u003C/a> Assi, H. A., Khoury, K. E., Dbouk, H., Khalil, L. E., Mouhieddine, T. H., and El Saghir, N. S. (2013). Epidemiology and prognosis of breast cancer in young women. \u003Ci>J. Thorac. Dis\u003C/i>. 5(Suppl. 1), S2&#x02013;S8. doi: 10.3978/j.issn.2072-1439.2013.05.24\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23819024\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3978/j.issn.2072-1439.2013.05.24\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H.+A.+Assi&#x00026;author=K.+E.+Khoury&#x00026;author=H.+Dbouk&#x00026;author=L.+E.+Khalil&#x00026;author=T.+H.+Mouhieddine&#x00026;author=N.+S.+El+Saghir+&#x00026;publication_year=2013&#x00026;title=Epidemiology+and+prognosis+of+breast+cancer+in+young+women&#x00026;journal=J.+Thorac.+Dis&#x00026;volume=5&#x00026;pages=S2-S8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B4\" id=\"B4\">\u003C/a> Ben Halim, N., Nagara, M., Regnault, B., Hsouna, S., Lasram, K., Kefi, R., et al. (2015). Estimation of recent and ancient inbreeding in a small endogamous tunisian community through genomic runs of homozygosity. \u003Ci>Ann. Hum. Genet\u003C/i>. 79, 402&#x02013;417. doi: 10.1111/ahg.12131\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26420437\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/ahg.12131\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=N.+Ben+Halim&#x00026;author=M.+Nagara&#x00026;author=B.+Regnault&#x00026;author=S.+Hsouna&#x00026;author=K.+Lasram&#x00026;author=R.+Kefi+&#x00026;publication_year=2015&#x00026;title=Estimation+of+recent+and+ancient+inbreeding+in+a+small+endogamous+tunisian+community+through+genomic+runs+of+homozygosity&#x00026;journal=Ann.+Hum.+Genet&#x00026;volume=79&#x00026;pages=402-417\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B5\" id=\"B5\">\u003C/a> Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. \u003Ci>CA Cancer J. Clin\u003C/i>. 68, 394&#x02013;424. doi: 10.3322/caac.21492\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32767693\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3322/caac.21492\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=F.+Bray&#x00026;author=J.+Ferlay&#x00026;author=I.+Soerjomataram&#x00026;author=R.+L.+Siegel&#x00026;author=L.+A.+Torre&#x00026;author=A.+Jemal+&#x00026;publication_year=2018&#x00026;title=Global+cancer+statistics+2018%3A+GLOBOCAN+estimates+of+incidence+and+mortality+worldwide+for+36+cancers+in+185+countries&#x00026;journal=CA+Cancer+J.+Clin&#x00026;volume=68&#x00026;pages=394-424\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B6\" id=\"B6\">\u003C/a> Caputo, S., Benboudjema, L., Sinilnikova, O., Rouleau, E., Beroud, C., Lidereau, R., et al. (2012). Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases. \u003Ci>Nucleic Acids Res\u003C/i>. 40(Database issue), D992&#x02013;1002. doi: 10.1093/nar/gkr1160\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/22144684\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/nar/gkr1160\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S.+Caputo&#x00026;author=L.+Benboudjema&#x00026;author=O.+Sinilnikova&#x00026;author=E.+Rouleau&#x00026;author=C.+Beroud&#x00026;author=R.+Lidereau+&#x00026;publication_year=2012&#x00026;title=Description+and+analysis+of+genetic+variants+in+French+hereditary+breast+and+ovarian+cancer+families+recorded+in+the+UMD-BRCA1%2FBRCA2+databases&#x00026;journal=Nucleic+Acids+Res&#x00026;volume=40&#x00026;pages=D992-1002\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B7\" id=\"B7\">\u003C/a> Cherbal, F., Bakour, R., Adane, S., and Boualga, K. (2012). BRCA1 and BRCA2 germline mutation spectrum in hereditary breast/ovarian cancer families from Maghrebian countries. \u003Ci>Breast Dis\u003C/i>. 34, 1&#x02013;8. doi: 10.3233/BD-130348\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23697973\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3233/BD-130348\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=F.+Cherbal&#x00026;author=R.+Bakour&#x00026;author=S.+Adane&#x00026;author=K.+Boualga+&#x00026;publication_year=2012&#x00026;title=BRCA1+and+BRCA2+germline+mutation+spectrum+in+hereditary+breast%2Fovarian+cancer+families+from+Maghrebian+countries&#x00026;journal=Breast+Dis&#x00026;volume=34&#x00026;pages=1-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B8\" id=\"B8\">\u003C/a> Chouchane, L., Boussen, H., and Sastry, K. S. R. (2013). Breast cancer in Arab populations: molecular characteristics and disease management implications. \u003Ci>Lancet Oncol\u003C/i>. 14:e417&#x02013;e24. doi: 10.1016/S1470-2045(13)70165-7\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23993386\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/S1470-2045(13)70165-7\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=L.+Chouchane&#x00026;author=H.+Boussen&#x00026;author=K.+S.+R.+Sastry+&#x00026;publication_year=2013&#x00026;title=Breast+cancer+in+Arab+populations%3A+molecular+characteristics+and+disease+management+implications&#x00026;journal=Lancet+Oncol&#x00026;volume=14&#x00026;pages=e417-e24\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B9\" id=\"B9\">\u003C/a> Colombo, M., Ripamonti, C., Pensotti, V., Foglia, C., Peissel, B., Pierotti, M., et al. (2009). An unusual BRCA2 allele carrying two splice site mutations. \u003Ci>Ann. Oncol\u003C/i>. 20, 1143&#x02013;1144. doi: 10.1093/annonc/mdp241\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/19423647\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/annonc/mdp241\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M.+Colombo&#x00026;author=C.+Ripamonti&#x00026;author=V.+Pensotti&#x00026;author=C.+Foglia&#x00026;author=B.+Peissel&#x00026;author=M.+Pierotti+&#x00026;publication_year=2009&#x00026;title=An+unusual+BRCA2+allele+carrying+two+splice+site+mutations&#x00026;journal=Ann.+Oncol&#x00026;volume=20&#x00026;pages=1143-1144\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B10\" id=\"B10\">\u003C/a> Corbex, M., Bouzbid, S., and Boffetta, P. (2014). Features of breast cancer in developing countries, examples from North-Africa. \u003Ci>Eur. J. Cancer\u003C/i> 50, 1808&#x02013;1818. doi: 10.1016/j.ejca.2014.03.016\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24767469\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.ejca.2014.03.016\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M.+Corbex&#x00026;author=S.+Bouzbid&#x00026;author=P.+Boffetta+&#x00026;publication_year=2014&#x00026;title=Features+of+breast+cancer+in+developing+countries,+examples+from+North-Africa&#x00026;journal=Eur.+J.+Cancer&#x00026;volume=50&#x00026;pages=1808-1818\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B11\" id=\"B11\">\u003C/a> Degrolard-Courcet, E., Sokolowska, J., Padeano, M.-M., Guiu, S., Bronner, M., Chery, C., et al. (2014). Development of primary early-onset colorectal cancers due to biallelic mutations of the FANCD1/BRCA2 gene. \u003Ci>Euro. J. Human Genet\u003C/i>. 22, 979&#x02013;987. doi: 10.1038/ejhg.2013.278\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24301060\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/ejhg.2013.278\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=E.+Degrolard-Courcet&#x00026;author=J.+Sokolowska&#x00026;author=M.+-M.+Padeano&#x00026;author=S.+Guiu&#x00026;author=M.+Bronner&#x00026;author=C.+Chery+&#x00026;publication_year=2014&#x00026;title=Development+of+primary+early-onset+colorectal+cancers+due+to+biallelic+mutations+of+the+FANCD1%2FBRCA2+gene&#x00026;journal=Euro.+J.+Human+Genet&#x00026;volume=22&#x00026;pages=979-987\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B12\" id=\"B12\">\u003C/a> Denic, S., and Bener, A. (2001). Consanguinity decreases risk of breast cancer&#x02013;cervical cancer unaffected. \u003Ci>Br. J. Cancer\u003C/i> 85, 1675&#x02013;1679. doi: 10.1054/bjoc.2001.2131\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/11742487\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1054/bjoc.2001.2131\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S.+Denic&#x00026;author=A.+Bener+&#x00026;publication_year=2001&#x00026;title=Consanguinity+decreases+risk+of+breast+cancer&#x02013;cervical+cancer+unaffected&#x00026;journal=Br.+J.+Cancer&#x00026;volume=85&#x00026;pages=1675-1679\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B13\" id=\"B13\">\u003C/a> Desmet, F. O., Hamroun, D., Lalande, M., Collod-Beroud, G., Claustres, M., and Beroud, C. (2009). Human splicing finder: an online bioinformatics tool to predict splicing signals. \u003Ci>Nucleic Acids Res\u003C/i>. 37:e67. doi: 10.1093/nar/gkp215\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/19339519\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/nar/gkp215\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=F.+O.+Desmet&#x00026;author=D.+Hamroun&#x00026;author=M.+Lalande&#x00026;author=G.+Collod-Beroud&#x00026;author=M.+Claustres&#x00026;author=C.+Beroud+&#x00026;publication_year=2009&#x00026;title=Human+splicing+finder%3A+an+online+bioinformatics+tool+to+predict+splicing+signals&#x00026;journal=Nucleic+Acids+Res&#x00026;volume=37&#x00026;pages=e67\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B14\" id=\"B14\">\u003C/a> Desvignes, J.-P., Bartoli, M., Delague, V., Krahn, M., Miltgen, M., B&#x000E9;roud, C., et al. (2018). VarAFT: a variant annotation and filtration system for human next generation sequencing data. \u003Ci>Nucleic Acids Res\u003C/i>. 46, W545&#x02013;W553. doi: 10.1093/nar/gky471\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29860484\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/nar/gky471\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J.+-P.+Desvignes&#x00026;author=M.+Bartoli&#x00026;author=V.+Delague&#x00026;author=M.+Krahn&#x00026;author=M.+Miltgen&#x00026;author=C.+B&#x000E9;roud+&#x00026;publication_year=2018&#x00026;title=VarAFT%3A+a+variant+annotation+and+filtration+system+for+human+next+generation+sequencing+data&#x00026;journal=Nucleic+Acids+Res&#x00026;volume=46&#x00026;pages=W545-W553\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B15\" id=\"B15\">\u003C/a> D&#x000ED;ez, O., Osorio, A., Dur&#x000E1;n, M., Martinez-Ferrandis, J. I., Hoya, M., dl Salazar, R., et al. (2003). Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. \u003Ci>Hum. Mutat\u003C/i>. 22, 301&#x02013;312. doi: 10.1002/humu.10260\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/12955716\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.10260\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=O.+D&#x000ED;ez&#x00026;author=A.+Osorio&#x00026;author=M.+Dur&#x000E1;n&#x00026;author=J.+I.+Martinez-Ferrandis&#x00026;author=M.+Hoya&#x00026;author=R.+dl+Salazar+&#x00026;publication_year=2003&#x00026;title=Analysis+of+BRCA1+and+BRCA2+genes+in+Spanish+breast%2Fovarian+cancer+patients%3A+a+high+proportion+of+mutations+unique+to+Spain+and+evidence+of+founder+effects&#x00026;journal=Hum.+Mutat&#x00026;volume=22&#x00026;pages=301-312\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B16\" id=\"B16\">\u003C/a> Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, H. T., Isaacs, C., et al. (2010). Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. \u003Ci>JAMA\u003C/i> 304, 967&#x02013;975. doi: 10.1001/jama.2010.1237\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/20810374\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1001/jama.2010.1237\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S.+M.+Domchek&#x00026;author=T.+M.+Friebel&#x00026;author=C.+F.+Singer&#x00026;author=D.+G.+Evans&#x00026;author=H.+T.+Lynch&#x00026;author=C.+Isaacs+&#x00026;publication_year=2010&#x00026;title=Association+of+risk-reducing+surgery+in+BRCA1+or+BRCA2+mutation+carriers+with+cancer+risk+and+mortality&#x00026;journal=JAMA&#x00026;volume=304&#x00026;pages=967-975\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B17\" id=\"B17\">\u003C/a> Domchek, S. M., Tang, J., Stopfer, J., Lilli, D. R., Hamel, N., Tischkowitz, M., et al. (2013). Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. \u003Ci>Cancer Discov\u003C/i>. 3, 399&#x02013;405. doi: 10.1158/2159-8290.CD-12-0421\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23269703\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1158/2159-8290.CD-12-0421\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S.+M.+Domchek&#x00026;author=J.+Tang&#x00026;author=J.+Stopfer&#x00026;author=D.+R.+Lilli&#x00026;author=N.+Hamel&#x00026;author=M.+Tischkowitz+&#x00026;publication_year=2013&#x00026;title=Biallelic+deleterious+BRCA1+mutations+in+a+woman+with+early-onset+ovarian+cancer&#x00026;journal=Cancer+Discov&#x00026;volume=3&#x00026;pages=399-405\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B18\" id=\"B18\">\u003C/a> Drost, R., Bouwman, P., Rottenberg, S., Boon, U., Schut, E., Klarenbeek, S., et al. (2011). BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. \u003Ci>Cancer Cell\u003C/i>. 20, 797&#x02013;809. doi: 10.1016/j.ccr.2011.11.014\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/22172724\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.ccr.2011.11.014\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R.+Drost&#x00026;author=P.+Bouwman&#x00026;author=S.+Rottenberg&#x00026;author=U.+Boon&#x00026;author=E.+Schut&#x00026;author=S.+Klarenbeek+&#x00026;publication_year=2011&#x00026;title=BRCA1+RING+function+is+essential+for+tumor+suppression+but+dispensable+for+therapy+resistance&#x00026;journal=Cancer+Cell&#x00026;volume=20&#x00026;pages=797-809\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B19\" id=\"B19\">\u003C/a> Drost, R., Dhillon, K. K., Van Der Gulden, H., Van Der Heijden, I., Brandsma, I., Cruz, C., et al. (2016). BRCA1 185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. \u003Ci>J. Clin. Invest\u003C/i>. 126, 2903&#x02013;2918. doi: 10.1172/JCI70196\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27454287\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1172/JCI70196\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R.+Drost&#x00026;author=K.+K.+Dhillon&#x00026;author=H.+Van+Der+Gulden&#x00026;author=I.+Van+Der+Heijden&#x00026;author=I.+Brandsma&#x00026;author=C.+Cruz+&#x00026;publication_year=2016&#x00026;title=BRCA1+185delAG+tumors+may+acquire+therapy+resistance+through+expression+of+RING-less+BRCA1&#x00026;journal=J.+Clin.+Invest&#x00026;volume=126&#x00026;pages=2903-2918\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B20\" id=\"B20\">\u003C/a> Drusedau, M., Dreesen, J. C., Derks-Smeets, I., Coonen, E., van Golde, R., van Echten-Arends, J., et al. (2013). PGD for hereditary breast and ovarian cancer: the route to universal tests for BRCA1 and BRCA2 mutation carriers. \u003Ci>Eur. J. Hum. Genet\u003C/i>. 21, 1361&#x02013;1368. doi: 10.1038/ejhg.2013.50\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23531862\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/ejhg.2013.50\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M.+Drusedau&#x00026;author=J.+C.+Dreesen&#x00026;author=I.+Derks-Smeets&#x00026;author=E.+Coonen&#x00026;author=R.+van+Golde&#x00026;author=J.+van+Echten-Arends+&#x00026;publication_year=2013&#x00026;title=PGD+for+hereditary+breast+and+ovarian+cancer%3A+the+route+to+universal+tests+for+BRCA1+and+BRCA2+mutation+carriers&#x00026;journal=Eur.+J.+Hum.+Genet&#x00026;volume=21&#x00026;pages=1361-1368\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B21\" id=\"B21\">\u003C/a> Edwards, S. M., Evans, D. G. R., Hope, Q., Norman, A., Barbachano, Y., Bullock, S., et al. (2010). Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. \u003Ci>Br. J. Cancer\u003C/i> 103, 918&#x02013;924. doi: 10.1038/sj.bjc.6605822\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/20736950\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/sj.bjc.6605822\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S.+M.+Edwards&#x00026;author=D.+G.+R.+Evans&#x00026;author=Q.+Hope&#x00026;author=A.+Norman&#x00026;author=Y.+Barbachano&#x00026;author=S.+Bullock+&#x00026;publication_year=2010&#x00026;title=Prostate+cancer+in+BRCA2+germline+mutation+carriers+is+associated+with+poorer+prognosis&#x00026;journal=Br.+J.+Cancer&#x00026;volume=103&#x00026;pages=918-924\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B22\" id=\"B22\">\u003C/a> Evers, B., and Jonkers, J. (2006). Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. \u003Ci>Oncogene\u003C/i>. 25, 5885&#x02013;5897. doi: 10.1038/sj.onc.1209871\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16998503\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/sj.onc.1209871\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=B.+Evers&#x00026;author=J.+Jonkers+&#x00026;publication_year=2006&#x00026;title=Mouse+models+of+BRCA1+and+BRCA2+deficiency%3A+past+lessons,+current+understanding+and+future+prospects&#x00026;journal=Oncogene&#x00026;volume=25&#x00026;pages=5885-5897\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B23\" id=\"B23\">\u003C/a> Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. \u003Ci>Nature\u003C/i> 434, 917&#x02013;921. doi: 10.1038/nature03445\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/15829967\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nature03445\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H.+Farmer&#x00026;author=N.+McCabe&#x00026;author=C.+J.+Lord&#x00026;author=A.+N.+Tutt&#x00026;author=D.+A.+Johnson&#x00026;author=T.+B.+Richardson+&#x00026;publication_year=2005&#x00026;title=Targeting+the+DNA+repair+defect+in+BRCA+mutant+cells+as+a+therapeutic+strategy&#x00026;journal=Nature&#x00026;volume=434&#x00026;pages=917-921\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B24\" id=\"B24\">\u003C/a> Finch, A., Beiner, M., Lubinski, J., Lynch, H. T., Moller, P., Rosen, B., et al. (2006). Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. \u003Ci>JAMA\u003C/i> 296, 185&#x02013;192. doi: 10.1001/jama.296.2.185\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16835424\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1001/jama.296.2.185\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A.+Finch&#x00026;author=M.+Beiner&#x00026;author=J.+Lubinski&#x00026;author=H.+T.+Lynch&#x00026;author=P.+Moller&#x00026;author=B.+Rosen+&#x00026;publication_year=2006&#x00026;title=Salpingo-oophorectomy+and+the+risk+of+ovarian,+fallopian+tube,+and+peritoneal+cancers+in+women+with+a+BRCA1+or+BRCA2+mutation&#x00026;journal=JAMA&#x00026;volume=296&#x00026;pages=185-192\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B25\" id=\"B25\">\u003C/a> Fourati, A., Louchez, M. M., Fournier, J., Gamoudi, A., Rahal, K., El May, M. V., et al. (2014). Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer. \u003Ci>Bull. Cancer\u003C/i> 101, E36&#x02013;E40. doi: 10.1684/bdc.2014.2049\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25418591\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1684/bdc.2014.2049\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A.+Fourati&#x00026;author=M.+M.+Louchez&#x00026;author=J.+Fournier&#x00026;author=A.+Gamoudi&#x00026;author=K.+Rahal&#x00026;author=M.+V.+El+May+&#x00026;publication_year=2014&#x00026;title=Screening+for+common+mutations+in+BRCA1+and+BRCA2+genes%3A+interest+in+genetic+testing+of+Tunisian+families+with+breast+and%2For+ovarian+cancer&#x00026;journal=Bull.+Cancer&#x00026;volume=101&#x00026;pages=E36-E40\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B26\" id=\"B26\">\u003C/a> Genomes Project, C., Auton, A., Brooks, L. D., Durbin, R. M., Garrison, E. P., Kang, H. M., et al. (2015). A global reference for human genetic variation. \u003Ci>Nature\u003C/i> 526, 68&#x02013;74. doi: 10.1038/nature15393\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26432245\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nature15393\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=C.+Genomes+Project&#x00026;author=A.+Auton&#x00026;author=L.+D.+Brooks&#x00026;author=R.+M.+Durbin&#x00026;author=E.+P.+Garrison&#x00026;author=H.+M.+Kang+&#x00026;publication_year=2015&#x00026;title=A+global+reference+for+human+genetic+variation&#x00026;journal=Nature&#x00026;volume=526&#x00026;pages=68-74\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B27\" id=\"B27\">\u003C/a> Heidemann, S., Fischer, C., Engel, C., Fischer, B., Harder, L., Schlegelberger, B., et al. (2012). Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management. \u003Ci>Breast Cancer Res. Treat\u003C/i>. 134, 1229&#x02013;1239. doi: 10.1007/s10549-012-2050-4\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/22535016\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10549-012-2050-4\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S.+Heidemann&#x00026;author=C.+Fischer&#x00026;author=C.+Engel&#x00026;author=B.+Fischer&#x00026;author=L.+Harder&#x00026;author=B.+Schlegelberger+&#x00026;publication_year=2012&#x00026;title=Double+heterozygosity+for+mutations+in+BRCA1+and+BRCA2+in+German+breast+cancer+patients%3A+implications+on+test+strategies+and+clinical+management&#x00026;journal=Breast+Cancer+Res.+Treat&#x00026;volume=134&#x00026;pages=1229-1239\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B28\" id=\"B28\">\u003C/a> Johnson, W. G. (1980). Metabolic interference and the&#x0002B;- heterozygote. a hypothetical form of simple inheritance which is neither dominant nor recessive. \u003Ci>Am. J. Hum. Genet\u003C/i>. 32:374.\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/6770678\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=W.+G.+Johnson+&#x00026;publication_year=1980&#x00026;title=Metabolic+interference+and+the+-+heterozygote.+a+hypothetical+form+of+simple+inheritance+which+is+neither+dominant+nor+recessive&#x00026;journal=Am.+J.+Hum.+Genet&#x00026;volume=32&#x00026;pages=374\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B29\" id=\"B29\">\u003C/a> Kelley, M. R., Kidd, S., Deutsch, W. A., and Young, M. W. (1987). Mutations altering the structure of epidermal growth factor-like coding sequences at the Drosophila Notch locus. \u003Ci>Cell\u003C/i>. 51, 539&#x02013;548. doi: 10.1016/0092-8674(87)90123-1\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/3119223\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/0092-8674(87)90123-1\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M.+R.+Kelley&#x00026;author=S.+Kidd&#x00026;author=W.+A.+Deutsch&#x00026;author=M.+W.+Young+&#x00026;publication_year=1987&#x00026;title=Mutations+altering+the+structure+of+epidermal+growth+factor-like+coding+sequences+at+the+Drosophila+Notch+locus&#x00026;journal=Cell&#x00026;volume=51&#x00026;pages=539-548\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B30\" id=\"B30\">\u003C/a> Kim, H., Cho, D. Y., Choi, D. H., Choi, S. Y., Shin, I., Park, W., et al. (2012). Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer. \u003Ci>Breast Cancer Res. Treat\u003C/i>. 134, 1315&#x02013;1326. doi: 10.1007/s10549-012-2159-5\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/22798144\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10549-012-2159-5\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H.+Kim&#x00026;author=D.+Y.+Cho&#x00026;author=D.+H.+Choi&#x00026;author=S.+Y.+Choi&#x00026;author=I.+Shin&#x00026;author=W.+Park+&#x00026;publication_year=2012&#x00026;title=Characteristics+and+spectrum+of+BRCA1+and+BRCA2+mutations+in+3,922+Korean+patients+with+breast+and+ovarian+cancer&#x00026;journal=Breast+Cancer+Res.+Treat&#x00026;volume=134&#x00026;pages=1315-1326\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B31\" id=\"B31\">\u003C/a> Laarabi, F. Z., Ratbi, I., Elalaoui, S. C., Mezzouar, L., Doubaj, Y., Bouguenouch, L., et al. (2017). High frequency of the recurrent c. 1310_1313delAAGA BRCA2 mutation in the North-East of Morocco and implication for hereditary breast-ovarian cancer prevention and control. \u003Ci>BMC Res. Notes\u003C/i> 10:188. doi: 10.1186/s13104-017-2511-2\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28577564\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s13104-017-2511-2\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=F.+Z.+Laarabi&#x00026;author=I.+Ratbi&#x00026;author=S.+C.+Elalaoui&#x00026;author=L.+Mezzouar&#x00026;author=Y.+Doubaj&#x00026;author=L.+Bouguenouch+&#x00026;publication_year=2017&#x00026;title=High+frequency+of+the+recurrent+c.+1310_1313delAAGA+BRCA2+mutation+in+the+North-East+of+Morocco+and+implication+for+hereditary+breast-ovarian+cancer+prevention+and+control&#x00026;journal=BMC+Res.+Notes&#x00026;volume=10&#x00026;pages=188\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B32\" id=\"B32\">\u003C/a> Landrum, M. J., Chitipiralla, S., Brown, G. R., Chen, C., Gu, B., Hart, J., et al. (2020). ClinVar: improvements to accessing data. \u003Ci>Nucleic Acids Res\u003C/i>. 48(D1), D835&#x02013;D844. doi: 10.1093/nar/gkz972\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31777943\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/nar/gkz972\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M.+J.+Landrum&#x00026;author=S.+Chitipiralla&#x00026;author=G.+R.+Brown&#x00026;author=C.+Chen&#x00026;author=B.+Gu&#x00026;author=J.+Hart+&#x00026;publication_year=2020&#x00026;title=ClinVar%3A+improvements+to+accessing+data&#x00026;journal=Nucleic+Acids+Res&#x00026;volume=48&#x00026;pages=D835-D844\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B33\" id=\"B33\">\u003C/a> Lavie, O., Narod, S., Lejbkowicz, F., Dishon, S., Goldberg, Y., Gemer, O., et al. (2011). Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population. \u003Ci>Ann. Oncol\u003C/i>. 22, 964&#x02013;966. doi: 10.1093/annonc/mdq460\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/20924075\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/annonc/mdq460\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=O.+Lavie&#x00026;author=S.+Narod&#x00026;author=F.+Lejbkowicz&#x00026;author=S.+Dishon&#x00026;author=Y.+Goldberg&#x00026;author=O.+Gemer+&#x00026;publication_year=2011&#x00026;title=Double+heterozygosity+in+the+BRCA1+and+BRCA2+genes+in+the+Jewish+population&#x00026;journal=Ann.+Oncol&#x00026;volume=22&#x00026;pages=964-966\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B34\" id=\"B34\">\u003C/a> Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., et al. (2016). Analysis of protein-coding genetic variation in 60,706 humans. \u003Ci>Nature\u003C/i> 536, 285&#x02013;291. doi: 10.1038/nature19057\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27535533\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nature19057\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M.+Lek&#x00026;author=K.+J.+Karczewski&#x00026;author=E.+V.+Minikel&#x00026;author=K.+E.+Samocha&#x00026;author=E.+Banks&#x00026;author=T.+Fennell+&#x00026;publication_year=2016&#x00026;title=Analysis+of+protein-coding+genetic+variation+in+60,706+humans&#x00026;journal=Nature&#x00026;volume=536&#x00026;pages=285-291\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B35\" id=\"B35\">\u003C/a> Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. \u003Ci>Bioinformatics\u003C/i> 25, 1754&#x02013;1760. doi: 10.1093/bioinformatics/btp324\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/19451168\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/bioinformatics/btp324\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H.+Li&#x00026;author=R.+Durbin+&#x00026;publication_year=2009&#x00026;title=Fast+and+accurate+short+read+alignment+with+Burrows-Wheeler+transform&#x00026;journal=Bioinformatics&#x00026;volume=25&#x00026;pages=1754-1760\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B36\" id=\"B36\">\u003C/a> Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., et al. (2009). The Sequence alignment/Map format and SAMtools. \u003Ci>Bioinformatics\u003C/i> 25, 2078&#x02013;2079. doi: 10.1093/bioinformatics/btp352\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/19505943\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/bioinformatics/btp352\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H.+Li&#x00026;author=B.+Handsaker&#x00026;author=A.+Wysoker&#x00026;author=T.+Fennell&#x00026;author=J.+Ruan&#x00026;author=N.+Homer+&#x00026;publication_year=2009&#x00026;title=The+Sequence+alignment%2FMap+format+and+SAMtools&#x00026;journal=Bioinformatics&#x00026;volume=25&#x00026;pages=2078-2079\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B37\" id=\"B37\">\u003C/a> Lubinski, J., Phelan, C. M., Ghadirian, P., Lynch, H. T., Garber, J., Weber, B., et al. (2004). Cancer variation associated with the position of the mutation in the BRCA2 gene. \u003Ci>Fam. Cancer\u003C/i> 3, 1&#x02013;10. doi: 10.1023/B:FAME.0000026816.32400.45\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/15131399\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1023/B:FAME.0000026816.32400.45\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J.+Lubinski&#x00026;author=C.+M.+Phelan&#x00026;author=P.+Ghadirian&#x00026;author=H.+T.+Lynch&#x00026;author=J.+Garber&#x00026;author=B.+Weber+&#x00026;publication_year=2004&#x00026;title=Cancer+variation+associated+with+the+position+of+the+mutation+in+the+BRCA2+gene&#x00026;journal=Fam.+Cancer&#x00026;volume=3&#x00026;pages=1-10\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B38\" id=\"B38\">\u003C/a> Masood Gilani, G., and Kamal, S. (2004). Risk factors for breast cancer in Pakistani women aged less than 45 years. \u003Ci>Ann. Hum. Biol\u003C/i>. 31, 398&#x02013;407. doi: 10.1080/0301446042000226763\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/15513691\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1080/0301446042000226763\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=G.+Masood+Gilani&#x00026;author=S.+Kamal+&#x00026;publication_year=2004&#x00026;title=Risk+factors+for+breast+cancer+in+Pakistani+women+aged+less+than+45+years&#x00026;journal=Ann.+Hum.+Biol&#x00026;volume=31&#x00026;pages=398-407\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B39\" id=\"B39\">\u003C/a> Mehrgou, A., and Akouchekian, M. (2016). The importance of BRCA1 and BRCA2 genes mutations in breast cancer development. \u003Ci>Med. J. Islam. Repub. Iran\u003C/i>. 30:369.\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27493913\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A.+Mehrgou&#x00026;author=M.+Akouchekian+&#x00026;publication_year=2016&#x00026;title=The+importance+of+BRCA1+and+BRCA2+genes+mutations+in+breast+cancer+development&#x00026;journal=Med.+J.+Islam.+Repub.+Iran&#x00026;volume=30&#x00026;pages=369\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B40\" id=\"B40\">\u003C/a> Nielsen, S. M., Eccles, D. M., Romero, I. L., Al-Mulla, F., Balmana, J., Biancolella, M., et al. (2018). Genetic testing and clinical management practices for variants in non-BRCA1/2 breast (and breast/ovarian) cancer susceptibility genes: an international survey by the evidence-based network for the interpretation of germline mutant alleles (ENIGMA) clinical working group. \u003Ci>JCO Precision Oncol\u003C/i>. 2:PO.18.00091. doi: 10.1200/PO.18.00091\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31517176\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1200/PO.18.00091\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S.+M.+Nielsen&#x00026;author=D.+M.+Eccles&#x00026;author=I.+L.+Romero&#x00026;author=F.+Al-Mulla&#x00026;author=J.+Balmana&#x00026;author=M.+Biancolella+&#x00026;publication_year=2018&#x00026;title=Genetic+testing+and+clinical+management+practices+for+variants+in+non-BRCA1%2F2+breast+(and+breast%2Fovarian)+cancer+susceptibility+genes%3A+an+international+survey+by+the+evidence-based+network+for+the+interpretation+of+germline+mutant+alleles+(ENIGMA)+clinical+working+group&#x00026;journal=JCO+Precision+Oncol&#x00026;volume=2&#x00026;pages=PO.18.00091\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B41\" id=\"B41\">\u003C/a> Pensabene, M., Spagnoletti, I., Capuano, I., Condello, C., Pepe, S., Contegiacomo, A., et al. (2009). Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling. \u003Ci>Ann. Oncol\u003C/i>. 20, 874&#x02013;878. doi: 10.1093/annonc/mdn724\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/19179552\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/annonc/mdn724\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M.+Pensabene&#x00026;author=I.+Spagnoletti&#x00026;author=I.+Capuano&#x00026;author=C.+Condello&#x00026;author=S.+Pepe&#x00026;author=A.+Contegiacomo+&#x00026;publication_year=2009&#x00026;title=Two+mutations+of+BRCA2+gene+at+exon+and+splicing+site+in+a+woman+who+underwent+oncogenetic+counseling&#x00026;journal=Ann.+Oncol&#x00026;volume=20&#x00026;pages=874-878\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B42\" id=\"B42\">\u003C/a> Rahman, N., and Scott, R. H. (2007). Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players. \u003Ci>Human Mol. Genet\u003C/i>. 16, R60&#x02013;R66. doi: 10.1093/hmg/ddm026\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/17613548\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/hmg/ddm026\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=N.+Rahman&#x00026;author=R.+H.+Scott+&#x00026;publication_year=2007&#x00026;title=Cancer+genes+associated+with+phenotypes+in+monoallelic+and+biallelic+mutation+carriers%3A+new+lessons+from+old+players&#x00026;journal=Human+Mol.+Genet&#x00026;volume=16&#x00026;pages=R60-R66\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B43\" id=\"B43\">\u003C/a> Rebbeck, T. R., Friebel, T. M., Mitra, N., Wan, F., Chen, S., Andrulis, I. L., et al. (2016). Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. \u003Ci>Breast Cancer Res\u003C/i>. 18:112. doi: 10.1186/s13058-016-0768-3\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27836010\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s13058-016-0768-3\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=T.+R.+Rebbeck&#x00026;author=T.+M.+Friebel&#x00026;author=N.+Mitra&#x00026;author=F.+Wan&#x00026;author=S.+Chen&#x00026;author=I.+L.+Andrulis+&#x00026;publication_year=2016&#x00026;title=Inheritance+of+deleterious+mutations+at+both+BRCA1+and+BRCA2+in+an+international+sample+of+32,295+women&#x00026;journal=Breast+Cancer+Res&#x00026;volume=18&#x00026;pages=112\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B44\" id=\"B44\">\u003C/a> Rebbeck, T. R., Mitra, N., Wan, F., Sinilnikova, O. M., Healey, S., McGuffog, L., et al. (2015). Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. \u003Ci>JAMA\u003C/i> 313, 1347&#x02013;1361. doi: 10.1001/jama.2014.5985\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25849179\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1001/jama.2014.5985\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=T.+R.+Rebbeck&#x00026;author=N.+Mitra&#x00026;author=F.+Wan&#x00026;author=O.+M.+Sinilnikova&#x00026;author=S.+Healey&#x00026;author=L.+McGuffog+&#x00026;publication_year=2015&#x00026;title=Association+of+type+and+location+of+BRCA1+and+BRCA2+mutations+with+risk+of+breast+and+ovarian+cancer&#x00026;journal=JAMA&#x00026;volume=313&#x00026;pages=1347-1361\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B45\" id=\"B45\">\u003C/a> Rojas, K., and Stuckey, A. (2016). Breast cancer epidemiology and risk factors. \u003Ci>Clin. Obstet. Gynecol\u003C/i>. 59, 651&#x02013;672. doi: 10.1097/GRF.0000000000000239\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27681694\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1097/GRF.0000000000000239\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=K.+Rojas&#x00026;author=A.+Stuckey+&#x00026;publication_year=2016&#x00026;title=Breast+cancer+epidemiology+and+risk+factors&#x00026;journal=Clin.+Obstet.+Gynecol&#x00026;volume=59&#x00026;pages=651-672\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B46\" id=\"B46\">\u003C/a> Romdhane, L., Mezzi, N., Hamdi, Y., El-Kamah, G., Barakat, A., and Abdelhak, S. (2019). Consanguinity and inbreeding in health and disease in North African populations. \u003Ci>Annu. Rev. Genomics Hum. Genet\u003C/i>. 20, 155&#x02013;179. doi: 10.1146/annurev-genom-083118-014954\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31039041\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1146/annurev-genom-083118-014954\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=L.+Romdhane&#x00026;author=N.+Mezzi&#x00026;author=Y.+Hamdi&#x00026;author=G.+El-Kamah&#x00026;author=A.+Barakat&#x00026;author=S.+Abdelhak+&#x00026;publication_year=2019&#x00026;title=Consanguinity+and+inbreeding+in+health+and+disease+in+North+African+populations&#x00026;journal=Annu.+Rev.+Genomics+Hum.+Genet&#x00026;volume=20&#x00026;pages=155-179\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B47\" id=\"B47\">\u003C/a> Sawyer, S. L., Tian, L., K&#x000E4;hk&#x000F6;nen, M., Schwartzentruber, J., Kircher, M., Majewski, J., et al. (2015). Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. \u003Ci>Cancer Discov\u003C/i>. 5, 135&#x02013;142. doi: 10.1158/2159-8290.CD-14-1156\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25472942\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1158/2159-8290.CD-14-1156\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S.+L.+Sawyer&#x00026;author=L.+Tian&#x00026;author=M.+K&#x000E4;hk&#x000F6;nen&#x00026;author=J.+Schwartzentruber&#x00026;author=M.+Kircher&#x00026;author=J.+Majewski+&#x00026;publication_year=2015&#x00026;title=Biallelic+mutations+in+BRCA1+cause+a+new+Fanconi+anemia+subtype&#x00026;journal=Cancer+Discov&#x00026;volume=5&#x00026;pages=135-142\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B48\" id=\"B48\">\u003C/a> Schwarz, J. M., Rodelsperger, C., Schuelke, M., and Seelow, D. (2010). MutationTaster evaluates disease-causing potential of sequence alterations. \u003Ci>Nat. Methods\u003C/i> 7, 575&#x02013;576. doi: 10.1038/nmeth0810-575\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/20676075\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nmeth0810-575\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J.+M.+Schwarz&#x00026;author=C.+Rodelsperger&#x00026;author=M.+Schuelke&#x00026;author=D.+Seelow+&#x00026;publication_year=2010&#x00026;title=MutationTaster+evaluates+disease-causing+potential+of+sequence+alterations&#x00026;journal=Nat.+Methods&#x00026;volume=7&#x00026;pages=575-576\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B49\" id=\"B49\">\u003C/a> Servick, K. (2014). Breast cancer: a world of differences. \u003Ci>Am. Assoc. Adv. Sci\u003C/i>. doi: 10.1126/science.343.6178.1452\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24675948\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1126/science.343.6178.1452\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=K.+Servick+&#x00026;publication_year=2014&#x00026;title=Breast+cancer%3A+a+world+of+differences&#x00026;journal=Am.+Assoc.+Adv.+Sci\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B50\" id=\"B50\">\u003C/a> Silvestri, V., Leslie, G., Barnes, D. R., Group, C., Agnarsson, B. A., Aittomaki, K., et al. (2020). Characterization of the cancer spectrum in men with germline BRCA1 and BRCA2 pathogenic variants: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). \u003Ci>JAMA Oncol\u003C/i>. 6, 1218&#x02013;1230. doi: 10.1001/jamaoncol.2020.2134\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32614418\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1001/jamaoncol.2020.2134\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=V.+Silvestri&#x00026;author=G.+Leslie&#x00026;author=D.+R.+Barnes&#x00026;author=C.+Group&#x00026;author=B.+A.+Agnarsson&#x00026;author=K.+Aittomaki+&#x00026;publication_year=2020&#x00026;title=Characterization+of+the+cancer+spectrum+in+men+with+germline+BRCA1+and+BRCA2+pathogenic+variants%3A+results+from+the+consortium+of+investigators+of+modifiers+of+BRCA1%2F2+(CIMBA)&#x00026;journal=JAMA+Oncol&#x00026;volume=6&#x00026;pages=1218-1230\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B51\" id=\"B51\">\u003C/a> Stephens, M., Smith, N. J., and Donnelly, P. (2001). A new statistical method for haplotype reconstruction from population data. \u003Ci>Am. J. Human Genet\u003C/i>. 68, 978&#x02013;989. doi: 10.1086/319501\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/11254454\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1086/319501\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M.+Stephens&#x00026;author=N.+J.+Smith&#x00026;author=P.+Donnelly+&#x00026;publication_year=2001&#x00026;title=A+new+statistical+method+for+haplotype+reconstruction+from+population+data&#x00026;journal=Am.+J.+Human+Genet&#x00026;volume=68&#x00026;pages=978-989\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B52\" id=\"B52\">\u003C/a> Szabo, C., Masiello, A., Ryan, J. F., Consortium, B., and Brody, L. C. (2000). The breast cancer information core: database design, structure, and scope. \u003Ci>Hum. Mutat\u003C/i>. 16, 123&#x02013;131. doi: 10.1002/1098-1004(200008)16:2&#x0003C;123::AID-HUMU4&#x0003E;3.0.CO;2-Y\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/10923033\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/1098-1004(200008)16:2&#x0003C;123::AID-HUMU4&#x0003E;3.0.CO;2-Y\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=C.+Szabo&#x00026;author=A.+Masiello&#x00026;author=J.+F.+Ryan&#x00026;author=B.+Consortium&#x00026;author=L.+C.+Brody+&#x00026;publication_year=2000&#x00026;title=The+breast+cancer+information+core%3A+database+design,+structure,+and+scope&#x00026;journal=Hum.+Mutat&#x00026;volume=16&#x00026;pages=123-131\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B53\" id=\"B53\">\u003C/a> Thomassen, M., Hansen, T. V., Borg, A., Lianee, H. T., Wikman, F., Pedersen, I. S., et al. (2008). BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer. \u003Ci>Acta Oncol\u003C/i>. 47, 772&#x02013;777. doi: 10.1080/02841860802004974\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/18465347\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1080/02841860802004974\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M.+Thomassen&#x00026;author=T.+V.+Hansen&#x00026;author=A.+Borg&#x00026;author=H.+T.+Lianee&#x00026;author=F.+Wikman&#x00026;author=I.+S.+Pedersen+&#x00026;publication_year=2008&#x00026;title=BRCA1+and+BRCA2+mutations+in+Danish+families+with+hereditary+breast+and%2For+ovarian+cancer&#x00026;journal=Acta+Oncol&#x00026;volume=47&#x00026;pages=772-777\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B54\" id=\"B54\">\u003C/a> Thompson, D., Easton, D., and Breast Cancer Linkage, C. (2001). Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. \u003Ci>Am. J. Hum. Genet\u003C/i>. 68, 410&#x02013;419. doi: 10.1086/318181\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/11170890\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1086/318181\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=D.+Thompson&#x00026;author=D.+Easton&#x00026;author=C.+Breast+Cancer+Linkage+&#x00026;publication_year=2001&#x00026;title=Variation+in+cancer+risks,+by+mutation+position,+in+BRCA2+mutation+carriers&#x00026;journal=Am.+J.+Hum.+Genet&#x00026;volume=68&#x00026;pages=410-419\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B55\" id=\"B55\">\u003C/a> Van der Auwera, G., and O&#x00027;Connor, B. (2020). \u003Ci>Genomics in the Cloud: Using Docker\u003C/i>, GATK, and WDL in Terra. O&#x00027;Reilly Media.\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?author=G.+Van+der+Auwera&#x00026;author=B.+O&#x00027;Connor+&#x00026;publication_year=2020&#x00026;title=Genomics+in+the+Cloud%3A+Using+Docker\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B56\" id=\"B56\">\u003C/a> Venkitaraman, A. R. (2019). How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility? \u003Ci>DNA Repair\u003C/i>. 81:102668. doi: 10.1016/j.dnarep.2019.102668\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31337537\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.dnarep.2019.102668\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A.+R.+Venkitaraman+&#x00026;publication_year=2019&#x00026;title=How+do+mutations+affecting+the+breast+cancer+genes+BRCA1+and+BRCA2+cause+cancer+susceptibility%3F&#x00026;journal=DNA+Repair&#x00026;volume=81&#x00026;pages=102668\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003Cdiv class=\"References\">\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B57\" id=\"B57\">\u003C/a> Zehani, S., Maalej, M., Hsairi, M., Hechiche, M., Romdhane, B., Boussen, H., et al. (2009). Breast cancer in Tunisia: epidemiologic characteristics and trends in incidence. \u003Ci>Tunis. Med\u003C/i>. 87, 417&#x02013;425.\u003C/p>\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/20063673\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S.+Zehani&#x00026;author=M.+Maalej&#x00026;author=M.+Hsairi&#x00026;author=M.+Hechiche&#x00026;author=B.+Romdhane&#x00026;author=H.+Boussen+&#x00026;publication_year=2009&#x00026;title=Breast+cancer+in+Tunisia%3A+epidemiologic+characteristics+and+trends+in+incidence&#x00026;journal=Tunis.+Med&#x00026;volume=87&#x00026;pages=417-425\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\n\u003C/div>\n\u003C/div>\n\u003Cdiv class=\"thinLineM20\">\u003C/div>\n\u003Cdiv class=\"AbstractSummary\">\n\u003Cp>\u003Cspan>Keywords:\u003C/span> breast cancer susceptibility, whole exome sequencing, \u003Ci>Cis\u003C/i> double heterozygosity, BRCA2 mutations, early age of onset, phenotype genotype correlation\u003C/p>\n\u003Cp>\u003Cspan>Citation:\u003C/span> Hamdi Y, Boujemaa M, Mighri N, Mejri N, Jaidane O, Ben Nasr S, Bouaziz H, Hassouna JB, Zribi A, Berrazaga Y, Rachdi H, Daoud N, El Benna H, Labidi S, Haddaoui A, Rahal K, Benna F, Boussen H, Abdelhak S and Boubaker S (2021) Identification of \u003Ci>BRCA2 Cis\u003C/i> Double Heterozygous Breast Cancer Cases Using Whole Exome Sequencing: Phenotypic Expression and Impact on Personalized Oncology. \u003Ci>Front. Genet.\u003C/i> 12:674990. doi: 10.3389/fgene.2021.674990\u003C/p>\n\u003Cp id=\"timestamps\">\u003Cspan>Received:\u003C/span> 17 April 2021; \u003Cspan>Accepted:\u003C/span> 08 July 2021;\u003Cbr> \u003Cspan>Published:\u003C/span> 12 August 2021.\u003C/p>\n\u003Cdiv>\u003Cp>Edited by:\u003C/p> \u003Ca href=\"http://loop.frontiersin.org/people/48619/overview\">Mehdi Pirooznia\u003C/a>, National Heart, Lung, and Blood Institute (NHLBI), United States\u003C/div>\n\u003Cdiv>\u003Cp>Reviewed by:\u003C/p> \u003Ca href=\"http://loop.frontiersin.org/people/955227/overview\">Stephen R. Piccolo\u003C/a>, Brigham Young University, United States\u003Cbr> \u003Ca href=\"http://loop.frontiersin.org/people/795534/overview\">Deli Liu\u003C/a>, Weill Cornell Medicine, United States\u003C/div>\n\u003Cp>\u003Cspan>Copyright\u003C/span> &#x000A9; 2021 Hamdi, Boujemaa, Mighri, Mejri, Jaidane, Ben Nasr, Bouaziz, Hassouna, Zribi, Berrazaga, Rachdi, Daoud, El Benna, Labidi, Haddaoui, Rahal, Benna, Boussen, Abdelhak and Boubaker. This is an open-access article distributed under the terms of the \u003Ca rel=\"license\" href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License (CC BY)\u003C/a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.\u003C/p>\n\u003Cp>\u003Cspan>&#x0002A;Correspondence:\u003C/span> Yosr Hamdi, \u003Ca id=\"encmail\">eW9zci5oYW1kaUBwYXN0ZXVyLnRu\u003C/a>\u003C/p>\n\u003Cdiv class=\"clear\">\u003C/div>\n\u003C/div>","\u003Cul class=\"flyoutJournal\">\r\n\u003Cli>\u003Ca href=\"#h1\">Abstract\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h2\">Introduction\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h3\">Materials and Methods\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h4\">Results\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h5\">Discussion\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h6\">Conclusion\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h7\">Data Availability Statement\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h8\">Ethics Statement\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h9\">Author Contributions\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h10\">Funding\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h11\">Conflict of Interest\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h12\">Publisher&#x00027;s Note\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h13\">Acknowledgments\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h14\">Supplementary Material\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h15\">Abbreviations\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h16\">References\u003C/a>\u003C/li>\r\n\u003C/ul>",[728,733,739,742,748],{"name":729,"fileServerPackageEntryId":19,"fileServerId":730,"fileServerVersionNumber":374,"type":731},"EPUB.epub","674990/epub",{"code":732,"name":732},"EPUB",{"name":734,"fileServerPackageEntryId":735,"fileServerId":736,"fileServerVersionNumber":374,"type":737},"fgene-12-674990.pdf","fgene-12-674990/fgene-12-674990.pdf","674990/pubmed-zip",{"code":738,"name":738},"PDF",{"name":734,"fileServerPackageEntryId":19,"fileServerId":740,"fileServerVersionNumber":374,"type":741},"674990/publishers-proof/pdf",{"code":738,"name":738},{"name":743,"fileServerPackageEntryId":744,"fileServerId":736,"fileServerVersionNumber":374,"type":745},"fgene-12-674990.xml","fgene-12-674990/fgene-12-674990.xml",{"code":746,"name":747},"NLM_XML","XML",{"name":749,"fileServerPackageEntryId":19,"fileServerId":750,"fileServerVersionNumber":374,"type":751},"Provisional PDF.pdf","674990/provisional-pdf",{"code":738,"name":738},"v3",{"title":754,"link":755,"meta":759,"script":941},"Frontiers | Identification of BRCA2 Cis Double Heterozygous Breast Cancer Cases Using Whole Exome Sequencing: Phenotypic Expression and Impact on Personalized Oncology",[756],{"rel":757,"href":758},"canonical","https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/full",[760,763,766,768,771,775,778,782,785,788,791,793,795,797,799,801,804,807,809,812,814,816,819,822,825,828,831,835,839,842,844,847,849,852,854,857,860,863,865,868,870,873,875,878,881,884,887,890,892,895,897,900,902,905,907,910,912,915,917,920,923,926,928,931,933,936,938],{"hid":761,"property":761,"name":761,"content":762},"description","BRCA1 and BRCA2 are the most commonly mutated breast cancer susceptibility genes that convey a high risk of breast and ovarian cancer. Most BRCA1 or BRCA2 mu...",{"hid":764,"property":764,"name":765,"content":754},"og:title","title",{"hid":767,"property":767,"name":761,"content":762},"og:description",{"hid":769,"name":769,"content":770},"keywords","Breast cancer susceptibility,whole exome sequencing,Cis double heterozygosity,BRCA2 mutations,Early age of onset,Phenotype genotype correlation",{"hid":772,"property":772,"name":773,"content":774},"og:site_name","site_name","Frontiers",{"hid":776,"property":776,"name":367,"content":777},"og:image","https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/674990/fgene-12-674990-HTML/image_m/fgene-12-674990-g001.jpg",{"hid":779,"property":779,"name":780,"content":781},"og:type","type","article",{"hid":783,"property":783,"name":784,"content":758},"og:url","url",{"hid":786,"name":786,"content":787},"twitter:card","summary_large_image",{"hid":789,"name":789,"content":790},"citation_volume","12",{"hid":792,"name":792,"content":116},"citation_journal_title",{"hid":794,"name":794,"content":774},"citation_publisher",{"hid":796,"name":796,"content":708},"citation_journal_abbrev",{"hid":798,"name":798,"content":709},"citation_issn",{"hid":800,"name":800,"content":518},"citation_doi",{"hid":802,"name":802,"content":803},"citation_firstpage","674990",{"hid":805,"name":805,"content":806},"citation_language","English",{"hid":808,"name":808,"content":519},"citation_title",{"hid":810,"name":810,"content":811},"citation_keywords","Breast cancer susceptibility; whole exome sequencing; Cis double heterozygosity; BRCA2 mutations; Early age of onset; Phenotype genotype correlation",{"hid":813,"name":813,"content":524},"citation_abstract",{"hid":815,"name":815,"content":527},"citation_article_type",{"hid":817,"name":817,"content":818},"citation_pdf_url","https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/pdf",{"hid":820,"name":820,"content":821},"citation_xml_url","https://public-pages-files-2025.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.674990/xml",{"hid":823,"name":823,"content":824},"citation_fulltext_world_readable","yes",{"hid":826,"name":826,"content":827},"citation_online_date","2021/07/08",{"hid":829,"name":829,"content":830},"citation_publication_date","2021/08/12",{"hid":832,"name":833,"content":834},"citation_author_0","citation_author","Hamdi, Yosr ",{"hid":836,"name":837,"content":838},"citation_author_institution_0","citation_author_institution","Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia",{"hid":840,"name":833,"content":841},"citation_author_1","Boujemaa, Maroua ",{"hid":843,"name":837,"content":838},"citation_author_institution_1",{"hid":845,"name":833,"content":846},"citation_author_2","Mighri, Najah ",{"hid":848,"name":837,"content":838},"citation_author_institution_2",{"hid":850,"name":833,"content":851},"citation_author_3","Mejri, Nesrine ",{"hid":853,"name":837,"content":838},"citation_author_institution_3",{"hid":855,"name":833,"content":856},"citation_author_4","Jaidane, Olfa ",{"hid":858,"name":837,"content":859},"citation_author_institution_4","Surgical Oncology Department, Salah Azaiez Institute of Cancer, Tunisia",{"hid":861,"name":833,"content":862},"citation_author_5","Ben Nasr, Sonia ",{"hid":864,"name":837,"content":838},"citation_author_institution_5",{"hid":866,"name":833,"content":867},"citation_author_6","Bouaziz, Hanen ",{"hid":869,"name":837,"content":838},"citation_author_institution_6",{"hid":871,"name":833,"content":872},"citation_author_7","Hassouna, Jamel Ben ",{"hid":874,"name":837,"content":859},"citation_author_institution_7",{"hid":876,"name":833,"content":877},"citation_author_8","Zribi, Aref ",{"hid":879,"name":837,"content":880},"citation_author_institution_8","Department of Medical Oncology, Military Hospital, Tunisia",{"hid":882,"name":833,"content":883},"citation_author_9","Berrazaga, Yossra ",{"hid":885,"name":837,"content":886},"citation_author_institution_9","Medical Oncology Department, Abderrahmen Mami Hospital, Tunisia",{"hid":888,"name":833,"content":889},"citation_author_10","Rachdi, Haifa ",{"hid":891,"name":837,"content":886},"citation_author_institution_10",{"hid":893,"name":833,"content":894},"citation_author_11","Daoud, Nouha ",{"hid":896,"name":837,"content":886},"citation_author_institution_11",{"hid":898,"name":833,"content":899},"citation_author_12","El Benna, Houda ",{"hid":901,"name":837,"content":886},"citation_author_institution_12",{"hid":903,"name":833,"content":904},"citation_author_13","Labidi, Soumaya ",{"hid":906,"name":837,"content":838},"citation_author_institution_13",{"hid":908,"name":833,"content":909},"citation_author_14","Haddaoui, Abderrazek ",{"hid":911,"name":837,"content":880},"citation_author_institution_14",{"hid":913,"name":833,"content":914},"citation_author_15","Rahal, Khaled ",{"hid":916,"name":837,"content":859},"citation_author_institution_15",{"hid":918,"name":833,"content":919},"citation_author_16","Benna, Farouk ",{"hid":921,"name":837,"content":922},"citation_author_institution_16","Department of Radiation Oncology, University of Tunis, Tunisia",{"hid":924,"name":833,"content":925},"citation_author_17","Boussen, Hamouda ",{"hid":927,"name":837,"content":838},"citation_author_institution_17",{"hid":929,"name":833,"content":930},"citation_author_18","Abdelhak, Sonia ",{"hid":932,"name":837,"content":838},"citation_author_institution_18",{"hid":934,"name":833,"content":935},"citation_author_19","Boubaker, Samir ",{"hid":937,"name":837,"content":838},"citation_author_institution_19",{"hid":939,"name":939,"content":940},"dc.identifier","doi:10.3389/fgene.2021.674990",[942,945,947,949,951],{"src":943,"body":13,"type":944,"async":13},"https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6","text/javascript",{"src":946,"body":13,"type":944,"async":13},"https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML",{"src":948,"body":13,"type":944,"async":13},"https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",{"src":950,"body":13,"type":944,"async":13},"https://api.altmetric.com/v1/doi/10.3389/fgene.2021.674990?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",{"src":952,"body":13,"type":944,"async":13},"https://crossmark-cdn.crossref.org/widget/v2.0/widget.js",{"articleHubSlug":19,"articleHubPage":954,"articleHubArticlesList":955,"canJournalHasArticleHub":359,"articleDoiList":956},{},[],[],{"title":19,"image":-1,"breadcrumbs":958,"linksCollection":959,"metricsCollection":961},[],{"total":371,"items":960},[],{"total":371,"items":962},[]]</script>
<script>window.__NUXT__={};window.__NUXT__.config={public:{isDevMode:false,appName:"article-pages-2024",baseUrl:"https://www.frontiersin.org",domain:"frontiersin.org",loopUrl:"https://loop.frontiersin.org",ssMainDomain:"frontiersin.org",contentfulUrl:"https://graphql.contentful.com/content/v1/spaces",spaceId:1,spaceName:"Frontiers",liveSpaceId:1,tenantLogoUrl:"",frontiersGraphUrl:"https://apollo-federation-gateway.frontiersin.org",registrationApiUrl:"https://onboarding-ui.frontiersin.org",emailDigestApiUrl:"https://api-email-digest.frontiersin.org",journalFilesApiUrl:"https://files-journal-api.frontiersin.org",publicPagesFilesUrl:"https://public-pages-files-2025.frontiersin.org",searchApiUrl:"https://search-api.frontiersin.org",productionForumApiUrl:"https://production-forum-api-v2.frontiersin.org",gtmServerUrl:"https://tag-manager.frontiersin.org",gtmId:"GTM-M322FV2",gtmAuth:"owVbWxfaJr21yQv1fe1cAQ",gtmPreview:"env-1",figsharePluginUrl:"https://widgets.figshare.com/static/figshare.js",figshareApiUrl:"https://api.figshare.com/v2/collections/search",figshareTimeout:3000,crossmarkPublishedDate:"2015/08/24",googleRecaptchaSiteKey:"6LdG3i0UAAAAAOC4qUh35ubHgJotEHp_STXHgr_v",googleRecaptchaKeyName:"FrontiersRecaptchaV2",faviconSize16:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png",faviconSize32:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png",faviconSize180:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_180-tenantFavicon-Frontiers.png",faviconSize192:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_192-tenantFavicon-Frontiers.png",faviconSize512:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_512-tenantFavicon-Frontiers.png",socialMediaImg:"https://brand.frontiersin.org/m/1c8bcb536c789e11/Guidelines-Frontiers_Logo_1200x628_1-91to1.png",linkedArticleCopyText:"'{\"articleTypeCopyText\":[{\"articleTypeId\":0,\"originalArticleCopyText\":\"Part of this article's content has been mentioned in:\",\"linkedArticleCopyText\":\"This article mentions parts of:\"},{\"articleTypeId\":122,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an erratum on:\"},{\"articleTypeId\":129,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an addendum to:\"},{\"articleTypeId\":128,\"originalArticleCopyText\":\"A correction has been applied to this article in:\",\"linkedArticleCopyText\":\"This article is a correction to:\"},{\"articleTypeId\":134,\"originalArticleCopyText\":\"A retraction of this article was approved in:\",\"linkedArticleCopyText\":\"This article is a retraction of:\"},{\"articleTypeId\":29,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"},{\"articleTypeId\":30,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"}],\"articleIdCopyText\":[]}'\n",acceptedArticleExcludedJournalIds:"'[2766,979]'\n",articleTypeConfigurableLabel:"\u003C\u003Carticle-type:uppercase>> article",settingsFeaturesSwitchers:"'{\"displayTitlePillLabels\":true,\"displayRelatedArticlesBox\":true,\"showEditors\":true,\"showReviewers\":true,\"showLoopImpactLink\":true,\"enableFigshare\":false}'\n",journalsWithArticleHub:"'{\"strings\":[\"science\"]}'\n",terminologySettings:"'{\"terms\":[{\"sequenceNumber\":1,\"key\":\"frontiers\",\"tenantTerm\":\"Frontiers\",\"frontiersDefaultTerm\":\"Frontiers\",\"category\":\"Customer\"},{\"sequenceNumber\":2,\"key\":\"submission_system\",\"tenantTerm\":\"submission system\",\"frontiersDefaultTerm\":\"submission system\",\"category\":\"Product\"},{\"sequenceNumber\":3,\"key\":\"public_pages\",\"tenantTerm\":\"public pages\",\"frontiersDefaultTerm\":\"public pages\",\"category\":\"Product\"},{\"sequenceNumber\":4,\"key\":\"my_frontiers\",\"tenantTerm\":\"my frontiers\",\"frontiersDefaultTerm\":\"my frontiers\",\"category\":\"Product\"},{\"sequenceNumber\":5,\"key\":\"digital_editorial_office\",\"tenantTerm\":\"digital editorial office\",\"frontiersDefaultTerm\":\"digital editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":6,\"key\":\"deo\",\"tenantTerm\":\"DEO\",\"frontiersDefaultTerm\":\"DEO\",\"category\":\"Product\"},{\"sequenceNumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantTerm\":\"digital editorial office for chiefs\",\"frontiersDefaultTerm\":\"digital editorial office for chiefs\",\"category\":\"Product\"},{\"sequenceNumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantTerm\":\"digital editorial office for eof\",\"frontiersDefaultTerm\":\"digital editorial office for eof\",\"category\":\"Product\"},{\"sequenceNumber\":9,\"key\":\"editorial_office\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":10,\"key\":\"eof\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"Product\"},{\"sequenceNumber\":11,\"key\":\"research_topic_management\",\"tenantTerm\":\"research topic management\",\"frontiersDefaultTerm\":\"research topic management\",\"category\":\"Product\"},{\"sequenceNumber\":12,\"key\":\"review_forum\",\"tenantTerm\":\"review forum\",\"frontiersDefaultTerm\":\"review forum\",\"category\":\"Product\"},{\"sequenceNumber\":13,\"key\":\"accounting_office\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"Product\"},{\"sequenceNumber\":14,\"key\":\"aof\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"Product\"},{\"sequenceNumber\":15,\"key\":\"publishing_office\",\"tenantTerm\":\"publishing office\",\"frontiersDefaultTerm\":\"publishing office\",\"category\":\"Product\"},{\"sequenceNumber\":16,\"key\":\"production_office\",\"tenantTerm\":\"production office forum\",\"frontiersDefaultTerm\":\"production office forum\",\"category\":\"Product\"},{\"sequenceNumber\":17,\"key\":\"pof\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"Product\"},{\"sequenceNumber\":18,\"key\":\"book_office_forum\",\"tenantTerm\":\"book office forum\",\"frontiersDefaultTerm\":\"book office forum\",\"category\":\"Product\"},{\"sequenceNumber\":19,\"key\":\"bof\",\"tenantTerm\":\"BOF\",\"frontiersDefaultTerm\":\"BOF\",\"category\":\"Product\"},{\"sequenceNumber\":20,\"key\":\"aira\",\"tenantTerm\":\"AIRA\",\"frontiersDefaultTerm\":\"AIRA\",\"category\":\"Product\"},{\"sequenceNumber\":21,\"key\":\"editorial_board_management\",\"tenantTerm\":\"editorial board management\",\"frontiersDefaultTerm\":\"editorial board management\",\"category\":\"Product\"},{\"sequenceNumber\":22,\"key\":\"ebm\",\"tenantTerm\":\"EBM\",\"frontiersDefaultTerm\":\"EBM\",\"category\":\"Product\"},{\"sequenceNumber\":23,\"key\":\"domain\",\"tenantTerm\":\"domain\",\"frontiersDefaultTerm\":\"domain\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":24,\"key\":\"journal\",\"tenantTerm\":\"journal\",\"frontiersDefaultTerm\":\"journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":25,\"key\":\"section\",\"tenantTerm\":\"section\",\"frontiersDefaultTerm\":\"section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":26,\"key\":\"domains\",\"tenantTerm\":\"domains\",\"frontiersDefaultTerm\":\"domains\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":27,\"key\":\"specialty_section\",\"tenantTerm\":\"specialty section\",\"frontiersDefaultTerm\":\"specialty section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":28,\"key\":\"specialty_journal\",\"tenantTerm\":\"specialty journal\",\"frontiersDefaultTerm\":\"specialty journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":29,\"key\":\"journals\",\"tenantTerm\":\"journals\",\"frontiersDefaultTerm\":\"journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":30,\"key\":\"sections\",\"tenantTerm\":\"sections\",\"frontiersDefaultTerm\":\"sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":31,\"key\":\"specialty_sections\",\"tenantTerm\":\"specialty sections\",\"frontiersDefaultTerm\":\"specialty sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":32,\"key\":\"specialty_journals\",\"tenantTerm\":\"specialty journals\",\"frontiersDefaultTerm\":\"specialty journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":33,\"key\":\"manuscript\",\"tenantTerm\":\"manuscript\",\"frontiersDefaultTerm\":\"manuscript\",\"category\":\"Core\"},{\"sequenceNumber\":34,\"key\":\"manuscripts\",\"tenantTerm\":\"manuscripts\",\"frontiersDefaultTerm\":\"manuscripts\",\"category\":\"Core\"},{\"sequenceNumber\":35,\"key\":\"article\",\"tenantTerm\":\"article\",\"frontiersDefaultTerm\":\"article\",\"category\":\"Core\"},{\"sequenceNumber\":36,\"key\":\"articles\",\"tenantTerm\":\"articles\",\"frontiersDefaultTerm\":\"articles\",\"category\":\"Core\"},{\"sequenceNumber\":37,\"key\":\"article_type\",\"tenantTerm\":\"article type\",\"frontiersDefaultTerm\":\"article type\",\"category\":\"Core\"},{\"sequenceNumber\":38,\"key\":\"article_types\",\"tenantTerm\":\"article types\",\"frontiersDefaultTerm\":\"article types\",\"category\":\"Core\"},{\"sequenceNumber\":39,\"key\":\"author\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":40,\"key\":\"authors\",\"tenantTerm\":\"authors\",\"frontiersDefaultTerm\":\"authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":41,\"key\":\"authoring\",\"tenantTerm\":\"authoring\",\"frontiersDefaultTerm\":\"authoring\",\"category\":\"Core\"},{\"sequenceNumber\":42,\"key\":\"authored\",\"tenantTerm\":\"authored\",\"frontiersDefaultTerm\":\"authored\",\"category\":\"Core\"},{\"sequenceNumber\":43,\"key\":\"accept\",\"tenantTerm\":\"accept\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":44,\"key\":\"accepted\",\"tenantTerm\":\"accepted\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantTerm\":\"Assistant Field Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editor\",\"description\":\"An editorial role on a Field Journal that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantTerm\":\"Assistant Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantTerm\":\"Assistant Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":48,\"key\":\"associate_editor\",\"tenantTerm\":\"Associate Editor\",\"frontiersDefaultTerm\":\"Associate Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":49,\"key\":\"specialty_chief_editor\",\"tenantTerm\":\"Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":50,\"key\":\"specialty_chief_editors\",\"tenantTerm\":\"Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":51,\"key\":\"chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":52,\"key\":\"chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":53,\"key\":\"call_for_participation\",\"tenantTerm\":\"call for participation\",\"frontiersDefaultTerm\":\"call for participation\",\"category\":\"Process\"},{\"sequenceNumber\":54,\"key\":\"citation\",\"tenantTerm\":\"citation\",\"frontiersDefaultTerm\":\"citation\",\"category\":\"Misc.\"},{\"sequenceNumber\":55,\"key\":\"citations\",\"tenantTerm\":\"citations\",\"frontiersDefaultTerm\":\"citations\",\"category\":\"Misc.\"},{\"sequenceNumber\":56,\"key\":\"contributor\",\"tenantTerm\":\"contributor\",\"frontiersDefaultTerm\":\"contributor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":57,\"key\":\"contributors\",\"tenantTerm\":\"contributors\",\"frontiersDefaultTerm\":\"contributors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":58,\"key\":\"corresponding_author\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":59,\"key\":\"corresponding_authors\",\"tenantTerm\":\"corresponding authors\",\"frontiersDefaultTerm\":\"corresponding authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":60,\"key\":\"decline\",\"tenantTerm\":\"decline\",\"frontiersDefaultTerm\":\"decline\",\"category\":\"Process\"},{\"sequenceNumber\":61,\"key\":\"declined\",\"tenantTerm\":\"declined\",\"frontiersDefaultTerm\":\"declined\",\"category\":\"Process\"},{\"sequenceNumber\":62,\"key\":\"reject\",\"tenantTerm\":\"reject\",\"frontiersDefaultTerm\":\"reject\",\"category\":\"Process\"},{\"sequenceNumber\":63,\"key\":\"rejected\",\"tenantTerm\":\"rejected\",\"frontiersDefaultTerm\":\"rejected\",\"category\":\"Process\"},{\"sequenceNumber\":64,\"key\":\"publish\",\"tenantTerm\":\"publish\",\"frontiersDefaultTerm\":\"publish\",\"category\":\"Core\"},{\"sequenceNumber\":65,\"key\":\"published\",\"tenantTerm\":\"published\",\"frontiersDefaultTerm\":\"published\",\"category\":\"Core\"},{\"sequenceNumber\":66,\"key\":\"publication\",\"tenantTerm\":\"publication\",\"frontiersDefaultTerm\":\"publication\",\"category\":\"Core\"},{\"sequenceNumber\":67,\"key\":\"peer_review\",\"tenantTerm\":\"peer review\",\"frontiersDefaultTerm\":\"peer review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":68,\"key\":\"peer_reviewed\",\"tenantTerm\":\"peer reviewed\",\"frontiersDefaultTerm\":\"peer reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":69,\"key\":\"initial_validation\",\"tenantTerm\":\"initial validation\",\"frontiersDefaultTerm\":\"initial validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":70,\"key\":\"editorial_assignment\",\"tenantTerm\":\"editorial assignment\",\"frontiersDefaultTerm\":\"editorial assignment\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":71,\"key\":\"independent_review\",\"tenantTerm\":\"independent review\",\"frontiersDefaultTerm\":\"independent review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":72,\"key\":\"interactive_review\",\"tenantTerm\":\"interactive review\",\"frontiersDefaultTerm\":\"interactive review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":73,\"key\":\"review\",\"tenantTerm\":\"review\",\"frontiersDefaultTerm\":\"review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":74,\"key\":\"reviewing\",\"tenantTerm\":\"reviewing\",\"frontiersDefaultTerm\":\"reviewing\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":75,\"key\":\"reviewer\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":76,\"key\":\"reviewers\",\"tenantTerm\":\"reviewers\",\"frontiersDefaultTerm\":\"reviewers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":77,\"key\":\"review_finalized\",\"tenantTerm\":\"review finalized\",\"frontiersDefaultTerm\":\"review finalized\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":78,\"key\":\"final_decision\",\"tenantTerm\":\"final decision\",\"frontiersDefaultTerm\":\"final decision\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":79,\"key\":\"final_validation\",\"tenantTerm\":\"final validation\",\"frontiersDefaultTerm\":\"final validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantTerm\":\"recommend to accept manuscript\",\"frontiersDefaultTerm\":\"accept manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":81,\"key\":\"fee\",\"tenantTerm\":\"fee\",\"frontiersDefaultTerm\":\"fee\",\"category\":\"Accounting\"},{\"sequenceNumber\":82,\"key\":\"fees\",\"tenantTerm\":\"fees\",\"frontiersDefaultTerm\":\"fees\",\"category\":\"Accounting\"},{\"sequenceNumber\":83,\"key\":\"guest_associate_editor\",\"tenantTerm\":\"Guest Associate Editor\",\"frontiersDefaultTerm\":\"Guest Associate Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":84,\"key\":\"guest_associate_editors\",\"tenantTerm\":\"Guest Associate Editors\",\"frontiersDefaultTerm\":\"Guest Associate Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":85,\"key\":\"in_review\",\"tenantTerm\":\"in review\",\"frontiersDefaultTerm\":\"in review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":86,\"key\":\"institutional_member\",\"tenantTerm\":\"institutional partner\",\"frontiersDefaultTerm\":\"institutional partner\",\"category\":\"Accounting\"},{\"sequenceNumber\":87,\"key\":\"institutional_membership\",\"tenantTerm\":\"institutional partnership\",\"frontiersDefaultTerm\":\"institutional partnership\",\"category\":\"Accounting\"},{\"sequenceNumber\":88,\"key\":\"article_processing_charge\",\"tenantTerm\":\"article processing charge\",\"frontiersDefaultTerm\":\"article processing charge\",\"category\":\"Accounting\"},{\"sequenceNumber\":89,\"key\":\"article_processing_charges\",\"tenantTerm\":\"article processing charges\",\"frontiersDefaultTerm\":\"article processing charges\",\"category\":\"Accounting\"},{\"sequenceNumber\":90,\"key\":\"apcs\",\"tenantTerm\":\"APCs\",\"frontiersDefaultTerm\":\"APCs\",\"category\":\"Accounting\"},{\"sequenceNumber\":91,\"key\":\"apc\",\"tenantTerm\":\"APC\",\"frontiersDefaultTerm\":\"APC\",\"category\":\"Accounting\"},{\"sequenceNumber\":92,\"key\":\"received\",\"tenantTerm\":\"received\",\"frontiersDefaultTerm\":\"received\",\"description\":\"Date manuscript was received on.\",\"category\":\"Core\"},{\"sequenceNumber\":93,\"key\":\"transferred\",\"tenantTerm\":\"transferred\",\"frontiersDefaultTerm\":\"transferred\",\"category\":\"Core\"},{\"sequenceNumber\":94,\"key\":\"transfer\",\"tenantTerm\":\"transfer\",\"frontiersDefaultTerm\":\"transfer\",\"category\":\"Core\"},{\"sequenceNumber\":95,\"key\":\"research_topic\",\"tenantTerm\":\"research topic\",\"frontiersDefaultTerm\":\"research topic\",\"category\":\"Core\"},{\"sequenceNumber\":96,\"key\":\"research_topics\",\"tenantTerm\":\"research topics\",\"frontiersDefaultTerm\":\"research topics\",\"category\":\"Core\"},{\"sequenceNumber\":97,\"key\":\"topic_editor\",\"tenantTerm\":\"Topic Editor\",\"frontiersDefaultTerm\":\"Topic Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":98,\"key\":\"review_editor\",\"tenantTerm\":\"Community Reviewer\",\"frontiersDefaultTerm\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":99,\"key\":\"title\",\"tenantTerm\":\"title\",\"frontiersDefaultTerm\":\"title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":100,\"key\":\"running_title\",\"tenantTerm\":\"running title\",\"frontiersDefaultTerm\":\"running title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":101,\"key\":\"submit\",\"tenantTerm\":\"submit\",\"frontiersDefaultTerm\":\"submit\",\"category\":\"Process\"},{\"sequenceNumber\":102,\"key\":\"submitted\",\"tenantTerm\":\"submitted\",\"frontiersDefaultTerm\":\"submitted\",\"category\":\"Process\"},{\"sequenceNumber\":103,\"key\":\"submitting\",\"tenantTerm\":\"submitting\",\"frontiersDefaultTerm\":\"submitting\",\"category\":\"Process\"},{\"sequenceNumber\":104,\"key\":\"t_e\",\"tenantTerm\":\"TE\",\"frontiersDefaultTerm\":\"TE\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":105,\"key\":\"topic\",\"tenantTerm\":\"topic\",\"frontiersDefaultTerm\":\"topic\",\"category\":\"Process\"},{\"sequenceNumber\":106,\"key\":\"topic_summary\",\"tenantTerm\":\"topic summary\",\"frontiersDefaultTerm\":\"topic summary\",\"category\":\"Process\"},{\"sequenceNumber\":107,\"key\":\"figure\",\"tenantTerm\":\"figure\",\"frontiersDefaultTerm\":\"figure\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":108,\"key\":\"figures\",\"tenantTerm\":\"figures\",\"frontiersDefaultTerm\":\"figures\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":109,\"key\":\"editorial_file\",\"tenantTerm\":\"editorial file\",\"frontiersDefaultTerm\":\"editorial file\",\"category\":\"Core\"},{\"sequenceNumber\":110,\"key\":\"editorial_files\",\"tenantTerm\":\"editorial files\",\"frontiersDefaultTerm\":\"editorial files\",\"category\":\"Core\"},{\"sequenceNumber\":111,\"key\":\"e_book\",\"tenantTerm\":\"e-book\",\"frontiersDefaultTerm\":\"e-book\",\"category\":\"Core\"},{\"sequenceNumber\":112,\"key\":\"organization\",\"tenantTerm\":\"organization\",\"frontiersDefaultTerm\":\"organization\",\"category\":\"Core\"},{\"sequenceNumber\":113,\"key\":\"institution\",\"tenantTerm\":\"institution\",\"frontiersDefaultTerm\":\"institution\",\"category\":\"Core\"},{\"sequenceNumber\":114,\"key\":\"reference\",\"tenantTerm\":\"reference\",\"frontiersDefaultTerm\":\"reference\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":115,\"key\":\"references\",\"tenantTerm\":\"references\",\"frontiersDefaultTerm\":\"references\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":116,\"key\":\"sce\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"description\":\"Abbreviation for Specialty Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":117,\"key\":\"submission\",\"tenantTerm\":\"submission\",\"frontiersDefaultTerm\":\"submission\",\"category\":\"Process\"},{\"sequenceNumber\":118,\"key\":\"submissions\",\"tenantTerm\":\"submissions\",\"frontiersDefaultTerm\":\"submissions\",\"category\":\"Process\"},{\"sequenceNumber\":119,\"key\":\"editing\",\"tenantTerm\":\"editing\",\"frontiersDefaultTerm\":\"editing\",\"category\":\"Process\"},{\"sequenceNumber\":120,\"key\":\"in_preparation\",\"tenantTerm\":\"in preparation\",\"frontiersDefaultTerm\":\"in preparation\",\"category\":\"Process\"},{\"sequenceNumber\":121,\"key\":\"country_region\",\"tenantTerm\":\"country/region\",\"frontiersDefaultTerm\":\"country/region\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":122,\"key\":\"countries_regions\",\"tenantTerm\":\"countries/regions\",\"frontiersDefaultTerm\":\"countries/regions\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":123,\"key\":\"specialty\",\"tenantTerm\":\"specialty\",\"frontiersDefaultTerm\":\"specialty\",\"category\":\"Core\"},{\"sequenceNumber\":124,\"key\":\"specialties\",\"tenantTerm\":\"specialties\",\"frontiersDefaultTerm\":\"specialties\",\"category\":\"Core\"},{\"sequenceNumber\":125,\"key\":\"associate_editors\",\"tenantTerm\":\"Associate Editors\",\"frontiersDefaultTerm\":\"Associate Editors\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":126,\"key\":\"reviewed\",\"tenantTerm\":\"reviewed\",\"frontiersDefaultTerm\":\"reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":127,\"key\":\"institutional_members\",\"tenantTerm\":\"institutional partners\",\"frontiersDefaultTerm\":\"institutional partners\",\"category\":\"Accounting\"},{\"sequenceNumber\":128,\"key\":\"institutional_memberships\",\"tenantTerm\":\"institutional partnerships\",\"frontiersDefaultTerm\":\"institutional partnerships\",\"category\":\"Accounting\"},{\"sequenceNumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantTerm\":\"Assistant Field Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":130,\"key\":\"publications\",\"tenantTerm\":\"publications\",\"frontiersDefaultTerm\":\"publications\",\"category\":\"Process\"},{\"sequenceNumber\":131,\"key\":\"ae_accepted\",\"tenantTerm\":\"recommended acceptance\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":132,\"key\":\"field_journal\",\"tenantTerm\":\"field journal\",\"frontiersDefaultTerm\":\"field journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":133,\"key\":\"field_journals\",\"tenantTerm\":\"field journals\",\"frontiersDefaultTerm\":\"field journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":134,\"key\":\"program_manager\",\"tenantTerm\":\"program manager\",\"frontiersDefaultTerm\":\"program manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":135,\"key\":\"journal_manager\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":136,\"key\":\"journal_specialist\",\"tenantTerm\":\"journal specialist\",\"frontiersDefaultTerm\":\"journal specialist\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":137,\"key\":\"program_managers\",\"tenantTerm\":\"program managers\",\"frontiersDefaultTerm\":\"program managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":138,\"key\":\"journal_managers\",\"tenantTerm\":\"journal managers\",\"frontiersDefaultTerm\":\"journal managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":139,\"key\":\"journal_specialists\",\"tenantTerm\":\"journal specialists\",\"frontiersDefaultTerm\":\"journal specialists\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":140,\"key\":\"cover_letter\",\"tenantTerm\":\"manuscript contribution to the field\",\"frontiersDefaultTerm\":\"manuscript contribution to the field\",\"category\":\"Process\"},{\"sequenceNumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantTerm\":\"recommended to accept manuscript\",\"frontiersDefaultTerm\":\"accepted manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":142,\"key\":\"recommend_for_rejection\",\"tenantTerm\":\"recommend for rejection\",\"frontiersDefaultTerm\":\"recommend for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":143,\"key\":\"recommended_for_rejection\",\"tenantTerm\":\"recommended for rejection\",\"frontiersDefaultTerm\":\"recommended for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":144,\"key\":\"ae\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"description\":\"Associate Editor - board member\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":145,\"key\":\"re\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"description\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":146,\"key\":\"rev\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"description\":\"Reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":147,\"key\":\"aut\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"description\":\"Author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":148,\"key\":\"coraut\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"description\":\"Corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":149,\"key\":\"saut\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"description\":\"Submitting author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":150,\"key\":\"coaut\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"description\":\"co-author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":151,\"key\":\"tsof\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"description\":\"Typesetter\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":152,\"key\":\"typesetting_office\",\"tenantTerm\":\"typesetting office\",\"frontiersDefaultTerm\":\"typesetting office\",\"category\":\"Product\"},{\"sequenceNumber\":153,\"key\":\"config\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"description\":\"Configuration office role\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":154,\"key\":\"jm\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"description\":\"Journal Manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":155,\"key\":\"rte\",\"tenantTerm\":\"RTE\",\"frontiersDefaultTerm\":\"RTE\",\"description\":\"Research topic editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":156,\"key\":\"organizations\",\"tenantTerm\":\"organizations\",\"frontiersDefaultTerm\":\"organizations\",\"category\":\"Core\"},{\"sequenceNumber\":157,\"key\":\"publishing\",\"tenantTerm\":\"publishing\",\"frontiersDefaultTerm\":\"publishing\",\"category\":\"Core\"},{\"sequenceNumber\":158,\"key\":\"acceptance\",\"tenantTerm\":\"acceptance\",\"frontiersDefaultTerm\":\"acceptance\",\"category\":\"Process\"},{\"sequenceNumber\":159,\"key\":\"preferred_associate_editor\",\"tenantTerm\":\"preferred associate editor\",\"frontiersDefaultTerm\":\"preferred associate editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":160,\"key\":\"topic_editors\",\"tenantTerm\":\"Topic Editors\",\"frontiersDefaultTerm\":\"Topic Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":161,\"key\":\"institutions\",\"tenantTerm\":\"institutions\",\"frontiersDefaultTerm\":\"institutions\",\"category\":\"Core\"},{\"sequenceNumber\":162,\"key\":\"author(s)\",\"tenantTerm\":\"author(s)\",\"frontiersDefaultTerm\":\"author(s)\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":163,\"key\":\"figure(s)\",\"tenantTerm\":\"figure(s)\",\"frontiersDefaultTerm\":\"figure(s)\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":164,\"key\":\"co-authors\",\"tenantTerm\":\"co-authors\",\"frontiersDefaultTerm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":165,\"key\":\"editorial_board_members\",\"tenantTerm\":\"editorial board members\",\"frontiersDefaultTerm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":166,\"key\":\"editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"Product\"},{\"sequenceNumber\":167,\"key\":\"co-authorship\",\"tenantTerm\":\"co-authorship\",\"frontiersDefaultTerm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"Misc.\"},{\"sequenceNumber\":168,\"key\":\"role_id_1\",\"tenantTerm\":\"registration office\",\"frontiersDefaultTerm\":\"registration office\",\"category\":\"User Role\"},{\"sequenceNumber\":169,\"key\":\"role_id_2\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"User Role\"},{\"sequenceNumber\":170,\"key\":\"role_id_7\",\"tenantTerm\":\"field chief editor\",\"frontiersDefaultTerm\":\"field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":171,\"key\":\"role_id_8\",\"tenantTerm\":\"assistant field chief editor\",\"frontiersDefaultTerm\":\"assistant field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":172,\"key\":\"role_id_9\",\"tenantTerm\":\"specialty chief editor\",\"frontiersDefaultTerm\":\"specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":173,\"key\":\"role_id_10\",\"tenantTerm\":\"assistant specialty chief editor\",\"frontiersDefaultTerm\":\"assistant specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":174,\"key\":\"role_id_11\",\"tenantTerm\":\"associate editor\",\"frontiersDefaultTerm\":\"associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":175,\"key\":\"role_id_12\",\"tenantTerm\":\"guest associate editor\",\"frontiersDefaultTerm\":\"guest associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":176,\"key\":\"role_id_13\",\"tenantTerm\":\"review editor\",\"frontiersDefaultTerm\":\"review editor\",\"category\":\"User Role\"},{\"sequenceNumber\":177,\"key\":\"role_id_14\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":178,\"key\":\"role_id_15\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"User Role\"},{\"sequenceNumber\":179,\"key\":\"role_id_16\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"User Role\"},{\"sequenceNumber\":180,\"key\":\"role_id_17\",\"tenantTerm\":\"submitting author\",\"frontiersDefaultTerm\":\"submitting author\",\"category\":\"User Role\"},{\"sequenceNumber\":181,\"key\":\"role_id_18\",\"tenantTerm\":\"co-author\",\"frontiersDefaultTerm\":\"co-author\",\"category\":\"User Role\"},{\"sequenceNumber\":182,\"key\":\"role_id_20\",\"tenantTerm\":\"production office\",\"frontiersDefaultTerm\":\"production office\",\"category\":\"User Role\"},{\"sequenceNumber\":183,\"key\":\"role_id_22\",\"tenantTerm\":\"typesetting office (typesetter)\",\"frontiersDefaultTerm\":\"typesetting office (typesetter)\",\"category\":\"User Role\"},{\"sequenceNumber\":184,\"key\":\"role_id_24\",\"tenantTerm\":\"registered user\",\"frontiersDefaultTerm\":\"registered user\",\"category\":\"User Role\"},{\"sequenceNumber\":185,\"key\":\"role_id_35\",\"tenantTerm\":\"job office\",\"frontiersDefaultTerm\":\"job office\",\"category\":\"User Role\"},{\"sequenceNumber\":186,\"key\":\"role_id_41\",\"tenantTerm\":\"special event administrator\",\"frontiersDefaultTerm\":\"special event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":187,\"key\":\"role_id_42\",\"tenantTerm\":\"special event reviewer\",\"frontiersDefaultTerm\":\"special event reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":188,\"key\":\"role_id_43\",\"tenantTerm\":\"submit abstract\",\"frontiersDefaultTerm\":\"submit abstract\",\"category\":\"User Role\"},{\"sequenceNumber\":189,\"key\":\"role_id_52\",\"tenantTerm\":\"events office\",\"frontiersDefaultTerm\":\"events office\",\"category\":\"User Role\"},{\"sequenceNumber\":190,\"key\":\"role_id_53\",\"tenantTerm\":\"event administrator\",\"frontiersDefaultTerm\":\"event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":191,\"key\":\"role_id_89\",\"tenantTerm\":\"content management office\",\"frontiersDefaultTerm\":\"content management office\",\"category\":\"User Role\"},{\"sequenceNumber\":192,\"key\":\"role_id_98\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"User Role\"},{\"sequenceNumber\":193,\"key\":\"role_id_99\",\"tenantTerm\":\"projects\",\"frontiersDefaultTerm\":\"projects\",\"category\":\"User Role\"},{\"sequenceNumber\":194,\"key\":\"role_id_103\",\"tenantTerm\":\"configuration office\",\"frontiersDefaultTerm\":\"configuration office\",\"category\":\"User Role\"},{\"sequenceNumber\":195,\"key\":\"role_id_104\",\"tenantTerm\":\"beta user\",\"frontiersDefaultTerm\":\"beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":196,\"key\":\"role_id_106\",\"tenantTerm\":\"wfconf\",\"frontiersDefaultTerm\":\"wfconf\",\"category\":\"User Role\"},{\"sequenceNumber\":197,\"key\":\"role_id_107\",\"tenantTerm\":\"rt management beta user\",\"frontiersDefaultTerm\":\"rt management beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":198,\"key\":\"role_id_108\",\"tenantTerm\":\"deo beta user\",\"frontiersDefaultTerm\":\"deo beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":199,\"key\":\"role_id_109\",\"tenantTerm\":\"search beta user\",\"frontiersDefaultTerm\":\"search beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":200,\"key\":\"role_id_110\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"User Role\"},{\"sequenceNumber\":201,\"key\":\"role_id_111\",\"tenantTerm\":\"myfrontiers beta user\",\"frontiersDefaultTerm\":\"myfrontiers beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":202,\"key\":\"role_id_21\",\"tenantTerm\":\"copy editor\",\"frontiersDefaultTerm\":\"copy editor\",\"category\":\"User Role\"},{\"sequenceNumber\":203,\"key\":\"role_id_1_abr\",\"tenantTerm\":\"ROF\",\"frontiersDefaultTerm\":\"ROF\",\"category\":\"User Role\"},{\"sequenceNumber\":204,\"key\":\"role_id_2_abr\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"User Role\"},{\"sequenceNumber\":205,\"key\":\"role_id_7_abr\",\"tenantTerm\":\"FCE\",\"frontiersDefaultTerm\":\"FCE\",\"category\":\"User Role\"},{\"sequenceNumber\":206,\"key\":\"role_id_8_abr\",\"tenantTerm\":\"AFCE\",\"frontiersDefaultTerm\":\"AFCE\",\"category\":\"User Role\"},{\"sequenceNumber\":207,\"key\":\"role_id_9_abr\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"category\":\"User Role\"},{\"sequenceNumber\":208,\"key\":\"role_id_10_abr\",\"tenantTerm\":\"ASCE\",\"frontiersDefaultTerm\":\"ASCE\",\"category\":\"User Role\"},{\"sequenceNumber\":209,\"key\":\"role_id_11_abr\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"category\":\"User Role\"},{\"sequenceNumber\":210,\"key\":\"role_id_12_abr\",\"tenantTerm\":\"GAE\",\"frontiersDefaultTerm\":\"GAE\",\"category\":\"User Role\"},{\"sequenceNumber\":211,\"key\":\"role_id_13_abr\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"category\":\"User Role\"},{\"sequenceNumber\":212,\"key\":\"role_id_14_abr\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"category\":\"User Role\"},{\"sequenceNumber\":213,\"key\":\"role_id_15_abr\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":214,\"key\":\"role_id_16_abr\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":215,\"key\":\"role_id_17_abr\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":216,\"key\":\"role_id_18_abr\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":217,\"key\":\"role_id_20_abr\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"User Role\"},{\"sequenceNumber\":218,\"key\":\"role_id_22_abr\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"category\":\"User Role\"},{\"sequenceNumber\":219,\"key\":\"role_id_24_abr\",\"tenantTerm\":\"RU\",\"frontiersDefaultTerm\":\"RU\",\"category\":\"User Role\"},{\"sequenceNumber\":220,\"key\":\"role_id_35_abr\",\"tenantTerm\":\"JOF\",\"frontiersDefaultTerm\":\"JOF\",\"category\":\"User Role\"},{\"sequenceNumber\":221,\"key\":\"role_id_41_abr\",\"tenantTerm\":\"SE-ADM\",\"frontiersDefaultTerm\":\"SE-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":222,\"key\":\"role_id_42_abr\",\"tenantTerm\":\"SE-REV\",\"frontiersDefaultTerm\":\"SE-REV\",\"category\":\"User Role\"},{\"sequenceNumber\":223,\"key\":\"role_id_43_abr\",\"tenantTerm\":\"SE-AUT\",\"frontiersDefaultTerm\":\"SE-AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":224,\"key\":\"role_id_52_abr\",\"tenantTerm\":\"EVOF\",\"frontiersDefaultTerm\":\"EVOF\",\"category\":\"User Role\"},{\"sequenceNumber\":225,\"key\":\"role_id_53_abr\",\"tenantTerm\":\"EV-ADM\",\"frontiersDefaultTerm\":\"EV-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":226,\"key\":\"role_id_89_abr\",\"tenantTerm\":\"COMOF\",\"frontiersDefaultTerm\":\"COMOF\",\"category\":\"User Role\"},{\"sequenceNumber\":227,\"key\":\"role_id_98_abr\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"User Role\"},{\"sequenceNumber\":228,\"key\":\"role_id_99_abr\",\"tenantTerm\":\"Projects\",\"frontiersDefaultTerm\":\"Projects\",\"category\":\"User Role\"},{\"sequenceNumber\":229,\"key\":\"role_id_103_abr\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"category\":\"User Role\"},{\"sequenceNumber\":230,\"key\":\"role_id_104_abr\",\"tenantTerm\":\"BETA\",\"frontiersDefaultTerm\":\"BETA\",\"category\":\"User Role\"},{\"sequenceNumber\":231,\"key\":\"role_id_106_abr\",\"tenantTerm\":\"WFCONF\",\"frontiersDefaultTerm\":\"WFCONF\",\"category\":\"User Role\"},{\"sequenceNumber\":232,\"key\":\"role_id_107_abr\",\"tenantTerm\":\"RTBETA\",\"frontiersDefaultTerm\":\"RTBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":233,\"key\":\"role_id_108_abr\",\"tenantTerm\":\"DEOBETA\",\"frontiersDefaultTerm\":\"DEOBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":234,\"key\":\"role_id_109_abr\",\"tenantTerm\":\"SEARCHBETA\",\"frontiersDefaultTerm\":\"SEARCHBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":235,\"key\":\"role_id_110_abr\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"category\":\"User Role\"},{\"sequenceNumber\":236,\"key\":\"role_id_111_abr\",\"tenantTerm\":\"MFBETA\",\"frontiersDefaultTerm\":\"MFBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":237,\"key\":\"role_id_21_abr\",\"tenantTerm\":\"COPED\",\"frontiersDefaultTerm\":\"COPED\",\"category\":\"User Role\"},{\"sequenceNumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"This is the label for the review editorial board\",\"category\":\"Label\"},{\"sequenceNumber\":239,\"key\":\"field_chief_editor\",\"tenantTerm\":\"Field Chief Editor\",\"frontiersDefaultTerm\":\"Field Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":240,\"key\":\"field_chief_editors\",\"tenantTerm\":\"Field Chief Editors\",\"frontiersDefaultTerm\":\"Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":241,\"key\":\"editor\",\"tenantTerm\":\"editor\",\"frontiersDefaultTerm\":\"editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":242,\"key\":\"editors\",\"tenantTerm\":\"editors\",\"frontiersDefaultTerm\":\"editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":243,\"key\":\"board\",\"tenantTerm\":\"board\",\"frontiersDefaultTerm\":\"board\",\"category\":\"Label\"},{\"sequenceNumber\":244,\"key\":\"boards\",\"tenantTerm\":\"boards\",\"frontiersDefaultTerm\":\"boards\",\"category\":\"Label\"},{\"sequenceNumber\":245,\"key\":\"article_collection\",\"tenantTerm\":\"article collection\",\"frontiersDefaultTerm\":\"article collection\",\"category\":\"Label\"},{\"sequenceNumber\":246,\"key\":\"article_collections\",\"tenantTerm\":\"article collections\",\"frontiersDefaultTerm\":\"article collections\",\"category\":\"Label\"},{\"sequenceNumber\":247,\"key\":\"handling_editor\",\"tenantTerm\":\"handling editor\",\"frontiersDefaultTerm\":\"associate editor\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":248,\"key\":\"handling_editors\",\"tenantTerm\":\"handling editors\",\"frontiersDefaultTerm\":\"associate editors\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":249,\"key\":\"ae_accept\",\"tenantTerm\":\"recommend acceptance\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":250,\"key\":\"rtm\",\"tenantTerm\":\"RTM\",\"frontiersDefaultTerm\":\"RTM\",\"category\":\"Product\"},{\"sequenceNumber\":251,\"key\":\"frontiers_media_sa\",\"tenantTerm\":\"Frontiers Media S.A\",\"frontiersDefaultTerm\":\"Frontiers Media S.A\",\"category\":\"Customer\"},{\"sequenceNumber\":252,\"key\":\"review_editors\",\"tenantTerm\":\"Community Reviewers\",\"frontiersDefaultTerm\":\"Review Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":255,\"key\":\"call_for_papers\",\"tenantTerm\":\"Call for papers\",\"frontiersDefaultTerm\":\"Call for papers\",\"category\":\"Label\"},{\"sequenceNumber\":256,\"key\":\"calls_for_papers\",\"tenantTerm\":\"Calls for papers\",\"frontiersDefaultTerm\":\"Calls for papers\",\"category\":\"Label\"},{\"sequenceNumber\":257,\"key\":\"supervising_editor\",\"tenantTerm\":\"Supervising Editor\",\"frontiersDefaultTerm\":\"Supervising Editor\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editor\"},{\"sequenceNumber\":258,\"key\":\"supervising_editors\",\"tenantTerm\":\"Supervising Editors\",\"frontiersDefaultTerm\":\"Supervising Editors\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editors\"},{\"sequenceNumber\":259,\"key\":\"reviewer_endorse\",\"tenantTerm\":\"endorse\",\"frontiersDefaultTerm\":\"endorse\",\"category\":\"Label\"},{\"sequenceNumber\":260,\"key\":\"reviewer_endorsed\",\"tenantTerm\":\"endorsed\",\"frontiersDefaultTerm\":\"endorsed\",\"category\":\"Label\"},{\"sequenceNumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantTerm\":\"endorse publication\",\"frontiersDefaultTerm\":\"endorse publication\",\"category\":\"Label\"},{\"sequenceNumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantTerm\":\"endorsed publication\",\"frontiersDefaultTerm\":\"endorsed publication\",\"category\":\"Label\"},{\"sequenceNumber\":263,\"key\":\"editor_role\",\"tenantTerm\":\"editor role\",\"frontiersDefaultTerm\":\"Editor Role\",\"category\":\"Label\"},{\"sequenceNumber\":264,\"key\":\"editor_roles\",\"tenantTerm\":\"editor roles\",\"frontiersDefaultTerm\":\"Editor Roles\",\"category\":\"Label\"},{\"sequenceNumber\":265,\"key\":\"editorial_role\",\"tenantTerm\":\"editorial role\",\"frontiersDefaultTerm\":\"Editorial Role\",\"category\":\"Label\"},{\"sequenceNumber\":266,\"key\":\"editorial_roles\",\"tenantTerm\":\"editorial roles\",\"frontiersDefaultTerm\":\"Editorial Roles\",\"category\":\"Label\"},{\"sequenceNumber\":267,\"key\":\"call_for_paper\",\"tenantTerm\":\"Call for paper\",\"frontiersDefaultTerm\":\"Call for paper\",\"category\":\"Label\"},{\"sequenceNumber\":268,\"key\":\"research_topic_abstract\",\"tenantTerm\":\"manuscript summary\",\"frontiersDefaultTerm\":\"manuscript summary\",\"category\":\"Process\"},{\"sequenceNumber\":269,\"key\":\"research_topic_abstracts\",\"tenantTerm\":\"manuscript summaries\",\"frontiersDefaultTerm\":\"manuscript summaries\",\"category\":\"Process\"},{\"sequenceNumber\":270,\"key\":\"submissions_team_manager\",\"tenantTerm\":\"Journal Manager\",\"frontiersDefaultTerm\":\"Content Manager\",\"category\":\"Process\"},{\"sequenceNumber\":271,\"key\":\"submissions_team\",\"tenantTerm\":\"Journal Team\",\"frontiersDefaultTerm\":\"Content Team\",\"category\":\"Process\"},{\"sequenceNumber\":272,\"key\":\"topic_coordinator\",\"tenantTerm\":\"topic coordinator\",\"frontiersDefaultTerm\":\"topic coordinator\",\"category\":\"Process\"},{\"sequenceNumber\":273,\"key\":\"topic_coordinators\",\"tenantTerm\":\"topic coordinators\",\"frontiersDefaultTerm\":\"topic coordinators\",\"category\":\"Process\"},{\"sequenceNumber\":274,\"key\":\"frontiers_journal_team\",\"tenantTerm\":\"frontiers journal team\",\"frontiersDefaultTerm\":\"frontiers journal team\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":275,\"key\":\"research_topic_ic_submission\",\"tenantTerm\":\"RT:IC Submission\",\"frontiersDefaultTerm\":\"RT:IC Submission\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":276,\"key\":\"research_topic_ic_submission_participant\",\"tenantTerm\":\"RT:IC Submission participant\",\"frontiersDefaultTerm\":\"RT:IC Submission participant\",\"category\":\"Label (Role)\"}]}'\n",impactGtmId:"GTM-NJF2ML9B",impactGtmAuth:"fYo-7NoDm9w37QgFMs03SA",impactGtmPreview:"env-1",impactGoogleMapsApiKey:"AIzaSyCTEhX2EU8PWfi86GW9FI00FTcyKk6Ifr8",qualtricsV4ToV3:"'{\"enabled\":true,\"interceptId\":\"SI_er0E2ze69Oz8Yn4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsUmux:"'{\"enabled\":false,\"interceptId\":\"SI_89fPHY3eTxQBwtU\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsContinuousBrand:"'{\"enabled\":true,\"interceptId\":\"SI_9ZuT94UT81FcRh4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",defaultArticleTemplate:"v3"},app:{baseURL:"/",buildId:"ed555f16-85f7-4f41-8f2f-451827c59120",buildAssetsDir:"ap-2024/_nuxt",cdnURL:""}}</script>
<script src="https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6" type="text/javascript" async></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML" type="text/javascript" async></script>
<script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js" type="text/javascript" async></script>
<script src="https://api.altmetric.com/v1/doi/10.3389/fgene.2021.674990?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15" type="text/javascript" async></script>
<script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript" async></script></body></html>